# Citation Report
List of articles citing

## Molecular portraits of human breast tumours

DOI: 10.1038/35021093
Nature, 2000, 406, 747-52.

| # | Paper | IF | Citations |
|---|---|---|---|
| 2268 | Methods of Microdissection and New Technologies. **2005**, 69-100 | | |
| 2267 | A matched group study of triple negative versus HER-2 positive (irrespective of hormonal status) breast cancer: two subtypes with high-risk features and poor outcome. **2010**, 4, 167 | | 0 |
| 2266 | . | | |
| 2265 | Clinicopathologic subtypes and compromise of lymph nodes in patients with breast cancer. **2014**, 8, 448 | | 6 |
| 2264 | How much survival benefit is necessary for breast cancer patients to opt for adjuvant chemotherapy? Results from a Chilean survey. **2014**, 8, 391 | | 3 |
| 2263 | p16 expression correlates with basal-like triple-negative breast carcinoma. **2013**, 7, 317 | | 9 |
| 2262 | Treatment plan for breast cancer with sentinel node metastasis. **2014**, 8, 383 | | 4 |
| 2261 | Relationship of CK8/18 expression pattern to breast cancer immunohistochemical subtyping in Egyptian patients. **2014**, 8, 404 | | 3 |
| 2260 | Endocrine-responsive breast cancer: a 28-year Odyssey. **2011**, 5, 237 | | |
| 2259 | Adrenocortical function in epilepsy: II. The role of corticosterone in the mechanism and management of epilepsy. **1961**, 11, 246-246 | | 2 |
| 2258 | Growth and molecular interactions of the anti-EGFR antibody Cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: New prospects in the treatment of triple-negative/basal-like breast cancer. **1992**, 33, 1165 | | 3 |
| 2257 | Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients. **1994**, 20, 987 | | 1 |
| 2256 | Applied genomics: integration of the technology within pharmaceutical research and development. **2000**, 11, 602-9 | | 34 |
| 2255 | Molecular profiling of human cancer. **2000**, 1, 48-56 | | 354 |
| 2254 | Genomics. Beyond the book of life. *Nature*, **2000**, 408, 894-6 | 50.4 | 6 |
| 2253 | Gene expression profiling of primary breast carcinomas using arrays of candidate genes. **2000**, 9, 2981-91 | | 147 |
| 2252 | Regulation of somatic growth by the p160 coactivator p/CIP. **2000**, 97, 13549-54 | | 168 |

| | | |
|---|---|---|
| 2251 | Fatal attractors: theoretical approaches to tumor differentiation. **2000**, 21, 459-460 | |
| 2250 | The molecular biology of cancer. **2000**, 21, 167-223 | 290 |
| 2249 | Does massively parallel transcriptome analysis signify the end of cancer histopathology as we know it?. **2000**, 1, REVIEWS1021 | 14 |
| 2248 | Tamoxifen resistance in breast cancer: elucidating mechanisms. **2001**, 61, 1721-33 | 72 |
| 2247 | GeneX: An Open Source gene expression database and integrated tool set. **2001**, 40, 552-569 | 22 |
| 2246 | Hypothermia for traumatic brain injury--a good idea proved ineffective. **2001**, 344, 602-3 | 26 |
| 2245 | Characterization of adjacent breast tumors using oligonucleotide microarrays. **2001**, 3, 336-41 | 31 |
| 2244 | Applications of microarray technology in breast cancer research. **2001**, 3, 158-75 | 47 |
| 2243 | More breast cancer genes?. **2001**, 3, 154-7 | 9 |
| 2242 | Molecular profiling of breast cancer: portraits but not physiognomy. **2001**, 3, 77-80 | 28 |
| 2241 | Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. **2001**, 2, RESEARCH0041 | 269 |
| 2240 | Proteomics. Proteomics in genomeland. **2001**, 291, 1221-4 | 196 |
| 2239 | Genomics and medicine. Dissecting human disease in the postgenomic era. **2001**, 291, 1224-9 | 297 |
| 2238 | Gene expression profiling. Methods and clinical applications in oncology. **2001**, 15, 911-30, ix | 17 |
| 2237 | Expression profiling of human tumors: the end of surgical pathology?. **2001**, 3, 92-7 | 22 |
| 2236 | DNA microarrays: an overview of technologies and applications to toxicology. **2001**, Chapter 1, Unit1.4 | 4 |
| 2235 | Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. **2001**, 285, 1244-9 | 67 |
| 2234 | Effects of ischemia on gene expression. **2001**, 99, 222-7 | 122 |

| | | |
|---|---|---|
| 2233 | Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. **2001**, 8, 847-65 | 170 |
| 2232 | Molecular signatures of sepsis: multiorgan gene expression profiles of systemic inflammation. **2001**, 159, 1199-209 | 173 |
| 2231 | Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray. **2001**, 158, 1231-7 | 59 |
| 2230 | Expression profiling of ductal carcinoma in situ by laser capture microdissection and high-density oligonucleotide arrays. **2001**, 158, 2005-10 | 108 |
| 2229 | Pathologic changes after interstitial laser therapy of infiltrating breast carcinoma. **2001**, 182, 384-8 | 53 |
| 2228 | Navigating gene expression using microarrays--a technology review. **2001**, 3, E190-5 | 392 |
| 2227 | Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. **2001**, 98, 10869-74 | 8341 |
| 2226 | Defining a future role for radiogenic therapy. **2001**, 27, 289-94 | 3 |
| 2225 | New molecular targets and biological therapies in sarcomas. **2001**, 27, 317-26 | 19 |
| 2224 | DNA microarray technology in cancer research. **2001**, 27, 504-8 | 31 |
| 2223 | Gene-expression profiles in hereditary breast cancer. **2001**, 344, 539-48 | 1462 |
| 2222 | Gene expression profiling of cancer by use of DNA arrays: how far from the clinic?. **2001**, 2, 674-82 | 56 |
| 2221 | Molecular markers of tumor initiation and progression. **2001**, 11, 60-3 | 5 |
| 2220 | Spotting the target: microarrays for disease gene discovery. **2001**, 11, 258-63 | 46 |
| 2219 | Molecular and pharmacological aspects of antiestrogen resistance. **2001**, 76, 71-84 | 113 |
| 2218 | Stepwise estrogen suppression manipulating the estrostat. **2001**, 79, 127-32 | 16 |
| 2217 | Towards a genomic-based diagnosis. **2001**, 357, 249-50 | 10 |
| 2216 | To blow or not to blow?. **2001**, 357, 250 | 0 |

| | | |
|---|---|---|
| 2215 | National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. **2001**, 93, 979-89 | 578 |
| 2214 | Innovative cancer drug targets: genomics, transcriptomics and clinomics. **2001**, 2, 911-5 | 7 |
| 2213 | Cystic fibrosis and the use of pharmacogenomics to determine surrogate endpoints for drug discovery. **2001**, 1, 223-38 | 8 |
| 2212 | Separation of samples into their constituents using gene expression data. **2001**, 17 Suppl 1, S279-87 | 102 |
| 2211 | Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. **2001**, 98, 13790-5 | 2003 |
| 2210 | Missing value estimation methods for DNA microarrays. **2001**, 17, 520-5 | 2414 |
| 2209 | Gene expression profiling can distinguish tumor subclasses of breast carcinomas. **2001**, 132-161 | 1 |
| 2208 | A streamlined process to phenotypically profile heterologous cDNAs in parallel using yeast cell-based assays. **2001**, 11, 1899-912 | 25 |
| 2207 | Progress in the application of DNA microarrays. **2001**, 109, 881-91 | 49 |
| 2206 | Impact of microarray technologies on cytopathology. Overview of technologies and commentary on current and future implications for pathologists and cytopathologists. **2001**, 45, 111-4 | 6 |
| 2205 | Toxicogenomics: "the call of the wild chip". **2001**, 109, A8-11 | 16 |
| 2204 | Analysis of expression patterns: the scope of the problem, the problem of scope. **2001**, 17, 59-65 | 8 |
| 2203 | Molecular Prognostic Indicators for Breast Cancer. **2001**, 87, 23-25 | 2 |
| 2202 | Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer. **2001**, 54, 281-4 | 11 |
| 2201 | What is Bioinformatics? A Proposed Definition and Overview of the Field. **2001**, 40, 346-358 | 218 |
| 2200 | CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors. **2001**, 22, 229-34 | 53 |
| 2199 | The application of protein microarrays to serum diagnostics: prostate cancer as a test case. **2001**, 17, 225-34 | 32 |
| 2198 | A comparison of gene expression signatures from breast tumors and breast tissue derived cell lines. **2001**, 17, 99-109 | 113 |

| | | |
|---|---|---|
| 2197 | Optimized T7 amplification system for microarray analysis. **2001**, 31, 874-9 | 75 |
| 2196 | Identification of disease-specific genes in chronic pancreatitis using DNA array technology. **2001**, 234, 769-78; discussion 778-9 | 49 |
| 2195 | Quantitative gene expression profiles of human liver-derived cell lines exposed to moderate hypoxia. **2001**, 11, 105-14 | 23 |
| 2194 | Angiogenesis and antiangiogenic approaches to sarcomas. **2001**, 13, 261-9 | 29 |
| 2193 | Recent advances in breast cancer biology. **2001**, 13, 415-9 | 3 |
| 2192 | New approaches to lymphoma diagnosis. **2001**, 2001, 194-220 | 60 |
| 2191 | Biomarker identification by feature wrappers. **2001**, 11, 1878-87 | 202 |
| 2190 | [New strategy on medical research after completion of genome sequencing]. **2001**, 118, 170-6 | 1 |
| 2189 | Microarray analysis of gene expression in human donor corneas. **2001**, 119, 1629-34 | 30 |
| 2188 | Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. **2001**, 11, 1861-70 | 165 |
| 2187 | What is bioinformatics? An introduction and overview. **2001**, 10, 83-100 | 34 |
| 2186 | [The increasing importance of tumor and tissue banks in the light of genomic and proteomic research]. **2001**, 22, 310-5 | 3 |
| 2185 | Recent advances in molecular genetics of breast cancer. **2001**, 79, 566-73 | 15 |
| 2184 | Tumorprofiling durch Microarray-Technologie. **2001**, 7, 1111-1119 | |
| 2183 | Klassische und molekulare Zytogenetik in der Hämatologie und Onkologie. **2001**, 7, 1028-1038 | |
| 2182 | 21st century molecular biology in urology. **2001**, 88, 451-7 | 11 |
| 2181 | DNA microarrays: raising the profile. **2001**, 12, 48-52 | 38 |
| 2180 | New developments in microarray technology. **2001**, 12, 41-7 | 151 |

| | | |
|---|---|---|
| 2179 | Functional genomics and target validation approaches using antisense oligonucleotide technology. **2001**, 12, 622-5 | 69 |
| 2178 | DNA microarrays for expression profiling. **2001**, 5, 21-5 | 62 |
| 2177 | Plant gene expression profiling with DNA microarrays. **2001**, 39, 917-926 | 45 |
| 2176 | Towards a novel classification of human malignancies based on gene expression patterns. **2001**, 195, 41-52 | 230 |
| 2175 | Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. **2001**, 92, 96-105 | 126 |
| 2174 | Analysing gene expression data from DNA microarrays to identify candidate genes. **2001**, 195, 53-65 | 108 |
| 2173 | Association for Molecular Pathology: Sixth annual meeting in Denver, November 9-12, 2000. **2001**, 188, 139-42 | 1 |
| 2172 | Protein functions and biological contexts. **2001**, 1, 169-78 | 82 |
| 2171 | New approaches to proteomic analysis of breast cancer. **2001**, 1, 1205-15 | 186 |
| 2170 | Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. **2001**, 31, 1239-46 | 39 |
| 2169 | Multiclass cancer diagnosis using tumor gene expression signatures. **2001**, 98, 15149-54 | 1540 |
| 2168 | From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. **2001**, 11, 395-401 | 19 |
| 2167 | Molecular profiling in prostate cancer. **2001**, 20, 165-71 | 6 |
| 2166 | Phosphatidylinositol 3' kinase signaling in mammary tumorigenesis. **2001**, 6, 83-99 | 31 |
| 2165 | Molecular genetics of ovarian cancer. **2001**, 19, 13-28 | 2 |
| 2164 | CGH analysis of ductal carcinoma of the breast with basaloid/myoepithelial cell differentiation. **2001**, 85, 422-7 | 113 |
| 2163 | Gene array technology to determine host responses to Salmonella. **2001**, 3, 1353-60 | 27 |
| 2162 | Profiling familial breast cancer. **2001**, 7, 408-10 | 21 |

| | | | |
|---|---|---|---|
| 2161 | Molecular targets for breast cancer therapy and prevention. **2001**, 7, 548-52 | | 235 |
| 2160 | Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. **2001**, 7, 673-9 | | 1928 |
| 2159 | Show me the data!. **2001**, 29, 373 | | 28 |
| 2158 | Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. **2001**, 29, 418-25 | | 807 |
| 2157 | Bioinformatic identification of potential autocrine signaling loops in cancers from gene expression profiles. **2001**, 29, 295-300 | | 93 |
| 2156 | PDGF-C is an EWS/FLI induced transforming growth factor in Ewing family tumors. **2001**, 20, 626-33 | | 104 |
| 2155 | Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. **2001**, 20, 1300-6 | | 96 |
| 2154 | Distinctive gene expression profiles associated with Hepatitis B virus x protein. **2001**, 20, 3674-82 | | 80 |
| 2153 | Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. **2001**, 20, 6196-204 | | 193 |
| 2152 | Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. **2001**, 20, 6617-26 | | 63 |
| 2151 | Gene expression profiles of pancreatic cancer and stromal desmoplasia. **2001**, 20, 7437-46 | | 175 |
| 2150 | At the interfaces of epidemiology, genetics and genomics. **2001**, 2, 142-7 | | 57 |
| 2149 | Microarrays: lost in a storm of data?. **2001**, 2, 441-3 | | 28 |
| 2148 | DNA microarrays and beyond: completing the journey from tissue to cell. **2001**, 3, E175-8 | | 106 |
| 2147 | Http://C. elegans: mining the functional genomic landscape. **2001**, 2, 681-9 | | 20 |
| 2146 | Delineation of prognostic biomarkers in prostate cancer. *Nature*, **2001**, 412, 822-6 | 50.4 | 1402 |
| 2145 | Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. *Nature*, **2001**, 412, 826-31 | 50.4 | 357 |
| 2144 | Cancer genetics: from Boveri and Mendel to microarrays. **2001**, 1, 77-82 | | 79 |

| | | | |
|---|---|---|---|
| 2143 | Microarray and histopathological analysis of tumours: the future and the past?. **2001**, 1, 151-7 | | 100 |
| 2142 | Stem cells, cancer, and cancer stem cells. *Nature*, **2001**, 414, 105-11 | 50.4 | 7504 |
| 2141 | Identification of novel ethanol-sensitive genes by expression profiling. **2001**, 92, 123-34 | | 22 |
| 2140 | FLEXGene repository: from sequenced genomes to gene repositories for high-throughput functional biology and proteomics. **2001**, 118, 155-65 | | 44 |
| 2139 | Ever since Knudson. **2001**, 17, 569-73 | | 90 |
| 2138 | Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. **2001**, 62, 1311-36 | | 167 |
| 2137 | New complexities for BRCA1 and BRCA2. **2001**, 11, R668-76 | | 88 |
| 2136 | DNA-microarrays: novel techniques to study aging and guide gerontologic medicine. **2001**, 36, 1189-98 | | 21 |
| 2135 | Impact of human genome sequencing for in silico target discovery. **2001**, 6, 316-323 | | 18 |
| 2134 | Gene expression and gene therapy in experimental duodenal ulceration. **2001**, 95, 325-35 | | 12 |
| 2133 | Profiling brain transcription: neurons learn a lesson from yeast. **2001**, 11, 615-20 | | 20 |
| 2132 | Genetic programs of epithelial cell plasticity directed by transforming growth factor-beta. **2001**, 98, 6686-91 | | 461 |
| 2131 | Molecular characteristics of non-small cell lung cancer. **2001**, 98, 15203-8 | | 111 |
| 2130 | Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. **2001**, 75, 4283-96 | | 300 |
| 2129 | Microarrays in primary breast cancer--lessons from chemotherapy studies. **2001**, 8, 259-63 | | 30 |
| 2128 | Adjuvant therapy for very young women with breast cancer: need for tailored treatments. **2001**, 44-51 | | 135 |
| 2127 | National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. **2001**, 2001, 5-15 | | 115 |
| 2126 | Who should not receive adjuvant chemotherapy? International databases. **2001**, 103-8 | | 18 |

| | | |
|---|---|---|
| 2125 | Functional genomics, gene arrays, and the future of pathology. **2001**, 14, 1294-9 | 21 |
| 2124 | Genes that co-cluster with estrogen receptor alpha in microarray analysis of breast biopsies. **2001**, 1, 135-41 | 44 |
| 2123 | T-cell-directed cancer vaccines: the melanoma model. **2001**, 1, 277-90 | 29 |
| 2122 | The impact of genomics on the biotechnology industry. **2001**, 1, 749-51 | |
| 2121 | A phosphatase associated with metastasis of colorectal cancer. **2001**, 294, 1343-6 | 539 |
| 2120 | n-CoDeR concept: unique types of antibodies for diagnostic use and therapy. **2001**, 1, 102-8 | 15 |
| 2119 | DNA microarrays in medical practice. **2001**, 323, 611-5 | 59 |
| 2118 | Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features. **2001**, 85, 538-45 | 13 |
| 2117 | Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. **2001**, 98, 9754-9 | 329 |
| 2116 | Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. **2001**, 98, 1124-9 | 242 |
| 2115 | Ceramic capillaries for use in microarray fabrication. **2001**, 11, 1780-3 | 12 |
| 2114 | Comparative expressed sequence hybridization to chromosomes for tumor classification and identification of genomic regions of differential gene expression. **2001**, 98, 9197-202 | 48 |
| 2113 | Genome-wide views of cancer. **2001**, 344, 601-2 | 68 |
| 2112 | Immunology. Chip shots--will functional genomics get functional?. **2001**, 294, 799-801 | 7 |
| 2111 | RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. **2001**, 276, 42259-67 | 120 |
| 2110 | Tamoxifen and contralateral breast cancer: the other side. **2001**, 93, 963-5 | 12 |
| 2109 | The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis. **2001**, 276, 25438-46 | 109 |
| 2108 | Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. **2001**, 21, 575-94 | 211 |

| | | |
|---|---|---|
| 2107 | Molekularbiologische Klassifikation von Hochrisiko-Patientinnen beim primären Mammakarzinom durch Genexpressionsanalysen. **2001**, 61, 954-963 | 1 |
| 2106 | Transcriptional profiling in cancer: the path to clinical pharmacogenomics. **2001**, 2, 123-36 | 27 |
| 2105 | Noninvasive ventilation in immunosuppressed patients. **2001**, 344, 2027-8 | |
| 2104 | Gene-expression profiles in hereditary breast cancer. **2001**, 344, 2028-9 | 25 |
| 2103 | Liver Biopsy. **2001**, 344, 2030-2030 | 24 |
| 2102 | Diagnosis of recurrent astrocytoma with fludeoxyglucose F18 PET scanning. **2001**, 344, 2030-1 | 7 |
| 2101 | Microarrays: spotlight on gene function and pharmacogenomics. **2001**, 1, 155-75 | 16 |
| 2100 | Diversity of gene expression in adenocarcinoma of the lung. **2001**, 98, 13784-9 | 1046 |
| 2099 | Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses. **2002**, 11, 469-81 | 36 |
| 2098 | Identifying and quantifying sources of variation in microarray data using high-density cDNA membrane arrays. **2002**, 9, 655-69 | 37 |
| 2097 | Gene expression in inherited breast cancer. **2002**, 84, 1-34 | 34 |
| 2096 | Lung Cancer. **2002**, | |
| 2095 | Diversity, topographic differentiation, and positional memory in human fibroblasts. **2002**, 99, 12877-82 | 852 |
| 2094 | Mixture modelling of gene expression data from microarray experiments. **2002**, 18, 275-86 | 170 |
| 2093 | Repuncturing the renal biopsy: strategies for molecular diagnosis in nephrology. **2002**, 13, 1961-72 | 47 |
| 2092 | External control of Her2 expression and cancer cell growth by targeting a Ras-linked coactivator. **2002**, 99, 12747-52 | 54 |
| 2091 | A highly reproducible, linear, and automated sample preparation method for DNA microarrays. **2002**, 12, 976-84 | 35 |
| 2090 | Tumor classification by partial least squares using microarray gene expression data. **2002**, 18, 39-50 | 621 |

| | | |
|---|---|---|
| 2089 | A bioinformatic strategy to rapidly characterize cDNA libraries. **2002**, 18, 949-52 | 14 |
| 2088 | Initiating oncogenic event determines gene-expression patterns of human breast cancer models. **2002**, 99, 6967-72 | 175 |
| 2087 | Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. **2002**, 99, 10008-13 | 215 |
| 2086 | Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. **2002**, 99, 10335-40 | 284 |
| 2085 | Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. **2002**, 99, 2830-5 | 80 |
| 2084 | Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. **2002**, 99, 12963-8 | 980 |
| 2083 | Deriving quantitative conclusions from microarray expression data. **2002**, 18, 961-70 | 50 |
| 2082 | Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. **2002**, 20, 2319-26 | 69 |
| 2081 | Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. **2002**, 86, 1457-64 | 53 |
| 2080 | Molecular classification of selective oestrogen receptor modulators on the basis of gene expression profiles of breast cancer cells expressing oestrogen receptor alpha. **2002**, 87, 449-56 | 23 |
| 2079 | Molecular classification of primary breast tumors possessing distinct prognostic properties. **2002**, 11, 199-206 | 46 |
| 2078 | Analysis of repeatability in spotted cDNA microarrays. **2002**, 30, 3235-44 | 41 |
| 2077 | Prediction of compound signature using high density gene expression profiling. **2002**, 67, 232-40 | 202 |
| 2076 | The impact of chip technology on cancer medicine. **2002**, 13 Suppl 4, 109-13 | 4 |
| 2075 | Unsupervised technique for robust target separation and analysis of DNA microarray spots through adaptive pixel clustering. **2002**, 18, 747-56 | 85 |
| 2074 | Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. **2002**, 11, 863-72 | 90 |
| 2073 | Phospholipase A2 group IIA expression in gastric adenocarcinoma is associated with prolonged survival and less frequent metastasis. **2002**, 99, 16203-8 | 134 |
| 2072 | Nuclear matrix proteins as biomarkers for breast cancer. **2002**, 2, 23-31 | 19 |

| | | |
|---|---|---|
| 2071 | Yellow pages to the transcriptome. **2002**, 3, 791-807 | 24 |
| 2070 | Influence of unrecognized molecular heterogeneity on randomized clinical trials. **2002**, 20, 2495-9 | 143 |
| 2069 | Analyzing array data using supervised methods. **2002**, 3, 403-15 | 59 |
| 2068 | In Situ Gene Expression Analysis of Cancer Using Laser Capture Microdissection, Microarrays and Real Time Quantitative PCR. **2002**, 1, 353-357 | 17 |
| 2067 | Amplified RNA for gene array hybridizations. **2002**, 193, 227-36 | 1 |
| 2066 | The emergence of resistance to targeted cancer therapeutics. **2002**, 3, 603-23 | 21 |
| 2065 | Pharmacogenomics and personalised medicine. SMI Conference on Pharmacogenomics and Personalised Medicine, 26-28 September, 2001, The Hatton, London, UK. **2002**, 3, 166-71 | 12 |
| 2064 | Molecular signatures of breast cancer--predicting the future. **2002**, 347, 2067-8 | 22 |
| 2063 | DNA arrays as diagnostic tools in human healthcare. **2002**, 2, 422-8 | 4 |
| 2062 | Multiparameter analyses of cell cycle regulatory proteins in human breast cancer: a key to definition of separate pathways in tumorigenesis. **2002**, 84, 35-56 | 15 |
| 2061 | Chromatin (dis)organization and cancer: BUR-binding proteins as biomarkers for cancer. **2002**, 2, 157-90 | 36 |
| 2060 | An international database and integrated analysis tools for the study of cancer gene expression. **2002**, 2, 156-64 | 29 |
| 2059 | Chapter 23. Tumor classification for tailored cancer therapy. **2002**, 37, 225-236 | |
| 2058 | Identification of genes periodically expressed in the human cell cycle and their expression in tumors. **2002**, 13, 1977-2000 | 1043 |
| 2057 | Microarray studies of gene expression in circulating leukocytes in kidney diseases. **2002**, 10, 139-49 | 40 |
| 2056 | Hormonal genomics. **2002**, 23, 369-81 | 18 |
| 2055 | Large-scale gene expression analysis in molecular target discovery. **2002**, 16, 473-7 | 38 |
| 2054 | The impact of genomic and proteomic technologies on the development of new cancer drugs. **2002** , 13 Suppl 4, 115-24 | 15 |

| | | |
|---|---|---|
| 2053 | alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. **2002**, 287, 1662-70 | 489 |
| 2052 | Partial least squares proportional hazard regression for application to DNA microarray survival data. **2002**, 18, 1625-32 | 282 |
| 2051 | Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. **2002**, 23, 1713-20 | 86 |
| 2050 | An assessment of Motorola CodeLink microarray performance for gene expression profiling applications. **2002**, 30, e30 | 146 |
| 2049 | A protein disulfide isomerase expressed in the embryonic midline is required for left/right asymmetries. **2002**, 16, 2518-29 | 31 |
| 2048 | cDNA microarray profiling of rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 7,12-dimethylbenz[a]anthracene. **2002**, 23, 1561-8 | 44 |
| 2047 | DQ 65-79, a peptide derived from HLA class II, induces I kappa B expression. **2002**, 168, 3323-8 | 5 |
| 2046 | Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. **2002**, 23, 311-5 | 44 |
| 2045 | Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. **2002**, 94, 990-1000 | 223 |
| 2044 | BRCA1 transcriptionally regulates genes involved in breast tumorigenesis. **2002**, 99, 7560-5 | 201 |
| 2043 | Large-scale analysis of gene expression profiles. **2002**, 3, 7-17 | 3 |
| 2042 | In vivo regulation of human skeletal muscle gene expression by thyroid hormone. **2002**, 12, 281-91 | 124 |
| 2041 | Fully automatic quantification of microarray image data. **2002**, 12, 325-32 | 255 |
| 2040 | Transcript profiling of functionally related groups of genes during conditional differentiation of a mammalian cochlear hair cell line. **2002**, 12, 1091-9 | 47 |
| 2039 | DNA microarrays: implications for cardiovascular medicine. **2002**, 91, 559-64 | 55 |
| 2038 | A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. **2002**, 11, 1977-85 | 52 |
| 2037 | TTF-1 expression in pulmonary adenocarcinomas. **2002**, 26, 767-73 | 307 |
| 2036 | Gene-expression profiles in hereditary breast cancer. **2002**, 9, 1-6 | 4 |

| | | |
|---|---|---|
| 2035 | Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. **2002**, 8, 461-8 | 75 |
| 2034 | Microarray analysis in prostate cancer research. **2002**, 12, 395-9 | 21 |
| 2033 | DNA microarrays: a bridge between genome sequence information and biological understanding. **2002**, 10, 389-408 | 3 |
| 2032 | Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. **2002**, 99, 282-9 | 124 |
| 2031 | Applications for microarrays in renal biology and medicine. **2002**, 10, 93-101 | 10 |
| 2030 | Detection of genes expressed in primary colon cancers by in situ hybridisation: overexpression of RACK 1. **2002**, 55, 34-9 | 25 |
| 2029 | DNA Microarrays Technology. **2002**, 1, 49-55 | |
| 2028 | Immunohistochemical Localization of Neuropilin-1 in Human Breast Carcinoma. **2002**, 1, 409-414 | |
| 2027 | Immunohistochemical Expression of Cytosolic Thymidine Kinase in Patients with Breast Carcinoma. **2002**, 463-469 | |
| 2026 | Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. **2002**, 15, 1374-80 | 135 |
| 2025 | Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. **2002**, 9, 280-9 | 84 |
| 2024 | Molecular techniques for studying gene expression in carcinogenesis. **2002**, 20, 77-116 | 31 |
| 2023 | Gene expression profiling of lymphoid malignancies. **2002**, 53, 303-18 | 101 |
| 2022 | Differential gene expression patterns in HER2/neu-positive and -negative breast cancer cell lines and tissues. **2002**, 161, 1171-85 | 91 |
| 2021 | Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. **2002**, 161, 1557-65 | 180 |
| 2020 | Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. **2002**, 161, 1587-95 | 160 |
| 2019 | Genes involved in breast cancer progression: analysis of global changes in gene expression or retroviral tagging?. **2002**, 161, 1973-7 | 2 |
| 2018 | Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. **2002**, 161, 1991-6 | 453 |

| | | |
|---|---|---|
| 2017 | Quantitative assessment of promoter hypermethylation during breast cancer development. **2002**, 160, 605-12 | 191 |
| 2016 | Profiling gene expression using onto-express. **2002**, 79, 266-70 | 398 |
| 2015 | Expression of cytokine- and chemokine-related genes in peripheral blood mononuclear cells from lupus patients by cDNA array. **2002**, 102, 283-90 | 88 |
| 2014 | Insights from gene arrays on the development and growth regulation of uterine leiomyomata. **2002** , 78, 114-21 | 166 |
| 2013 | Genomics Applications That Facilitate the Understanding of Drug Action and Toxicity. 83-125 | 2 |
| 2012 | Microarrays in pharmacogenomics--advances and future promise. **2002**, 3, 589-601 | 37 |
| 2011 | Artificial neural networks distinguish among subtypes of neoplastic colorectal lesions. **2002**, 122, 606-13 | 100 |
| 2010 | A gene-expression signature as a predictor of survival in breast cancer. **2002**, 347, 1999-2009 | 5020 |
| 2009 | Algorithms in Bioinformatics. **2002**, | 3 |
| 2008 | RT-PCR Protocols. **2002**, | 11 |
| 2007 | Expression profiling to predict outcome in breast cancer: the influence of sample selection. **2003**, 5, 23-6 | 32 |
| 2006 | The importance of being a myoepithelial cell. **2002**, 4, 224-30 | 113 |
| 2005 | Within the fold: assessing differential expression measures and reproducibility in microarray assays. **2002**, 3, research0062 | 147 |
| 2004 | Have microarrays failed to deliver for developmental biology?. **2002**, 3, comment2009 | 11 |
| 2003 | Transcriptional programs activated by exposure of human prostate cancer cells to androgen. **2002**, 3, RESEARCH0032 | 140 |
| 2002 | Physical mapping of genes in somatic cell radiation hybrids by comparative genomic hybridization to cDNA microarrays. **2002**, 3, RESEARCH0026 | 5 |
| 2001 | Microarray profile of differentially expressed genes in a monkey model of allergic asthma. **2002**, 3, research0020 | 62 |
| 2000 | Microarrays and molecular markers for tumor classification. **2002**, 3, comment2005 | 12 |

| | | |
|---|---|---|
| 1999 | Vector algebra in the analysis of genome-wide expression data. **2002**, 3, RESEARCH0011 | 36 |
| 1998 | Rules for making human tumor cells. **2002**, 347, 1593-603 | 750 |
| 1997 | Early detection of pancreatic carcinoma. **2002**, 16, 37-52 | 109 |
| 1996 | Extreme self-organization in networks constructed from gene expression data. **2002**, 89, 268702 | 52 |
| 1995 | Perspective: microarray technology, seeing more than spots. **2002**, 143, 1983-9 | 43 |
| 1994 | In silico approaches to microarray-based disease classification and gene function discovery. **2002**, 34, 299-305 | 5 |
| 1993 | Gene expression patterns in human liver cancers. **2002**, 13, 1929-39 | 680 |
| 1992 | Strong feature sets from small samples. **2002**, 9, 127-46 | 68 |
| 1991 | Mechanisms of disease. **2002**, 359, 2-3 | 1 |
| 1990 | Identification of high risk breast-cancer patients by gene expression profiling. **2002**, 359, 131-2 | 163 |
| 1989 | Molecular characterisation of soft tissue tumours: a gene expression study. **2002**, 359, 1301-7 | 484 |
| 1988 | Gene-expression profiling to classify soft-tissue sarcomas. **2002**, 359, 1263-4 | 7 |
| 1987 | Gene expression profiling of cell lines derived from T-cell malignancies. **2002**, 522, 183-8 | 18 |
| 1986 | Interactive gene expression pattern in prostate cancer cells exposed to phenolic antioxidants. **2002**, 70, 1821-39 | 41 |
| 1985 | Dimension reduction strategies for analyzing global gene expression data with a response. **2002**, 176, 123-44 | 58 |
| 1984 | Expression profiles of 109 apoptosis pathway-related genes in 82 mouse tissues and experimental conditions. **2002**, 297, 537-44 | 7 |
| 1983 | Classifying toxicity and pathology by gene-expression profile--taking a lead from studies in neoplasia. **2002**, 23, 388-93 | 13 |
| 1982 | Gene expression phenotype in heterozygous carriers of ataxia telangiectasia. **2002**, 71, 791-800 | 44 |

| | | |
|---|---|---|
| 1981 | Impact of the Human Genome Project on the clinical management of sporadic cancers. **2002**, 3, 349-56 | 11 |
| 1980 | Applications of microarrays in the pharmaceutical industry. **2002**, 2, 551-4 | 18 |
| 1979 | The promise of biomarkers in cancer screening and detection. **2002**, 8, 288-93 | 82 |
| 1978 | Gene Expression Patterns in Breast Cancer May Identify Specific Tumor Phenotypes and Predict Disease Outcome. **2002**, 3, 240-242 | |
| 1977 | The fabric of cancer cell biology-Weaving together the strands. **2002**, 1, 3-10 | 44 |
| 1976 | Functional genomics and the breast cancer problem. **2002**, 1, 15-7 | 17 |
| 1975 | Cancer genomics. **2002**, 1, 37-47 | 51 |
| 1974 | Gene expression correlates of clinical prostate cancer behavior. **2002**, 1, 203-9 | 1829 |
| 1973 | Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report. **2002**, 38, 1730-8 | 15 |
| 1972 | Understanding cancer as a formless phenomenon. **2002**, 59, 68-75 | 9 |
| 1971 | Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. **2002**, 184, 197-206 | 56 |
| 1970 | Mining the National Cancer Institute's tumor-screening database: identification of compounds with similar cellular activities. **2002**, 45, 818-40 | 119 |
| 1969 | Exploring genetic regulatory networks in metazoan development: methods and models. **2002**, 10, 131-43 | 24 |
| 1968 | Microarray analysis of B-cell lymphoma cell lines with the t(14;18). **2002**, 4, 123-36 | 19 |
| 1967 | Insulin-like growth factor-1 inscribes a gene expression profile for angiogenic factors and cancer progression in breast epithelial cells. **2002**, 4, 204-17 | 48 |
| 1966 | Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. **2002**, 4, 30-6 | 38 |
| 1965 | Transcript array analysis in rheumatology. **2002**, 28, 151-76, vii-viii | |
| 1964 | Microarrays as cancer keys: an array of possibilities. **2002**, 20, 3165-75 | 102 |

| | | |
|---|---|---|
| 1963 | Application of a Multigene Reverse Transcription-PCR Assay for Detection of Mammaglobin and Complementary Transcribed Genes in Breast Cancer Lymph Nodes. **2002**, 48, 1225-1231 | 47 |
| 1962 | Application of Microarrays to the Analysis of Gene Expression in Cancer. **2002**, 48, 1170-1177 | 116 |
| 1961 | Gene Expression Profiling as a Tool for the Identification of Molecular Targets. **2002**, 1, S17-S20 | 1 |
| 1960 | Tumor Microenvironment: What have we Learned Studying the Immune Response in this Puzzling Battlefield?. **2002**, 88, 437-444 | 4 |
| 1959 | The implications of microarray technology for animal use in scientific research. **2002**, 30, 459-65 | 6 |
| 1958 | Use of RNA and genomic DNA references for inferred comparisons in DNA microarray analyses. **2002**, 33, 924-30 | 34 |
| 1957 | Prospects. **2002**, 407-410 | |
| 1956 | Recent advances and dilemmas in the radiotherapeutic management of locally advanced non-small cell lung cancer. **2003**, 75, 489-505 | |
| 1955 | Molecular profiling in prostate cancer. **2002**, 29-35 | |
| 1954 | DNA microarrays in clinical oncology. **2002**, 20, 1932-41 | 283 |
| 1953 | Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. **2002**, 23, 139-45 | 49 |
| 1952 | Automatic quantitation of hybridization signals on cDNA arrays. **2002**, 32, 1386-8, 1390, 1392, 1394, 1396-7 | 5 |
| 1951 | Analysis of multiple gene expression array experiments after repetitive hybridizations on nylon membranes. **2002**, 33, 108, 110, 112-3, passim | 4 |
| 1950 | Variations in cell surfaces of estrogen treated breast cancer cells detected by a combined instrument for far-field and near-field microscopy. **2002**, 24, 89-100 | 8 |
| 1949 | The role of SSeCKS/Gravin/AKAP12 scaffolding proteins in the spaciotemporal control of signaling pathways in oncogenesis and development. **2002**, 7, d1782 | 35 |
| 1948 | The progressing clinical utility of DNA microarrays. **2002**, 52, 50-9 | 16 |
| 1947 | Clustering of the SOM easily reveals distinct gene expression patterns: results of a reanalysis of lymphoma study. **2002**, 3, 36 | 84 |
| 1946 | Optimization and evaluation of T7 based RNA linear amplification protocols for cDNA microarray analysis. **2002**, 3, 31 | 105 |

| | | |
|---|---|---|
| 1945 | Challenges in developing a molecular characterization of cancer. **2002**, 29, 280-5 | 9 |
| 1944 | Differential gene expression in renal-cell cancer. **2002**, 140, 52-64 | 46 |
| 1943 | Gene expression profiling diagnosis through DNA molecular computation. **2002**, 20, 137-40 | 11 |
| 1942 | Factor analysis of cluster-specific gene expression levels from cDNA microarrays. **2002**, 69, 179-88 | 28 |
| 1941 | DNA microarrays for malaria. **2002**, 18, 39-45 | 50 |
| 1940 | Optimal gene expression analysis by microarrays. **2002**, 2, 353-61 | 128 |
| 1939 | The organizing principle: microenvironmental influences in the normal and malignant breast. **2002**, 70, 537-46 | 473 |
| 1938 | BRCA1 methylation: a significant role in tumour development?. **2002**, 12, 359-371 | 92 |
| 1937 | Unravelling novel intracellular pathways in cell-based assays. **2002**, 7, 179-86 | 25 |
| 1936 | News in brief. **2002**, 7, 93-97 | |
| 1935 | Gene expression profiling by DNA microarrays and its application to dental research. **2002**, 38, 650-6 | 9 |
| 1934 | Applying genomics technologies to neural development. **2002**, 12, 110-4 | 13 |
| 1933 | Fabrication of Carbohydrate Chips for Studying Proteinâ□arbohydrate Interactions. **2002**, 114, 3312-3314 | 23 |
| 1932 | Fabrication of carbohydrate chips for studying protein-carbohydrate interactions. **2002**, 41, 3180-2 | 231 |
| 1931 | Expression profiling in transformed human B cells: influence of Btk mutations and comparison to B cell lymphomas using filter and oligonucleotide arrays. **2002**, 32, 982-93 | 23 |
| 1930 | Cytogenetics and molecular genetics of bladder cancer: a personal view. **2002**, 115, 173-82 | 32 |
| 1929 | Chromosome and gene alterations in breast cancer as markers for diagnosis and prognosis as well as pathogenetic targets for therapy. **2002**, 115, 142-9 | 18 |
| 1928 | Proteomic analysis of human prostate cancer. **2002**, 33, 9-15 | 111 |

| | | |
|---|---|---|
| 1927 | Gene expression profiles: creating new perspectives in arthritis research. **2002**, 46, 874-84 | 21 |
| 1926 | Zipf's law in importance of genes for cancer classification using microarray data. **2002**, 219, 539-51 | 42 |
| 1925 | Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2. **2002**, 98, 205-9 | 35 |
| 1924 | Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. **2002**, 98, 883-8 | 79 |
| 1923 | Differential gene expression in breast cancer cell lines and stroma-tumor differences in microdissected breast cancer biopsies revealed by display array analysis. **2002**, 100, 172-80 | 27 |
| 1922 | Understanding cancer metastasis: an urgent need for using differential gene expression analysis. **2002**, 94, 1821-9 | 49 |
| 1921 | Quantitative examination of mechanophysical tumor cell enrichment in fine-needle aspiration specimens. **2002**, 96, 275-9 | 9 |
| 1920 | Using mRNA expression profiling to determine anticancer drug efficacy. **2002**, 47, 66-71 | 20 |
| 1919 | Plant functional genomics. **2002**, 89, 235-49 | 100 |
| 1918 | Genes involved in breast cancer metastasis to bone. **2002**, 59, 1491-502 | 54 |
| 1917 | Molecular characterization of breast cancer cell lines by expression profiling. **2002**, 128, 125-34 | 16 |
| 1916 | DNA microarrays: a new diagnostic tool and its implications in colorectal cancer. **2002**, 17, 131-6 | 25 |
| 1915 | Clinical and functional target validation using tissue and cell microarrays. **2002**, 6, 97-101 | 35 |
| 1914 | Modular design of artificial transcription factors. **2002**, 6, 765-72 | 89 |
| 1913 | Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: role in vasculogenic mimicry. **2002**, 44, 17-27 | 119 |
| 1912 | Symposium 15: Expression and profiling in surgical pathology. **2002**, 41, 249-262 | 0 |
| 1911 | Quantitative assessment of the use of modified nucleoside triphosphates in expression profiling: differential effects on signal intensities and impacts on expression ratios. **2002**, 2, 14 | 3 |
| 1910 | The transcriptional response of human macrophages to murabutide reflects a spectrum of biological effects for the synthetic immunomodulator. **2002**, 128, 474-82 | 11 |

| | | |
|---|---|---|
| 1909 | Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. **2002**, 32, 207-17 | 46 |
| 1908 | Targeting molecular mechanisms in cancer. **2002**, 72, 760-3 | 1 |
| 1907 | Analysis and visualization of gene expression data using self-organizing maps. **2002**, 15, 953-66 | 107 |
| 1906 | Transcription and alternative splicing of telomerase reverse transcriptase in benign and malignant breast tumours and in adjacent mammary glandular tissues: implications for telomerase activity. **2002**, 198, 37-46 | 29 |
| 1905 | Global gene expression profiling in Barrett's esophagus and esophageal cancer: a comparative analysis using cDNA microarrays. **2002**, 21, 475-8 | 104 |
| 1904 | Novel estrogen and tamoxifen induced genes identified by SAGE (Serial Analysis of Gene Expression). **2002**, 21, 836-43 | 95 |
| 1903 | The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. **2002**, 21, 2768-73 | 157 |
| 1902 | Identification, using cDNA macroarray analysis, of distinct gene expression profiles associated with pathological and virological features of hepatocellular carcinoma. **2002**, 21, 2926-37 | 90 |
| 1901 | Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. **2002**, 21, 3095-102 | 77 |
| 1900 | Reactivating the expression of methylation silenced genes in human cancer. **2002**, 21, 5496-503 | 220 |
| 1899 | Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. **2002**, 21, 4855-62 | 124 |
| 1898 | NATH, a novel gene overexpressed in papillary thyroid carcinomas. **2002**, 21, 5056-68 | 46 |
| 1897 | Comprehensive analysis of the gene expression profiles in human gastric cancer cell lines. **2002**, 21, 6549-56 | 51 |
| 1896 | Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. **2002**, 21, 7593-7 | 68 |
| 1895 | Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential. **2002**, 21, 8310-9 | 29 |
| 1894 | Application of genome-wide gene expression profiling by high-density DNA arrays to the treatment and study of inflammatory bowel disease. **2002**, 8, 140-57 | 16 |
| 1893 | Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept. **2002**, 82, 737-46 | 223 |
| 1892 | Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. **2002**, 82, 1525-33 | 194 |

| | | | |
|---|---|---|---|
| 1891 | The molecular outlook. *Nature*, **2002**, 415, 484-5 | 50.4 | 76 |
| 1890 | Gene expression profiling predicts clinical outcome of breast cancer. *Nature*, **2002**, 415, 530-6 | 50.4 | 7432 |
| 1889 | Molecular portraits and the family tree of cancer. **2002**, 32 Suppl, 533-40 | | 223 |
| 1888 | The microarray way to tailored cancer treatment. **2002**, 8, 13-4 | | 41 |
| 1887 | Endocrine-responsive breast cancer and strategies for combating resistance. **2002**, 2, 101-12 | | 665 |
| 1886 | Modelling the molecular circuitry of cancer. **2002**, 2, 331-41 | | 759 |
| 1885 | Transcription factors as targets for cancer therapy. **2002**, 2, 740-9 | | 941 |
| 1884 | Candidate-gene approaches for studying complex genetic traits: practical considerations. **2002**, 3, 391-7 | | 763 |
| 1883 | Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aim. **2002**, 86, 1093-6 | | 22 |
| 1882 | Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. **2002**, 87, 1105-11 | | 50 |
| 1881 | Mechanisms of action of estrogen and progesterone. **2002**, 955, 48-59; discussion 86-8, 396-406 | | 63 |
| 1880 | Single-nucleotide polymorphism analysis by hybridization protection assay on solid support. **2002**, 307, 25-32 | | 13 |
| 1879 | Associations between gene expressions in breast cancer and patient survival. **2002**, 111, 411-20 | | 72 |
| 1878 | The greater impact of menopause on ER- than ER+ breast cancer incidence: a possible explanation (United States). **2002**, 13, 7-14 | | 52 |
| 1877 | Ductal carcinoma in situ of the breast: a new phenotype classification system and its relation to prognosis. **2002**, 73, 215-21 | | 14 |
| 1876 | Molecular Portrait of Human Kidney Carcinomas: The cDNA Microarray Profiling of Kinases and Phosphatases Involved in the Cell Signaling Control. **2002**, 36, 376-384 | | 5 |
| 1875 | Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. **2002**, 74, 199-211 | | 87 |
| 1874 | Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. **2002**, 76, 27-36 | | 408 |

| | | |
|---|---|---|
| 1873 | Expression profiling with oligonucleotide arrays: technologies and applications for neurobiology. **2002**, 27, 1005-26 | 8 |
| 1872 | Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. **2002**, 35, 1134-43 | 92 |
| 1871 | NF-kappaB and breast cancer. **2002**, 26, 282-309 | 57 |
| 1870 | Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer?. **2002**, 198, 795-801 | 32 |
| 1869 | Feasibility of global gene expression analysis in testicular biopsies from infertile men. **2003**, 66, 403-21 | 41 |
| 1868 | Expression profiling of breast cancer cells by differential peptide display. **2003**, 79, 83-93 | 32 |
| 1867 | Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. **2003**, 82, 113-23 | 56 |
| 1866 | Expression profiling of human breast cancers and gene regulation by progesterone receptors. **2003**, 8, 257-68 | 44 |
| 1865 | Interrogating mouse mammary cancer models: insights from gene expression profiling. **2003**, 8, 321-34 | 10 |
| 1864 | Laser capture microdissection and advanced molecular analysis of human breast cancer. **2003**, 8, 335-45 | 37 |
| 1863 | Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. **2003**, 442, 271-7 | 110 |
| 1862 | Overexpression of a novel imprinted gene,PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. **2003**, 10, 625-635 | 5 |
| 1861 | The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. **2003**, 52, 253-61 | 18 |
| 1860 | Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. **2003**, 81, 536-48 | 111 |
| 1859 | Analyzing tumor gene expression profiles. **2003**, 28, 59-74 | 32 |
| 1858 | Evolving connectionist systems for knowledge discovery from gene expression data of cancer tissue. **2003**, 28, 165-89 | 48 |
| 1857 | Profiling cancer. **2003**, 15, 213-20 | 12 |
| 1856 | Histopathology of primary breast cancer 2003. **2003**, 12, 391-6 | 8 |

| | | |
|---|---|---|
| 1855 | Best use of adjuvant systemic therapies II, chemotherapy aspects: dose of chemotherapy-cytotoxicity, duration and responsiveness. **2003**, 12, 529-37 | 7 |
| 1854 | Tailoring adjuvant treatments for the individual breast cancer patient. **2003**, 12, 558-68 | 18 |
| 1853 | Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. **2003**, 3, 173-83 | 353 |
| 1852 | Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. **2003**, 4, 41-53 | 70 |
| 1851 | Fulfilling the promise: drug discovery in the post-genomic era. **2003**, 8, 168-74 | 88 |
| 1850 | Molecular techniques and prostate cancer diagnostic. **2003**, 44, 390-400 | 9 |
| 1849 | Epidemiology, cancer genetics and microarrays: making correct inferences, using appropriate designs. **2003**, 19, 690-5 | 40 |
| 1848 | Neural network analysis of lymphoma microarray data: prognosis and diagnosis near-perfect. **2003**, 4, 13 | 54 |
| 1847 | Expression profiling of blood samples from an SU5416 Phase III metastatic colorectal cancer clinical trial: a novel strategy for biomarker identification. **2003**, 3, 3 | 73 |
| 1846 | Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer. **2003**, 12, 569-82 | 30 |
| 1845 | Developmental noise, ageing and cancer. **2003**, 124, 711-20 | 14 |
| 1844 | Partitioning large-sample microarray-based gene expression profiles using principal components analysis. **2003**, 70, 107-19 | 34 |
| 1843 | Genealogy, expression, and cellular function of transforming growth factor-beta. **2003**, 98, 257-65 | 184 |
| 1842 | Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study. **2003**, 141, 148-53 | 11 |
| 1841 | From the top down: towards a predictive biology of signalling networks. **2003**, 21, 290-3 | 53 |
| 1840 | Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples. **2003**, 99, 172-9 | 35 |
| 1839 | Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. **2003**, 97, 2960-71 | 157 |
| 1838 | TP53 and breast cancer. **2003**, 21, 292-300 | 226 |

| | | |
|---|---|---|
| 1837 | Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system. **2003**, 104, 550-8 | 94 |
| 1836 | Breast cell invasive potential relates to the myoepithelial phenotype. **2003**, 106, 8-16 | 106 |
| 1835 | Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. **2003**, 106, 745-51 | 109 |
| 1834 | Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. **2003**, 107, 317-22 | 22 |
| 1833 | Gene expression profiling of tumor xenografts: In vivo analysis of organ-specific metastasis. **2003**, 107, 528-34 | 45 |
| 1832 | Protein-Mikroarray-Technologie â Prinzipien und neuere Entwicklungen. **2003**, 115, 510-517 | 31 |
| 1831 | Recent developments in protein microarray technology. **2003**, 42, 494-500 | 259 |
| 1830 | Validation of consensus between proteomic and clinical chemistry datasets by applying a new randomisation F-test for generalised procrustes analysis. **2003**, 490, 365-378 | 5 |
| 1829 | Expression profiles in the progression of ductal carcinoma in the breast. **2003**, 27, 115-20 | 4 |
| 1828 | Gene expression analysis on small numbers of invasive cells collected by chemotaxis from primary mammary tumors of the mouse. **2003**, 3, 13 | 34 |
| 1827 | Examination of tumour histopathology and gene expression in a neu/S100A4 transgenic model of metastatic breast cancer. **2003**, 84, 173-84 | 6 |
| 1826 | Altered mRNA expression in renal biopsy tissue from patients with IgA nephropathy. **2003**, 64, 1253-64 | 16 |
| 1825 | Use of a cDNA microarray to determine molecular mechanisms involved in grey platelet syndrome. **2003**, 122, 142-9 | 12 |
| 1824 | Regulation of human breast epithelial stem cells. **2003**, 36 Suppl 1, 45-58 | 93 |
| 1823 | Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept. **2003**, 36 Suppl 1, 73-84 | 106 |
| 1822 | Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. **2003**, 3, 1720-4 | 111 |
| 1821 | Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. **2003**, 3, 2085-90 | 215 |
| 1820 | Generation of bioreagents for protein chips. **2003**, 3, 2123-34 | 41 |

| | | | |
|---|---|---|---|
| 1819 | Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. **2003**, 3, 413-21 | | 163 |
| 1818 | The zinc finger protein OZF (ZNF146) is overexpressed in colorectal cancer. **2003**, 200, 177-82 | | 14 |
| 1817 | Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. **2003**, 201, 63-74 | | 148 |
| 1816 | WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. **2003**, 201, 204-12 | | 286 |
| 1815 | Ubiquitin-immunoreactive degradation products of cytokeratin 8/18 correlate with aggressive breast cancer. **2003**, 94, 864-70 | | 23 |
| 1814 | Molecular classification of synovial sarcomas, leiomyosarcomas and malignant fibrous histiocytomas by gene expression profiling. **2003**, 88, 510-5 | | 75 |
| 1813 | Disease proteomics. *Nature*, **2003**, 422, 226-32 | 50.4 | 845 |
| 1812 | BARCODE-ALL: accelerated and cost-effective genetic risk stratification in acute leukemia using spectrally addressable liquid bead microarrays. **2003**, 17, 1404-10 | | 20 |
| 1811 | Identification of molecular subtypes of glioblastoma by gene expression profiling. **2003**, 22, 2361-73 | | 226 |
| 1810 | cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. **2003**, 22, 2680-8 | | 131 |
| 1809 | Gene-expression profiling in human cutaneous melanoma. **2003**, 22, 3076-80 | | 97 |
| 1808 | Metastatic lymph node 64 (MLN64), a gene overexpressed in breast cancers, is regulated by Sp/KLF transcription factors. **2003**, 22, 3770-80 | | 23 |
| 1807 | Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach. **2003**, 22, 4287-300 | | 62 |
| 1806 | Gene expression profiling identifies molecular subtypes of gliomas. **2003**, 22, 4918-23 | | 241 |
| 1805 | Axis of evil: molecular mechanisms of cancer metastasis. **2003**, 22, 6524-36 | | 479 |
| 1804 | Biologic and therapeutic role of HER2 in cancer. **2003**, 22, 6570-8 | | 304 |
| 1803 | Advantages and limitations of microarray technology in human cancer. **2003**, 22, 6497-507 | | 204 |
| 1802 | Expression profiling of epithelial plasticity in tumor progression. **2003**, 22, 7155-69 | | 249 |

| | | |
|---|---|---|
| 1801 | Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. **2003**, 22, 7316-39 | 370 |
| 1800 | Analysis of gene expression in carbon tetrachloride-treated rat livers using a novel bioarray technology. **2003**, 3, 41-52 | 14 |
| 1799 | Class struggle: expression profiling and categorizing cancer. **2003**, 3, 257-60 | 7 |
| 1798 | Gene expression in brain: a window on ethanol dependence, neuroadaptation, and preference. **2003**, 27, 155-68 | 32 |
| 1797 | A molecular signature of metastasis in primary solid tumors. **2003**, 33, 49-54 | 1973 |
| 1796 | Identifying distinct classes of bladder carcinoma using microarrays. **2003**, 33, 90-6 | 401 |
| 1795 | Predicting the future of breast cancer. **2003**, 9, 16-8 | 18 |
| 1794 | Myelin management. **2003**, 9, 18-18 | |
| 1793 | Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. **2003**, 9, 416-23 | 701 |
| 1792 | SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. **2003**, 9, 900-6 | 398 |
| 1791 | Applying the principles of stem-cell biology to cancer. **2003**, 3, 895-902 | 1329 |
| 1790 | Remodeling of the microenvironment by aggressive melanoma tumor cells. **2003**, 995, 151-61 | 93 |
| 1789 | Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. **2003**, 21, 3357-65 | 573 |
| 1788 | Application of microarray technology in environmental and comparative physiology. **2003**, 65, 231-59 | 141 |
| 1787 | Comparing genomic and histologic correlations to radiographic changes in tumors: a murine SCC VII model study. **2003**, 10, 1165-75 | 19 |
| 1786 | Microarray analysis in the clinical management of cancer. **2003**, 17, 377-87 | 14 |
| 1785 | Cancer diagnosis using proteomic patterns. **2003**, 3, 411-20 | 128 |
| 1784 | Cancer pharmacogenomics: SNPs, chips, and the individual patient. **2003**, 21, 630-40 | 50 |

| | | |
|---|---|---|
| 1783 | Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics. **2003**, 3, 635-47 | 32 |
| 1782 | Protein expression profiling arrays: tools for the multiplexed high-throughput analysis of proteins. **2003**, 1, 3 | 29 |
| 1781 | From peas to "chips" - the new millennium of molecular biology: a primer for the surgeon. **2003**, 1, 21 | 3 |
| 1780 | Prognostic and predictive indicators in operable breast cancer. **2003**, 3, 381-90 | 28 |
| 1779 | Targeting the transcriptional machinery with unique artificial transcriptional activators. **2003**, 125, 12390-1 | 31 |
| 1778 | Multiple mutations and cancer. **2003**, 100, 776-81 | 557 |
| 1777 | Comparison of fluorescence and resonance light scattering for highly sensitive microarray detection of bacterial pathogens. **2003**, 55, 755-62 | 41 |
| 1776 | Tissue microarray study for classification of breast tumors. **2003**, 73, 3189-99 | 31 |
| 1775 | Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. **2003**, 163, 1449-56 | 123 |
| 1774 | Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. **2003**, 163, 1979-84 | 79 |
| 1773 | Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. **2003**, 163, 2009-19 | 50 |
| 1772 | Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. **2003**, 163, 2383-95 | 115 |
| 1771 | Identification of novel cellular targets in biliary tract cancers using global gene expression technology. **2003**, 163, 217-29 | 106 |
| 1770 | Expression profiling of mouse endometrial cancers microdissected from ethanol-fixed, paraffin-embedded tissues. **2003**, 162, 755-62 | 29 |
| 1769 | Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. **2003**, 162, 925-32 | 216 |
| 1768 | Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. **2003**, 202, 219-30 | 106 |
| 1767 | Gene expression profiling of breast carcinomas using nylon DNA arrays. **2003**, 326, 1031-9 | 3 |
| 1766 | Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both?. **2003**, 113, 821-3 | 139 |

| | | |
|---|---|---|
| 1765 | A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. **2003**, 114, 323-34 | 353 |
| 1764 | Gene expression predictors of breast cancer outcomes. **2003**, 361, 1590-6 | 509 |
| 1763 | DNA microarrays in breast cancer: the promise of personalised medicine. **2003**, 361, 1576-7 | 47 |
| 1762 | Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. **2003**, 362, 362-9 | 708 |
| 1761 | Differentially expressed genes in gastric tumors identified by cDNA array. **2003**, 190, 199-211 | 22 |
| 1760 | Common malignancy-associated regions of transcriptional activation (MARTA) in human prostate, breast, ovarian, and colon cancers are targets for DNA amplification. **2003**, 201, 67-77 | 17 |
| 1759 | Glycosyltransferase expression in human colonic tissue examined by oligonucleotide arrays. **2003**, 1621, 272-9 | 24 |
| 1758 | Genetic chaos and antichaos in human cancers. **2003**, 60, 258-62 | 20 |
| 1757 | Repeated observation of breast tumor subtypes in independent gene expression data sets. **2003**, 100, 8418-23 | 4262 |
| 1756 | Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. **2003**, 95, 1482-5 | 737 |
| 1755 | Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. **2003**, 349, 125-38 | 583 |
| 1754 | Classification of cancers by expression profiling. **2003**, 13, 97-103 | 50 |
| 1753 | Genomics and proteomics in cancer. **2003**, 39, 1199-215 | 76 |
| 1752 | Small RNAs: a new class of genome regulators and their significance. **2003**, 29, 764-5 | 3 |
| 1751 | Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. **2003**, 30, 256-68 | 1507 |
| 1750 | Global functional profiling of gene expression. **2003**, 81, 98-104 | 479 |
| 1749 | Cancer diagnosis and microarrays. **2003**, 35, 119-24 | 30 |
| 1748 | Study of suboptimum treatment response: lessons from breast cancer. **2003**, 4, 177-85 | 49 |

1747 Classifying human cancer by analysis of gene expression. **2003**, 9, 5-10 21

1746 Gene Expression Profiling to Predict Outcome of Chemotherapy for Early-Stage Breast Cancer. **2003**, 4, 176-178

1745 Functional genomics and proteomics in control of breathing. **2003**, 135, 231-8 4

1744 Comparison between aromatase inhibitors and sequential use. **2003**, 86, 275-82 7

1743 Use of expression analysis to predict outcome after radical prostatectomy. **2003**, 170, S11-9; discussion S19-20 17

1742 Malignancy-associated regions of transcriptional activation: gene expression profiling identifies common chromosomal regions of a recurrent transcriptional activation in human prostate, breast, ovarian, and colon cancers. **2003**, 5, 218-28 26

1741 Microarrays bring new insights into understanding of breast cancer metastasis to bone. **2004**, 6, 61-4 31

1740 Models of breast cancer: quo vadis, animal modeling?. **2004**, 6, 31-8 49

1739 The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. **2003**, 5, 320-8 18

1738 Expression profiling of breast cancer, influence of tumor genotype and patient genotype. **2003**, 5, 1 78

1737 Differential gene-expression patterns in genital fibroblasts of normal males and 46,XY females with androgen insensitivity syndrome: evidence for early programming involving the androgen receptor. **2003**, 4, R37 35

1736 MicroSAGE is highly representative and reproducible but reveals major differences in gene expression among samples obtained from similar tissues. **2003**, 4, R17 29

1735 Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data. **2003**, 4, R21 50

1734 Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. **2003**, 60, 1180-99 107

1733 Looking beyond morphology: cancer gene expression profiling using DNA microarrays. **2003**, 21, 937-49 38

1732 Functional Genomics. **2003**, 4

1731 Regulating gene expression using optimal control theory.

1730 PATHOGENESIS OF RESPIRATORY DISEASES: NEW SOLUTIONS TO OLD PROBLEMS?. **2003**, 29, 3-92

| | | |
|---|---|---|
| 1729 | Breast cancer classification and prognosis based on gene expression profiles from a population-based study. **2003**, 100, 10393-8 | 1562 |
| 1728 | New algorithms for multi-class cancer diagnosis using tumor gene expression signatures. **2003**, 19, 1800-7 | 28 |
| 1727 | Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. **2003**, 144, 4562-74 | 806 |
| 1726 | Clinical application of cDNA microarrays in oncology. **2003**, 8, 252-8 | 64 |
| 1725 | Elucidation of molecular targets of mammary cancer chemoprevention in the rat by organoselenium compounds using cDNA microarray. **2003**, 24, 1505-14 | 31 |
| 1724 | IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. **2003**, 171, 6714-22 | 75 |
| 1723 | Using gene expression ratios to predict outcome among patients with mesothelioma. **2003**, 95, 598-605 | 151 |
| 1722 | Hereditary breast-ovarian cancer at the bedside: role of the medical oncologist. **2003**, 21, 740-53 | 51 |
| 1721 | Gene expression profiles of primary breast tumors maintained in distant metastases. **2003**, 100, 15901-5 | 367 |
| 1720 | Profiling the global tyrosine phosphorylation state. **2003**, 2, 215-33 | 66 |
| 1719 | Proteomics in the postgenomic age. **2003**, 65, 1-23 | 11 |
| 1718 | Fluorescent labelling of cRNA for microarray applications. **2003**, 31, e20 | 78 |
| 1717 | Ligand-independent activation of estrogen receptor alpha by XBP-1. **2003**, 31, 5266-74 | 102 |
| 1716 | Clustering-based approaches to discovering and visualising microarray data patterns. **2003**, 4, 31-42 | 19 |
| 1715 | Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. **2003**, 2, 242-7 | 51 |
| 1714 | Variation in gene expression patterns in human gastric cancers. **2003**, 14, 3208-15 | 253 |
| 1713 | A classification-based machine learning approach for the analysis of genome-wide expression data. **2003**, 13, 503-12 | 35 |
| 1712 | Transcriptional profiling of medulloblastoma in children. **2003**, 99, 534-41 | 32 |

| | | |
|---|---|---|
| 1711 | Variation in gene expression patterns in follicular lymphoma and the response to rituximab. **2003**, 100, 1926-30 | 128 |
| 1710 | Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. **2003**, 100, 15853-8 | 451 |
| 1709 | A neural survival factor is a candidate oncogene in breast cancer. **2003**, 100, 10931-6 | 100 |
| 1708 | EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. **2003**, 100, 11606-11 | 1295 |
| 1707 | Evolving Connectionist Systems. **2003**, | 46 |
| 1706 | Coupled two-way clustering analysis of breast cancer and colon cancer gene expression data. **2003**, 19, 1079-89 | 54 |
| 1705 | Controlling false-negative errors in microarray differential expression analysis: a PRIM approach. **2003**, 19, 1808-16 | 94 |
| 1704 | Statistical significance analysis of longitudinal gene expression data. **2003**, 19, 1628-35 | 32 |
| 1703 | Molecular phenotyping of the immune system by microarray analysis. **2003**, 21, 293-303 | 4 |
| 1702 | Salivary gland-like tumours of the breast: surgical and molecular pathology. **2003**, 56, 497-506 | 139 |
| 1701 | Purified malignant mammary epithelial cells maintain hormone responsiveness in culture. **2003**, 88, 1071-6 | 15 |
| 1700 | Epstein-Barr virus gene expression in human breast cancer: protagonist or passenger?. **2003**, 89, 113-9 | 52 |
| 1699 | Gene Selection and Sample Classification Using a Genetic Algorithm and k-Nearest Neighbor Method. **2003**, 216-229 | 4 |
| 1698 | Gene expression array profile of human osteosarcoma. **2003**, 89, 2284-8 | 28 |
| 1697 | A Bayesian missing value estimation method for gene expression profile data. **2003**, 19, 2088-96 | 471 |
| 1696 | Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. **2003**, 100, 13350-5 | 557 |
| 1695 | Transcriptional network controlled by the trithorax-group gene ash2 in Drosophila melanogaster. **2003**, 100, 3293-8 | 19 |
| 1694 | Molecular classification of familial non-BRCA1/BRCA2 breast cancer. **2003**, 100, 2532-7 | 157 |

| | | |
|---|---|---|
| 1693 | Microarray analysis using amplified mRNA from laser capture microdissection of microscopic hepatocellular precancerous lesions and frozen hepatocellular carcinomas reveals unique and consistent gene expression profiles. **2003**, 31, 295-303 | 21 |
| 1692 | Extending the utility of gene profiling data by bridging microarray platforms. **2003**, 100, 10585-7 | 12 |
| 1691 | Genomewide view of gene silencing by small interfering RNAs. **2003**, 100, 6343-6 | 249 |
| 1690 | The interacting binding domains of the beta(4) integrin and calcium-activated chloride channels (CLCAs) in metastasis. **2003**, 278, 49406-16 | 46 |
| 1689 | Gene expression patterns in ovarian carcinomas. **2003**, 14, 4376-86 | 273 |
| 1688 | The application of rule-based methods to class prediction problems in genomics. **2003**, 10, 689-98 | 4 |
| 1687 | Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles in vitro. **2003**, 100, 9608-13 | 166 |
| 1686 | In Reply:. **2003**, 21, 3180-3180 | |
| 1685 | Discovery of the breast cancer gene BASE using a molecular approach to enrich for genes encoding membrane and secreted proteins. **2003**, 100, 1099-104 | 47 |
| 1684 | The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. **2003**, 21, 3683-95 | 99 |
| 1683 | Spurious spatial periodicity of co-expression in microarray data due to printing design. **2003**, 31, 4425-33 | 32 |
| 1682 | Genomic strategies for diabetic nephropathy. **2003**, 14, S271-8 | 36 |
| 1681 | Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. **2003**, 21, 3469-78 | 387 |
| 1680 | DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. **2003**, 278, 51673-84 | 109 |
| 1679 | Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. **2003**, 10, 625-35 | 47 |
| 1678 | Microarray standard data set and figures of merit for comparing data processing methods and experiment designs. **2003**, 19, 956-65 | 76 |
| 1677 | Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. **2003**, 95, 661-8 | 220 |
| 1676 | HIN-1 and the nosology of breast cancer. **2003**, 2, 564-5 | 1 |

| | | |
|---|---|---|
| 1675 | Cyclin D1 and molecular chaperones: implications for tumorigenesis. **2003**, 2, 525-7 | 26 |
| 1674 | Differentially expressed genes and estrogen receptor status in breast cancer. **2003**, 23, 1425 | |
| 1673 | Microarray analysis in drug discovery: an uplifting view of depression. **2003**, 2003, pe46 | 3 |
| 1672 | SEP: score for expression profile-a novel method for predicting clinical outcome in breast cancer. | 1 |
| 1671 | Overview of bioinformatics and its application to oral genomics. **2003**, 17, 89-94 | 13 |
| 1670 | DNA microarrays and development. **2003**, 12 Spec No 1, R1-8 | 39 |
| 1669 | High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. **2003**, 349, 7-16 | 217 |
| 1668 | Functional genomics guided with MR imaging: mouse tumor model study. **2003**, 228, 560-8 | 20 |
| 1667 | Parallel analysis of gene copy number and expression using cDNA microarrays. **2003**, 224, 89-97 | 1 |
| 1666 | Differential expression, class discovery and class prediction using S-PLUS and S+ArrayAnalyzer. **2003**, 5, 38-47 | 2 |
| 1665 | Probabilistic neural networks for multi-class tissue discrimination with gene expression data. | |
| 1664 | Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast. **2003**, 11, 1-8 | 78 |
| 1663 | Tissue-specific gene expression of head and neck squamous cell carcinoma in vivo by complementary DNA microarray analysis. **2003**, 129, 760-70 | 43 |
| 1662 | Clustering Genomic Expression Data: Design and Evaluation Principles. **2003**, 230-245 | 2 |
| 1661 | Molecular classification of breast carcinomas using tissue microarrays. **2003**, 12, 27-34 | 142 |
| 1660 | CHIPing soft tissue tumors: will the paradigms be changed?. **2003**, 10, 1-7 | 4 |
| 1659 | Gene-expression profiles and breast-cancer prognosis. **2003**, 10, 338-46 | 1 |
| 1658 | Liquid-based pap smears as a source of RNA for gene expression analysis. **2003**, 11, 345-51 | 4 |

| | | |
|---|---|---|
| 1657 | Global Functional Profiling of Gene Expression Data. **2003**, 306-325 | 4 |
| 1656 | Missing Value Estimation. **2003**, 65-75 | 1 |
| 1655 | . **2003**, 11, 1-8 | 26 |
| 1654 | Advances in Pituitary Pathology. **2003**, 13, 347-350 | |
| 1653 | Pathology of Interstitial Laser Therapy of the Breast. **2003**, 8, 111-114 | |
| 1652 | II, 9.Microarrays and host-virus interactions: A transcriptional analysis of Caco-2 cells following rotavirus infection. **2003**, 9, 255-289 | |
| 1651 | Clinical trial methods to discover and validate predictive markers for treatment response in cancer. **2003**, 9, 259-67 | 14 |
| 1650 | Identification of endothelial cell genes by combined database mining and microarray analysis. **2003**, 13, 249-62 | 99 |
| 1649 | Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. **2003**, 101, 4998-5006 | 109 |
| 1648 | Reconstructing gene networks: what are the limits?. **2003**, 31, 1519-25 | 18 |
| 1647 | An assessment of MMP and TIMP gene expression in cell lines and stroma - tumour differences in microdissected breast cancer biopsies. **2003**, 24, 258-70 | 13 |
| 1646 | Demystified...tissue microarray technology. **2003**, 56, 198-204 | 93 |
| 1645 | Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas. **2003**, 56, 318-22 | 48 |
| 1644 | Microarrays in Cancer: Research and Applications. **2003**, 34, S4-S15 | 29 |
| 1643 | Gene Expression Analysis Using Microarrays. 269-286 | |
| 1642 | Molecular Characterization of Breast Cancer Aggressiveness. **2003**, 18, 36-39 | |
| 1641 | Genetic Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility. **2003**, 18, 54-56 | 2 |
| 1640 | . **2003**, | 3 |

| | | |
|---|---|---|
| 1639 | Application of DNA Microarray Technology to Clinical Biopsies of Breast Cancer. **2003**, 257-275 | |
| 1638 | Argon laser photocoagulation-induced modification of gene expression in the retina. **2003**, 44, 1426-34 | 65 |
| 1637 | Validation of cDNA microarray gene expression data obtained from linearly amplified RNA. **2003**, 56, 307-12 | 48 |
| 1636 | Systems Toxicology and the Chemical Effects in Biological Systems (CEBS) Knowledge Base. **2003**, 111, 811-812 | 58 |
| 1635 | Integration of genomic technologies for accelerated cancer drug development. **2003**, 35, 580-2, 584, 586 passim | 15 |
| 1634 | Microarray-Based Cancer Diagnosis with Artificial Neural Networks. **2003**, 34, S30-S35 | 28 |
| 1633 | Open Source Software for the Analysis of Microarray Data. **2003**, 34, S45-S51 | 172 |
| 1632 | Signaling Protein Networks as Targets of New Antineoplastic Drugs. **2003**, 18, 57-61 | 2 |
| 1631 | Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. **2004**, 112, 1607-13 | 12 |
| 1630 | Universal mouse reference RNA derived from neonatal mice. **2004**, 37, 464-8 | 11 |
| 1629 | . **2004**, | 4 |
| 1628 | Novel technologies and recent advances in metastasis research. **2004**, 48, 573-81 | 27 |
| 1627 | Microarray Analysis of Stem Cells and Differentiation. **2004**, 643-650 | 1 |
| 1626 | Genomic approaches to understanding and treating breast cancer. **2004**, 19, 35-46 | 4 |
| 1625 | Advances in pituitary pathology: use of novel techniques. **2004**, 32, 146-74 | 11 |
| 1624 | Gene expression profiling in breast cancer research. **2004**, 19, 23-7 | 1 |
| 1623 | The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems. **2004**, 4, 1327-1343 | 27 |
| 1622 | Analysis of DNA microarray data. **2004**, 4, 1357-70 | 22 |

| | | |
|---|---|---|
| 1621 | Fishing in the bloodstream: insights into the mechanisms of pulmonary hypertension?. **2004**, 170, 827-8 | 6 |
| 1620 | Microarray analysis of human nervous system gene expression in neurological disease. **2004**, 60, 135-51 | 1 |
| 1619 | Adjustment of systematic microarray data biases. **2004**, 20, 105-14 | 313 |
| 1618 | Novel strategies in cancer therapeutics: targeting enzymes involved in cell cycle regulation and cellular proliferation. **2004**, 4, 403-24 | 19 |
| 1617 | Hematopoietic Growth Factors in Oncology. **2004**, | |
| 1616 | Prognostic and predictive factors. **2004**, 97, 1-11 | 5 |
| 1615 | Classification of cDNA array genes that have a highly significant discriminative power due to their unique distribution in four brain regions. **2004**, 23, 661-74 | 4 |
| 1614 | Principles of Molecular Oncology. **2004**, | 6 |
| 1613 | Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer. **2004**, 10, 708-17 | 90 |
| 1612 | Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. **2004**, 10, 981-7 | 183 |
| 1611 | Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. **2004**, 10, 6418-31 | 53 |
| 1610 | Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. **2004**, 64, 3525-32 | 103 |
| 1609 | DNA amplification method tolerant to sample degradation. **2004**, 14, 2357-66 | 73 |
| 1608 | Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. **2004**, 15, 2523-36 | 488 |
| 1607 | Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. **2004**, 64, 844-56 | 190 |
| 1606 | Evaluation of quality-control criteria for microarray gene expression analysis. **2004**, 50, 1994-2002 | 92 |
| 1605 | Array comparative genomic hybridization analysis of genomic alterations in breast cancer subtypes. **2004**, 64, 8541-9 | 187 |
| 1604 | Histopathology Specimens. **2004**, | 37 |

| | | |
|---|---|---|
| 1603 | Lessons from genetic profiling in soft tissue sarcomas. **2004**, 75, 35-50 | 8 |
| 1602 | Ductal carcinoma in situ, complexities and challenges. **2004**, 96, 906-20 | 291 |
| 1601 | A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. **2004**, 32, 719-75 | 74 |
| 1600 | Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. **2004**, 64, 3807-13 | 284 |
| 1599 | RESPONSE: Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer. **2004** , 96, 714-714 | 1 |
| 1598 | Application of toxicogenomics to toxicology: basic concepts in the analysis of microarray data. **2004** , 32 Suppl 1, 72-83 | 73 |
| 1597 | DNA array-based gene profiling in tumor immunology. **2004**, 10, 4597-606 | 24 |
| 1596 | Genomic DNA as a cohybridization standard for mammalian microarray measurements. **2004**, 32, e81 | 30 |
| 1595 | Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. **2004**, 64, 3037-45 | 208 |
| 1594 | A gene expression signature associated with metastatic outcome in human leiomyosarcomas. **2004**, 64, 7201-4 | 65 |
| 1593 | Gesamt-Genom-Microarray-Analyse und Target-Validierung mittels qPCR / Whole genome microarray analysis and target validation by using qPCR. **2004**, 28, 215-224 | |
| 1592 | A molecular signature of the Nottingham prognostic index in breast cancer. **2004**, 64, 2962-8 | 55 |
| 1591 | Gene expression in the normal adult human kidney assessed by complementary DNA microarray. **2004**, 15, 649-56 | 90 |
| 1590 | Re: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. **2004**, 96, 1040-1; author reply 1041 | 2 |
| 1589 | Cell-type-specific responses to chemotherapeutics in breast cancer. **2004**, 64, 4218-26 | 307 |
| 1588 | Classification of human breast cancer using gene expression profiling as a component of the survival predictor algorithm. **2004**, 10, 2272-83 | 58 |
| 1587 | Molecular cytogenetic identification of subgroups of grade III invasive ductal breast carcinomas with different clinical outcomes. **2004**, 10, 5988-97 | 121 |
| 1586 | Discovery and immunologic validation of new antigens for therapeutic cancer vaccines. **2004**, 133, 179-97 | 17 |

| | | |
|---|---|---|
| 1585 | Reliability of t7-based mRNA linear amplification validated by gene expression analysis of human kidney cells using cDNA microarrays. **2004**, 97, e86-95 | 22 |
| 1584 | Identification and validation of cell surface antigens for antibody targeting in oncology. **2004**, 11, 659-87 | 91 |
| 1583 | Design of a real time quantitative PCR assay to assess global mRNA amplification of small size specimens for microarray hybridisation. **2004**, 57, 1278-87 | 4 |
| 1582 | BRCA1 functions as a breast stem cell regulator. **2004**, 41, 1-5 | 122 |
| 1581 | Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. **2004**, 96, 516-23 | 81 |
| 1580 | Quantitative assessment of a novel flow-through porous microarray for the rapid analysis of gene expression profiles. **2004**, 32, e123 | 40 |
| 1579 | Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. **2004**, 101, 8431-6 | 174 |
| 1578 | The host response to smallpox: analysis of the gene expression program in peripheral blood cells in a nonhuman primate model. **2004**, 101, 15190-5 | 93 |
| 1577 | Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. **2004**, 22, 691-8 | 65 |
| 1576 | Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. **2004**, 64, 7279-87 | 28 |
| 1575 | MYC is amplified in BRCA1-associated breast cancers. **2004**, 10, 499-507 | 71 |
| 1574 | Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. **2004**, 101, 18147-52 | 90 |
| 1573 | Finding the bEST routes to cancer. **2004**, 3, 1090-1 | 7 |
| 1572 | Gene expression profiling of human cutaneous melanoma: are we there yet?. **2004**, 3, 121-3 | 9 |
| 1571 | Tissue microarrays: a current medical research tool. **2004**, 20, 707-12 | 55 |
| 1570 | Using microarrays to predict resistance to chemotherapy in cancer patients. **2004**, 5, 611-25 | 13 |
| 1569 | LSimpute: accurate estimation of missing values in microarray data with least squares methods. **2004**, 32, e34 | 227 |
| 1568 | Molecular Diagnosis of Cancer. **2004**, | 1 |

| | | |
|---|---|---|
| 1567 | Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. **2004**, 64, 8558-65 | 155 |
| 1566 | Selective gene expression in magnocellular neurons in rat supraoptic nucleus. **2004**, 24, 7174-85 | 33 |
| 1565 | Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. **2004**, 24, 8681-90 | 136 |
| 1564 | Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. **2004**, 10, 5508-17 | 98 |
| 1563 | Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. **2004**, 24, 3992-4003 | 260 |
| 1562 | The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. **2004**, 101, 4158-63 | 267 |
| 1561 | Oncogene expression and genetic background influence the frequency of DNA copy number abnormalities in mouse pancreatic islet cell carcinomas. **2004**, 64, 2406-10 | 24 |
| 1560 | Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer. **2004**, 10, 5546-53 | 61 |
| 1559 | NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. **2004**, 101, 10137-42 | 367 |
| 1558 | Survivin is an independent prognostic marker for risk stratification of breast cancer patients. **2004**, 50, 1986-93 | 106 |
| 1557 | Microarrays in veterinary diagnostics. **2004**, 5, 249-55 | 9 |
| 1556 | Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. **2004**, 64, 1522-33 | 279 |
| 1555 | Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. **2004**, 10, 2776-83 | 40 |
| 1554 | Coexpression analysis of human genes across many microarray data sets. **2004**, 14, 1085-94 | 571 |
| 1553 | Differential gene-expression profiles associated with gastric adenoma. **2004**, 90, 216-23 | 23 |
| 1552 | Cellular responses to ErbB-2 overexpression in human mammary luminal epithelial cells: comparison of mRNA and protein expression. **2004**, 90, 173-81 | 37 |
| 1551 | Metagenes and molecular pattern discovery using matrix factorization. **2004**, 101, 4164-9 | 1178 |
| 1550 | Identification of transcriptional biomarkers induced by SERMS in human endometrial cells using multivariate analysis of DNA microarrays. **2004**, 9, 447-60 | 2 |

| | | |
|---|---|---|
| 1549 | Antisense Therapeutics. **2004**, | 1 |
| 1548 | Gold nanoparticle probe-based gene expression analysis with unamplified total human RNA. **2004**, 32, e137 | 73 |
| 1547 | Profiling Breast Cancer Using Real-Time Quantitative PCR. **2004**, 95-106 | 1 |
| 1546 | A versatile assay for high-throughput gene expression profiling on universal array matrices. **2004**, 14, 878-85 | 151 |
| 1545 | Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. **2004**, 2, E7 | 698 |
| 1544 | Genomics and proteomics: expression arrays in clinical oncology. **2004**, 15 Suppl 4, iv163-5 | 4 |
| 1543 | High lib mRNA expression in breast carcinomas. **2004**, 11, 199-203 | 13 |
| 1542 | Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. **2004**, 96, 712-4; author reply 714 | 28 |
| 1541 | D' j^vu for breast cancer two?. **2004**, 96, 497-9 | 3 |
| 1540 | Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. **2004**, 96, 712-3; author reply 714 | 63 |
| 1539 | RNA expression microarrays (REMs), a high-throughput method to measure differences in gene expression in diverse biological samples. **2004**, 32, e120 | 9 |
| 1538 | Impact of microarray technology in clinical oncology. **2004**, 22, 312-20 | 23 |
| 1537 | Abstracts BCI Conference 2004. **2004**, 64, 317-441 | 0 |
| 1536 | Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray. **2004**, 95, 218-25 | 181 |
| 1535 | Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. **2004**, 95, 496-502 | 68 |
| 1534 | Low expression of the putative tumour suppressor gene gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. **2004**, 126, 508-11 | 10 |
| 1533 | Gene expression fingerprints in human tubulointerstitial inflammation and fibrosis as prognostic markers of disease progression. **2004**, 65, 904-17 | 68 |
| 1532 | Gene expression signatures in chronic and aggressive periodontitis: a pilot study. **2004**, 112, 216-23 | 31 |

| | | |
|---|---|---|
| 1531 | Gene expression profiling of in vivo UVB-irradiated human epidermis. **2004**, 20, 129-37 | 30 |
| 1530 | Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. **2004**, 6, 507-14 | 471 |
| 1529 | Molecular determinants of resistance to antiandrogen therapy. **2004**, 10, 33-9 | 1874 |
| 1528 | Dissecting the metastatic cascade. **2004**, 4, 448-56 | 1026 |
| 1527 | BRCA1 and BRCA2: 1994 and beyond. **2004**, 4, 665-76 | 694 |
| 1526 | Hallmarks of 'BRCAness' in sporadic cancers. **2004**, 4, 814-9 | 1268 |
| 1525 | DNA microarray allows molecular profiling of rheumatoid arthritis and identification of pathophysiological targets. **2004**, 5, 597-608 | 78 |
| 1524 | Expression of activated M-Ras in a murine mammary epithelial cell line induces epithelial-mesenchymal transition and tumorigenesis. **2004**, 23, 1187-96 | 32 |
| 1523 | Identification and validation of an ERBB2 gene expression signature in breast cancers. **2004**, 23, 2564-75 | 101 |
| 1522 | Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. **2004**, 23, 4041-9 | 48 |
| 1521 | Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. **2004**, 23, 4930-7 | 63 |
| 1520 | A multigene expression panel for the molecular diagnosis of Barrett's esophagus and Barrett's adenocarcinoma of the esophagus. **2004**, 23, 4780-8 | 61 |
| 1519 | Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. **2004**, 23, 5360-70 | 120 |
| 1518 | Mutation of GATA3 in human breast tumors. **2004**, 23, 7669-78 | 209 |
| 1517 | Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. **2004**, 23, 7780-90 | 121 |
| 1516 | DNA-microarray analysis of brain cancer: molecular classification for therapy. **2004**, 5, 782-92 | 166 |
| 1515 | Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry. **2004**, 90, 1422-8 | 30 |
| 1514 | Molecular profiling of breast cancer: clinical implications. **2004**, 90, 1120-4 | 77 |

| | | | |
|---|---|---|---|
| 1513 | Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function. **2004**, 84, 353-61 | | 114 |
| 1512 | cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. **2004**, 84, 320-31 | | 57 |
| 1511 | Molecular genetics of human prostate cancer. **2004**, 17, 380-8 | | 34 |
| 1510 | Different proliferative activity of the glandular and myoepithelial lineages in benign proliferative and early malignant breast diseases. **2004**, 17, 1051-61 | | 44 |
| 1509 | Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. **2004**, 17, 756-64 | | 28 |
| 1508 | Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. *Nature*, **2004**, 429, 629-35 | 50.4 | 431 |
| 1507 | Pharmacogenetics in the treatment of breast cancer. **2004**, 4, 143-53 | | 48 |
| 1506 | Alterations in gene expression in cadaveric vs. live donor kidneys suggest impaired tubular counterbalance of oxidative stress at implantation. **2004**, 4, 1595-604 | | 45 |
| 1505 | Genomic approaches in cancer biology. **2004**, 136, 511-8 | | 3 |
| 1504 | Application of microarray profiling to clinical trials in cancer. **2004**, 136, 519-23 | | 13 |
| 1503 | Characterization of sarcomas by means of gene expression. **2004**, 144, 78-91 | | 34 |
| 1502 | Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. **2004**, 5, 489-500 | | 516 |
| 1501 | Apoptosis in cancer--implications for therapy. **2004**, 31, 90-119 | | 120 |
| 1500 | Therapeutic targeting in the estrogen receptor hormonal pathway. **2004**, 31, 28-38 | | 81 |
| 1499 | Targeting the HER-kinase axis in cancer. **2004**, 31, 9-20 | | 53 |
| 1498 | Improving patient care through molecular diagnostics. **2004**, 31, 14-20 | | 21 |
| 1497 | ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. **2004**, 92, 31-9 | | 84 |
| 1496 | Gene expression profiling in human endometrial cancer tissue samples: utility and diagnostic value. **2004**, 93, 292-300 | | 13 |

| | | |
|---|---|---|
| 1495 | Tests for finding complex patterns of differential expression in cancers: towards individualized medicine. **2004**, 5, 110 | 34 |
| 1494 | Cancer characterization and feature set extraction by discriminative margin clustering. **2004**, 5, 21 | 23 |
| 1493 | Multiclass discovery in array data. **2004**, 5, 70 | 9 |
| 1492 | A comparative analysis of data generated using two different target preparation methods for hybridization to high-density oligonucleotide microarrays. **2004**, 5, 2 | 36 |
| 1491 | Universal Reference RNA as a standard for microarray experiments. **2004**, 5, 20 | 124 |
| 1490 | CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. **2004**, 4, 73 | 164 |
| 1489 | Preoperative chemotherapy and endocrine therapy in patients with breast cancer. **2004**, 5, 198-207 | 5 |
| 1488 | Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. **2004**, 5, 364-9 | 12 |
| 1487 | A primer on gene expression and microarrays for machine learning researchers. **2004**, 37, 293-303 | 24 |
| 1486 | Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. **2004**, 154, 63-6 | 47 |
| 1485 | Relevance of breast cancer cell lines as models for breast tumours: an update. **2004**, 83, 249-89 | 602 |
| 1484 | The genetic epidemiology of breast cancer genes. **2004**, 9, 221-36 | 174 |
| 1483 | High density peptide microarrays. In situ synthesis and applications. **2004**, 8, 177-87 | 33 |
| 1482 | Overview of commonly used bioinformatics methods and their applications. **2004**, 1020, 10-21 | 53 |
| 1481 | Data-driven computer simulation of human cancer cell. **2004**, 1020, 132-53 | 76 |
| 1480 | Traitement adjuvant du cancer du sein, aujourdâ‰ui et demain: « Carte » ou « Menu »?. **2004**, 6, 99-106 | |
| 1479 | The impact of progesterone receptor in prediction of complete pathological response to preoperative chemotherapy in primary breast cancer patients. **2004**, 36, 46-48 | |
| 1478 | Gene expression profiling in breast cancer: from molecular portraits to personalized medicine. **2004**, 6, 192-202 | 1 |

| | | |
|---|---|---|
| 1477 | Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. **2004**, 328, 101-8 | 74 |
| 1476 | In situ hybridization in the pathology laboratory: general principles, automation, and emerging research applications for tissue-based studies of gene expression. **2004**, 35, 595-601 | 9 |
| 1475 | Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. **2004**, 9, 297-310 | 115 |
| 1474 | [Microarrays]. **2004**, 43, 653-8 | 4 |
| 1473 | Biomolecular features of clinical relevance in breast cancer. **2004**, 31 Suppl 1, S3-14 | 8 |
| 1472 | Role of HER2/neu in tumor progression and therapy. **2004**, 61, 2965-78 | 110 |
| 1471 | Statistics in clinical trials. **2004**, 6, 36-41 | 3 |
| 1470 | Controlling the number of false discoveries: application to high-dimensional genomic data. **2004**, 124, 379-398 | 172 |
| 1469 | Distribution and significance of 14-3-3sigma, a novel myoepithelial marker, in normal, benign, and malignant breast tissue. **2004**, 202, 274-85 | 60 |
| 1468 | Expression of luminal and basal cytokeratins in human breast carcinoma. **2004**, 203, 661-71 | 442 |
| 1467 | Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. **2004**, 204, 65-74 | 81 |
| 1466 | Gene expression profiling for prognosis using Cox regression. **2004**, 23, 1767-80 | 22 |
| 1465 | Polyamides as artificial transcription factors: novel tools for molecular medicine?. **2004**, 43, 2472-5 | 17 |
| 1464 | In situ synthesis of oligonucleotide microarrays. **2004**, 73, 579-96 | 178 |
| 1463 | Polyamide als artifizielle Transkriptionsfaktoren: neue Hilfsmittel der molekularen Medizin?. **2004**, 116, 2526-2529 | 3 |
| 1462 | Systematic multiplex polymerase chain reaction and reverse transcription-polymerase chain reaction analyses of changes in copy number and expression of proto-oncogenes and tumor suppressor genes in cancer tissues and cell lines. **2004**, 25, 3349-56 | 5 |
| 1461 | Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. **2004**, 39, 518-27 | 111 |
| 1460 | A new way to look at liver cancer. **2004**, 40, 521-3 | 8 |

| | | |
|---|---|---|
| 1459 | Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. **2004**, 101, 379-84 | 53 |
| 1458 | Getting the right cells to the array: Gene expression microarray analysis of cell mixtures and sorted cells. **2004**, 59, 191-202 | 54 |
| 1457 | Resolution of cellular physiology by genomic expression signature analysis: Bridging the content gap between in vitro and in vivo drug development. **2004**, 62, 119-123 | |
| 1456 | Expression genomics and cancer drug development. **2004**, 62, 295-302 | 2 |
| 1455 | Translating the Genome into individualized therapeutics. **2004**, 62, 371-382 | 5 |
| 1454 | Gene expression profiles in breast tumors regarding the presence or absence of estrogen and progesterone receptors. **2004**, 111, 892-9 | 20 |
| 1453 | Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes. **2004**, 200, 440-50 | 39 |
| 1452 | Optimized procedures for microarray analysis of histological specimens processed by laser capture microdissection. **2004**, 201, 366-73 | 22 |
| 1451 | Use of RNA amplification in the optimal characterization of global gene expression using cDNA microarrays. **2004**, 201, 359-65 | 13 |
| 1450 | Mapping phenotypic landscapes using DNA micro-arrays. **2004**, 6, 177-85 | 10 |
| 1449 | Comparison of microarray-based mRNA profiling technologies for identification of psychiatric disease and drug signatures. **2004**, 138, 173-88 | 46 |
| 1448 | Finding their groove; bifunctional molecules arrest growth of cancer cells. **2004**, 11, 1480-2 | 2 |
| 1447 | State of the science: molecular classifications of breast cancer for clinical diagnostics. **2004**, 37, 572-8 | 13 |
| 1446 | Hypermethylation in histologically distinct classes of breast cancer. **2004**, 10, 5998-6005 | 102 |
| 1445 | Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. **2004**, 10, 3291-300 | 358 |
| 1444 | Microfabricated systems for nucleic acid analysis. **2004**, 41, 429-65 | 21 |
| 1443 | An Example of Slow Convergence of the Bootstrap in High Dimensions. **2004**, 58, 25-29 | 15 |
| 1442 | Hypermethylation of CpG islands in primary and metastatic human prostate cancer. **2004**, 64, 1975-86 | 416 |

| | | |
|---|---|---|
| 1441 | In vivo epinephrine-mediated regulation of gene expression in human skeletal muscle. **2004**, 89, 2000-14 | 48 |
| 1440 | Feature selection and classification of gene expression profile in hereditary breast cancer. | 4 |
| 1439 | Models of understanding: historical constructions of breast cancer in medicine and public health. **2004**, 17, 537-555 | 1 |
| 1438 | The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. **2004**, 57, 1009-14 | 525 |
| 1437 | Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. **2004**, 10, 5367-74 | 2156 |
| 1436 | Class discovery analysis of the lung cancer gene expression data. **2004**, 23, 715-21 | 6 |
| 1435 | Micro- and nanofabrication of robust reactive arrays based on the covalent coupling of dendrimers to activated monolayers. **2004**, 20, 6216-24 | 62 |
| 1434 | Expression and motogenic activity of TFF2 in human breast cancer cells. **2004**, 25, 865-865 | |
| 1433 | Using molecular markers to predict outcome. **2004**, 172, S18-21; discussion S21-2 | 12 |
| 1432 | Gene expression profiling identifies clinically relevant subtypes of prostate cancer. **2004**, 101, 811-6 | 1047 |
| 1431 | The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. **2004**, 64, 830-5 | 307 |
| 1430 | Breast Cancer Prognostic and Predictive Factors. **2004**, 7, 91-100 | |
| 1429 | Future Prospects. **2004**, 7, 135-137 | |
| 1428 | Carbohydrate chips for studying high-throughput carbohydrate-protein interactions. **2004**, 126, 4812-9 | 207 |
| 1427 | Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. **2004**, 76, 1560-70 | 435 |
| 1426 | A simple strategy for detecting outlier samples in microarray data. | |
| 1425 | Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. **2004**, 5, 125-30 | 15 |
| 1424 | Genetic alteration and gene expression modulation during cancer progression. **2004**, 3, 9 | 70 |

| | | |
|---|---|---|
| 1423 | Methods to find out the expression of activated genes. **2004**, 2, 68 | 5 |
| 1422 | caGEDA: a web application for the integrated analysis of global gene expression patterns in cancer. **2004**, 3, 49-62 | 71 |
| 1421 | Rapid Cycle Real-Time PCR â Methods and Applications. **2004**, | 3 |
| 1420 | Transcription Factors. **2004**, | 2 |
| 1419 | Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. **2004**, 350, 1605-16 | 822 |
| 1418 | CNS metastases in breast cancer. **2004**, 22, 3608-17 | 526 |
| 1417 | A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. **2004**, 351, 2817-26 | 4778 |
| 1416 | Targeting Syk as a treatment for allergic and autoimmune disorders. **2004**, 13, 743-62 | 120 |
| 1415 | The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. **2004**, 6, 240-5 | 145 |
| 1414 | Recent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?. **2004**, 6, 192-200 | 18 |
| 1413 | S100A7 and the progression of breast cancer. **2004**, 6, 153-9 | 66 |
| 1412 | Prognostic molecular markers in early breast cancer. **2004**, 6, 109-18 | 156 |
| 1411 | Malignant myoepithelial cells are associated with the differentiated papillary structure and metastatic ability of a syngeneic murine mammary adenocarcinoma model. **2004**, 6, R116-29 | 10 |
| 1410 | Intratumoural mRNA expression of genes from the oestradiol metabolic pathway and clinical and histopathological parameters of breast cancer. **2004**, 6, R46-55 | 35 |
| 1409 | Statistical modeling for selecting housekeeper genes. **2004**, 5, R59 | 139 |
| 1408 | ONCOMINE: a cancer microarray database and integrated data-mining platform. **2004**, 6, 1-6 | 2548 |
| 1407 | Applications of eTag trade mark assay platform to systems biology approaches in molecular oncology and toxicology studies. **2004**, 111, 162-74 | 21 |
| 1406 | Network responses to DNA damaging agents. **2004**, 3, 1123-32 | 45 |

| | | |
|---|---|---|
| 1405 | Gene expression based classification of gastric carcinoma. **2004**, 210, 227-37 | 24 |
| 1404 | Genomic and proteomic technologies for individualisation and improvement of cancer treatment. **2004**, 40, 2623-32 | 77 |
| 1403 | Biomarkers of ovarian tumours. **2004**, 40, 2604-12 | 68 |
| 1402 | Understanding cancer at the chromosome level: 40 years of progress. **2004**, 40, 1960-7 | 6 |
| 1401 | Gene expression microarray technologies in the development of new therapeutic agents. **2004**, 40, 2560-91 | 70 |
| 1400 | Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. **2004**, 40, 2667-75 | 267 |
| 1399 | XBP-1 increases ERalpha transcriptional activity through regulation of large-scale chromatin unfolding. **2004**, 323, 269-74 | 26 |
| 1398 | Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. **2005**, 326, 218-27 | 59 |
| 1397 | Expression and motogenic activity of TFF2 in human breast cancer cells. **2004**, 25, 865-72 | 22 |
| 1396 | Phenotypic and microarray gene expression analysis of tri-dimensional raft-modeled human head and neck squamous cell carcinoma. **2004**, 131, 577-84 | 3 |
| 1395 | Multi-platform, multi-site, microarray-based human tumor classification. **2004**, 164, 9-16 | 178 |
| 1394 | Quantitative gene expression profiling in formalin-fixed, paraffin-embedded tissues using universal bead arrays. **2004**, 165, 1799-807 | 138 |
| 1393 | Biologie mol‵ culaire des cancers. **2004**, 19, 13-22 | 2 |
| 1392 | Time-dependent changes in transcriptional profiles within five rat brain regions in response to nicotine treatment. **2004**, 132, 168-80 | 58 |
| 1391 | The activities of cyclin D1 that drive tumorigenesis. **2004**, 10, 158-62 | 125 |
| 1390 | About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer. **2004**, 219, 1-7 | 114 |
| 1389 | Identification of differentially expressed genes in salivary gland tumors with cDNA microarray. **2004**, 31, 261-8 | 4 |
| 1388 | Studying DNA microarray data using independent component analysis. | 6 |

| | | |
|---|---|---|
| 1387 | Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. **2004**, 64, 6058-64 | 112 |
| 1386 | E4. Gene expression profiles: What the clinicians need to know. **2004**, 2, 10-11 | |
| 1385 | Knowledge-based neural networks for gene expression data analysis, modelling and profile discovery. **2004**, 2, 253-261 | 5 |
| 1384 | Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. **2004**, 9, 361-77 | 150 |
| 1383 | Systematic comparison of the fidelity of aRNA, mRNA and T-RNA on gene expression profiling using cDNA microarray. **2004**, 107, 19-28 | 46 |
| 1382 | Hedgehog--Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer. **2004**, 204, 145-57 | 95 |
| 1381 | Injury research in the genomic era. **2004**, 363, 2076-83 | 101 |
| 1380 | HER-2/neu evaluation in breast cancer are we there yet?. **2004**, 121 Suppl, S33-49 | 19 |
| 1379 | Challenges in Genome-Wide Transcription Analysis when Using Microarrays for Non-Model Bacteria. **2004**, 2, 71-78 | |
| 1378 | Expression genomics and cancer biology. **2004**, 5, 1117-28 | 4 |
| 1377 | Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. **2004**, 23, 321-9 | 34 |
| 1376 | Genomic Signal Processing: The Salient Issues. **2004**, 2004, 1 | 10 |
| 1375 | Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. **2004**, 64, 64-71 | 166 |
| 1374 | Gene Mutations and Aneuploidy: The Instability That Causes Cancer. **2004**, 3, 1099-1101 | 4 |
| 1373 | Review of: Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. **2004**, 7, | |
| 1372 | Data mining as a tool for research and knowledge development in nursing. **2004**, 22, 123-31 | 30 |
| 1371 | MR spectroscopy of brain tumors. **2004**, 15, 291-313 | 68 |
| 1370 | Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia. **2004**, 103, 1043-9 | 82 |

| | | |
|---|---|---|
| 1369 | Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. **2004**, 1, 134-40 | 49 |
| 1368 | Radionuclide-peptide nucleic acid in diagnosis and treatment of pancreatic cancer. **2005**, 106, 135-91 | 1 |
| 1367 | DNA microarray technology: insights for oral and maxillofacial surgeons. **2004**, 42, 542-545 | 1 |
| 1366 | Introduction to Relationships between Toxicology and Gene Expression. **2005**, 195-214 | |
| 1365 | The Chemical Effects in Biological Systems (CEBS) Knowledge Base. **2005**, 201-232 | |
| 1364 | Functional profiling: from microarrays via cell-based assays to novel tumor relevant modulators of the cell cycle. **2005**, 65, 7733-42 | 18 |
| 1363 | Gene expression analysis using filter cDNA microarrays. **2006**, 120, 415-24 | 2 |
| 1362 | Application of Microarray Technologies for Translational Genomics. **2005**, 361-374 | |
| 1361 | Identifying site-specific metastasis genes and functions. **2005**, 70, 149-58 | 79 |
| 1360 | Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. **2005**, 28, 79-119 | 27 |
| 1359 | Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer?. **2005**, 17, 551-8 | 19 |
| 1358 | Immunohistochemistry of tissue prepared by a molecular-friendly fixation and processing system. **2005**, 13, 277-82 | 32 |
| 1357 | Quantitative in´situ cancer proteomics: molecular pathology comes of age with automated tissue microarray analysis. **2005**, 2, 291-300 | 2 |
| 1356 | Clinical application of molecular profiling in breast cancer. **2005**, 1, 485-96 | 11 |
| 1355 | Abnormalities of the inactive X chromosome are a common feature of BRCA1 mutant and sporadic basal-like breast cancer. **2005**, 70, 93-7 | 18 |
| 1354 | EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. **2005**, 29, 633-9 | 206 |
| 1353 | Systems Biology: Applications in Drug Discovery. **2005**, 123-183 | 14 |
| 1352 | Genomics-based prognosis and therapeutic prediction in breast cancer. **2005**, 3, 291-300 | 47 |

1351 Statistical methods for gene expression analysis. **2005**,

1350 Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. **2005**, 5, 217-218

1349 Caveolin and Cancer. **2005**, 161-190 8

1348 Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. **2005**, 12, 10-9 106

1347 High Sensitivity Expression Profiling. **2005**, 229-250 1

1346 The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. **2005**, 201, 713-25 93

1345 SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. **2005**, 201, 763-70 20

1344 Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. **2005**, 62, 351-7 98

1343 Functional specificity of artificial transcriptional activators. **2005**, 12, 313-21 14

1342 Gene expression measurement technologies: innovations and ethical considerations. **2005**, 29, 589-596 2

1341 External imaging of CCND1, MYC, and KRAS oncogene mRNAs with tumor-targeted radionuclide-PNA-peptide chimeras. **2005**, 1059, 106-44 38

1340 Staging systems in hepatocellular carcinoma. **2005**, 7, 35-41 183

1339 Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes. **2005**, 12, 166-77 7

1338 Transcriptional response in the unaffected kidney after contralateral hydronephrosis or nephrectomy. **2005**, 68, 2497-507 21

1337 Transcriptional analysis of the molecular basis of human kidney aging using cDNA microarray profiling. **2005**, 68, 2667-79 83

1336 Geometric representation of high dimension, low sample size data. **2005**, 67, 427-444 254

1335 p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. **2005**, 47, 458-66 77

1334 Isolation and characterization of human mammary stem cells. **2005**, 38, 375-86 64

| | | |
|---|---|---|
| 1333 | Genomic approaches in the management and treatment of breast cancer. **2005**, 92, 618-24 | 26 |
| 1332 | Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. **2005**, 93, 346-54 | 54 |
| 1331 | No common denominator for breast cancer lymph node metastasis. **2005**, 93, 924-32 | 78 |
| 1330 | An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. **2005**, 37, 182-6 | 346 |
| 1329 | Integrative analysis of the cancer transcriptome. **2005**, 37 Suppl, S31-7 | 385 |
| 1328 | Breast cancer metastasis: markers and models. **2005**, 5, 591-602 | 1591 |
| 1327 | Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. **2005**, 5, 735-43 | 249 |
| 1326 | Modelling glandular epithelial cancers in three-dimensional cultures. **2005**, 5, 675-88 | 824 |
| 1325 | Biomarkers in cancer staging, prognosis and treatment selection. **2005**, 5, 845-56 | 1278 |
| 1324 | Expression of AMAP1, an ArfGAP, provides novel targets to inhibit breast cancer invasive activities. **2005**, 24, 963-73 | 131 |
| 1323 | Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer. **2005**, 24, 2705-14 | 70 |
| 1322 | Identification of molecular apocrine breast tumours by microarray analysis. **2005**, 24, 4660-71 | 594 |
| 1321 | Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice. **2005**, 24, 5173-90 | 58 |
| 1320 | von Willebrand factor expression in osteosarcoma metastasis. **2005**, 18, 388-97 | 43 |
| 1319 | Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer. **2005**, 18, 1165-75 | 57 |
| 1318 | The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. **2005**, 18, 1305-20 | 125 |
| 1317 | Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. **2005**, 18, 1321-8 | 153 |
| 1316 | KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome. **2005**, 18, 1623-31 | 121 |

| | | | |
|---|---|---|---|
| 1315 | Genes that mediate breast cancer metastasis to lung. *Nature*, **2005**, 436, 518-24 | 50.4 | 2242 |
| 1314 | A network-based analysis of systemic inflammation in humans. *Nature*, **2005**, 437, 1032-7 | 50.4 | 1236 |
| 1313 | Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. **2005**, 96, 343-51 | | 62 |
| 1312 | Microarray gene expression profiling of cell lines from primary and metastatic tongue squamous cell carcinoma: possible insights from emerging technology. **2005**, 34, 77-86 | | 25 |
| 1311 | Stem cell biology and the cellular pathways of carcinogenesis. **2005**, 113, 922-9 | | 38 |
| 1310 | Gene expression profiling of breast cancer in ethnic populations: an aid to gene discovery for the benefit of all. **2005**, 11, 89-91 | | 3 |
| 1309 | Gene expression profile of an adenomyoepithelioma of the breast with a reciprocal translocation involving chromosomes 8 and 16. **2005**, 156, 14-22 | | 16 |
| 1308 | Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. **2005**, 8, 393-406 | | 625 |
| 1307 | Analysis of paired primary lung and lymph node tumor cells: a model of metastatic potential by multiple genetic programs. **2005**, 29, 509-17 | | 17 |
| 1306 | Adjuvant chemotherapy for breast cancer--"one fits all"?. **2005**, 14, 564-9 | | 7 |
| 1305 | Predicting response to systemic treatments: learning from the past to plan for the future. **2005**, 14, 582-93 | | 23 |
| 1304 | Prognostic and predictive factors revisited. **2005**, 14, 493-9 | | 85 |
| 1303 | Gene identification by cDNA arrays in HPV-positive cervical cancer. **2005**, 36, 448-58 | | 24 |
| 1302 | Recent advances in biomarkers for cancer diagnosis and treatment. **2005**, 10, 965-76 | | 81 |
| 1301 | Molecular changes in prostatic cancer. **2005**, 14, 91-104 | | 10 |
| 1300 | Accumulation of ubiquitin-conjugated cytokeratin fragments in tumor cells. **2005**, 15, 309-18 | | 8 |
| 1299 | Cyclin E as a prognostic and predictive marker in breast cancer. **2005**, 15, 319-26 | | 51 |
| 1298 | Bringing molecular prognosis and prediction to the clinic. **2005**, 6, 61-76 | | 30 |

| | | |
|---|---|---|
| 1297 | Sample phenotype clusters in high-density oligonucleotide microarray data sets are revealed using Isomap, a nonlinear algorithm. **2005**, 6, 195 | 34 |
| 1296 | stam--a Bioconductor compliant R package for structured analysis of microarray data. **2005**, 6, 211 | 2 |
| 1295 | An adaptive method for cDNA microarray normalization. **2005**, 6, 28 | 23 |
| 1294 | An entropy-based gene selection method for cancer classification using microarray data. **2005**, 6, 76 | 91 |
| 1293 | An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention. **2005**, 6 Suppl 4, S7 | 25 |
| 1292 | Gene expression signature of estrogen receptor alpha status in breast cancer. **2005**, 6, 37 | 114 |
| 1291 | Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors. **2005**, 6, 55 | 8 |
| 1290 | A molecular analysis by gene expression profiling reveals Bik/NBK overexpression in sporadic breast tumor samples of Mexican females. **2005**, 5, 93 | 18 |
| 1289 | Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. **2005**, 96, 684-94 | 93 |
| 1288 | Novel regions of chromosomal amplification at 6p21, 5p13, and 12q14 in gastric cancer identified by array comparative genomic hybridization. **2005**, 42, 247-59 | 85 |
| 1287 | Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. **2005**, 113, 600-4 | 67 |
| 1286 | Altered expression and deletion of RMO1 in osteosarcoma. **2005**, 114, 738-46 | 6 |
| 1285 | High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. **2005**, 116, 340-50 | 443 |
| 1284 | Expression of RPIP9 (Rap2 interacting protein 9) is activated in breast carcinoma and correlates with a poor prognosis. **2005**, 117, 934-41 | 14 |
| 1283 | Overview of Microarrays in Genomic Analysis. **2005**, 127-165 | |
| 1282 | References. **2005**, 152-182 | |
| 1281 | Characterization of medroxyprogesterone and DMBA-induced multilineage mammary tumors by gene expression profiling. **2005**, 44, 42-50 | 32 |
| 1280 | Artificial transcriptional activation domains. **2005**, 6, 1311-5 | 7 |

1279 Carbohydrate microarrays: an advanced technology for functional studies of glycans. **2005**, 11, 2894-901 156

1278 Gene expression profiling: cell cycle deregulation and aneuploidy do not cause breast cancer formation in WAP-SVT/t transgenic animals. **2005**, 83, 362-76 23

1277 The coefficient of intrinsic dependence (feature selection using el CID). **2005**, 38, 623-636 17

1276 p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. **2005**, 447, 688-94 177

1275 Molekulare Diagnostik bei nicht-hÕmatologischen malignen Erkrankungen. **2005**, 11, 873-888

1274 Vers de nouveaux tests biologiques pour prˆ dire le potentiel mˆ tastatique dâÕn cancer. **2005**, 17, 30-33

1273 Gene expression profiling of primary breast cancer. **2005**, 7, 38-44 15

1272 Stem/progenitor cells in mouse mammary gland development and breast cancer. **2005**, 10, 17-24 64

1271 Epithelial progenitors in the normal human mammary gland. **2005**, 10, 49-59 131

1270 Maintenance of cell type diversification in the human breast. **2005**, 10, 61-74 13

1269 Intrauterine breast development and the mammary myoepithelial lineage. **2005**, 10, 199-210 27

1268 Myoepithelial cells in the control of mammary development and tumorigenesis: data from genetically modified mice. **2005**, 10, 211-9 30

1267 Myoepithelial cells: autocrine and paracrine suppressors of breast cancer progression. **2005**, 10, 249-60 96

1266 Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. **2005**, 10, 261-72 188

1265 Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. **2005**, 90, 5-14 135

1264 Comparison of cryopreservation and standard needle biopsy for gene expression profiling of human breast cancer specimens. **2005**, 90, 93-6 9

1263 Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome. **2005**, 90, 127-37 90

1262 BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. **2005**, 91, 179-86 143

| | | |
|---|---|---|
| 1261 | Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. **2005**, 94, 205-11 | 14 |
| 1260 | Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. **2005**, 93, 237-46 | 92 |
| 1259 | The current understanding of the molecular determinants of inflammatory breast cancer metastasis. **2005**, 22, 615-20 | 14 |
| 1258 | A cell behavior screen: identification, sorting, and enrichment of cells based on motility. **2005**, 6, 14 | 16 |
| 1257 | A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. **2005**, 5, 22 | 87 |
| 1256 | Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. **2005**, 63, 187-97 | 60 |
| 1255 | Molecular evolution of breast cancer. **2005**, 205, 248-54 | 391 |
| 1254 | First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. **2005**, 206, 366-76 | 80 |
| 1253 | The gene expression profile of extraskeletal myxoid chondrosarcoma. **2005**, 206, 433-44 | 58 |
| 1252 | Re: Korsching et al. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential? J Pathol 2005; 206: 451-457. **2005**, 207, 367-9; author reply 370-1 | 3 |
| 1251 | Typical medullary breast carcinomas have a basal/myoepithelial phenotype. **2005**, 207, 260-8 | 172 |
| 1250 | On the efficiency of targeted clinical trials. **2005**, 24, 329-39 | 175 |
| 1249 | BeadArray-based solutions for enabling the promise of pharmacogenomics. **2005**, 39, S583-8 | 23 |
| 1248 | Early detection markers in Pancreas Cancer. **2005**, 1, 157-75 | 7 |
| 1247 | Clinical applications of microarray-based diagnostic tests. **2005**, 39, S577-82 | 16 |
| 1246 | Expression profiling using cDNA microarrays. **2006**, 120, 403-14 | 3 |
| 1245 | Gene Expression: Microarray Data Analysis. **2005**, 188-221 | |
| 1244 | Molecular diagnosis of micrometastasis in the sentinel lymph node. **2005**, 127, 221-52 | 2 |

| | | |
|---|---|---|
| 1243 | Can animal models help us select specific compounds for cancer prevention trials?. **2005**, 166, 71-87 | 9 |
| 1242 | Differential expression of alphaB-crystallin and Hsp27-1 in anaplastic thyroid carcinomas because of tumor-specific alphaB-crystallin gene (CRYAB) silencing. **2005**, 10, 171-84 | 28 |
| 1241 | High reproducibility using sodium hydroxide-stripped long oligonucleotide DNA microarrays. **2005**, 38, 121-4 | 31 |
| 1240 | DNA array-based gene profiling: from surgical specimen to the molecular portrait of cancer. **2005**, 241, 16-26 | 29 |
| 1239 | Parallel Computing in the Analysis of Gene Expression Relationships. **2005**, 265-283 | 1 |
| 1238 | . **2005**, | 3 |
| 1237 | Expression Profiling of Breast Cancer: From Molecular Portraits to Clinical Utility. **2005**, 77-100 | 1 |
| 1236 | . **2005**, | |
| 1235 | Molecular Cytogenetics: Increasing Resolution Using Array-Based CGH. **2005**, 37-55 | 1 |
| 1234 | Microarray analysis and RNA silencing to determine genes functionally important in mesothelioma. **2005**, 447-469 | |
| 1233 | . **2005**, | 4 |
| 1232 | Gene Expression Data and Survival Analysis. **2005**, 21-34 | 2 |
| 1231 | Genomic Resources for Cancer Biologists. **2005**, 3-17 | |
| 1230 | Gene expression profiling predicts survival in conventional renal cell carcinoma. **2006**, 3, e13 | 154 |
| 1229 | Microarray profiling of lymphocytes in internal diseases with an altered immune response: potential and methodology. **2005**, 2005, 317-30 | 17 |
| 1228 | Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. **2005**, 7, 20-31 | 55 |
| 1227 | DNA microarrays in clinical cancer research. **2005**, 5, 111-20 | 42 |
| 1226 | Gene profile and response to treatment. **2005**, 16 Suppl 2, ii195-202 | 11 |

| | | |
|---|---|---|
| 1225 | Expression genomics and drug development: towards predictive pharmacology. **2005**, 3, 303-21 | 7 |
| 1224 | Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentiated carcinoma of the stomach. **2005**, 35, 580-6 | 15 |
| 1223 | Telomeres, telomerase and malignant transformation. **2005**, 5, 219-26 | 25 |
| 1222 | Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials. **2005**, 5, 83-102 | 31 |
| 1221 | The Role of DNA-Microarray in Translational Cancer Research. **2005**, 3, 201-216 | 1 |
| 1220 | Functional genomic analysis of cancer metastasis: biologic insights and clinical implications. **2005**, 5, 385-95 | 25 |
| 1219 | New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. **2005**, 16 Suppl 2, ii191-4 | 21 |
| 1218 | Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. **2005**, 23, 7265-77 | 461 |
| 1217 | Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. **2005**, 11, 8623-31 | 173 |
| 1216 | Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. **2005**, 23, 3331-42 | 138 |
| 1215 | Multi-species microarrays reveal the effect of sequence divergence on gene expression profiles. **2005**, 15, 674-80 | 139 |
| 1214 | A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. **2005**, 65, 4059-66 | 212 |
| 1213 | The emergence of toxicogenomics: a case study of molecularization. **2005**, 35, 367-403 | 63 |
| 1212 | Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer. **2005**, 11, 6872-9 | 42 |
| 1211 | A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. **2005**, 14, 1108-12 | 159 |
| 1210 | Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. **2005**, 65, 4101-17 | 98 |
| 1209 | Testing chemotherapy for breast cancer: timing is everything. **2005**, 23, 5434-6 | 8 |
| 1208 | DIG--a system for gene annotation and functional discovery. **2005**, 21, 2957-9 | 1 |

| | | |
|---|---|---|
| 1207 | A Bayesian method for analysing spotted microarray data. **2005**, 6, 318-30 | 17 |
| 1206 | How many samples are needed to build a classifier: a general sequential approach. **2005**, 21, 63-70 | 22 |
| 1205 | Gene expression profiling of breast cancer: a new tumor marker. **2005**, 23, 1631-5 | 126 |
| 1204 | Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. **2005**, 65, 3796-805 | 189 |
| 1203 | Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. **2005**, 11, 3315-9 | 149 |
| 1202 | Improving molecular cancer class discovery through sparse non-negative matrix factorization. **2005**, 21, 3970-5 | 218 |
| 1201 | Gene expression profiling of microsatellite unstable and microsatellite stable endometrial cancers indicates distinct pathways of aberrant signaling. **2005**, 65, 5031-7 | 49 |
| 1200 | CREB-binding protein regulates apoptosis and growth of HMECs grown in reconstituted ECM via laminin-5. **2005**, 118, 5005-22 | 13 |
| 1199 | Resveratrol-induced gene expression profiles in human prostate cancer cells. **2005**, 14, 596-604 | 66 |
| 1198 | On reference designs for microarray experiments. **2005**, 4, Article36 | 15 |
| 1197 | Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. **2005**, 65, 11259-64 | 221 |
| 1196 | Microarray Technology and Its Applications. **2005**, | 30 |
| 1195 | A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. **2005**, 12, 1059-69 | 35 |
| 1194 | Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. **2005**, 11, 1863-9 | 18 |
| 1193 | MCT-1 oncogene contributes to increased in vivo tumorigenicity of MCF7 cells by promotion of angiogenesis and inhibition of apoptosis. **2005**, 65, 10651-6 | 38 |
| 1192 | Contralateral breast cancer: where does it all begin?. **2005**, 23, 4585-7 | 6 |
| 1191 | Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. **2005**, 21, 4205-8 | 316 |
| 1190 | Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. **2005**, 11, 5175-80 | 511 |

| | | |
|---|---|---|
| 1189 | HER2 or not HER2: that is the question. **2005**, 23, 3656-9 | 17 |
| 1188 | Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer. **2005**, 26, 1343-53 | 91 |
| 1187 | Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. **2005**, 26, 1241-6 | 319 |
| 1186 | Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. **2005**, 19, 1543-54 | 93 |
| 1185 | A variational Bayesian mixture modelling framework for cluster analysis of gene-expression data. **2005**, 21, 3025-33 | 58 |
| 1184 | Breast cancer gene expression profiling: clinical trial and practice implications. **2005**, 6, 49-58 | 10 |
| 1183 | Comparative study of multivariate classification methods using microarray gene expression data for BRCA1/BRCA2 cancer tumors. | 0 |
| 1182 | Prognostic relevance of basal cytokeratin expression in operable breast cancer. **2005**, 69, 478-85 | 83 |
| 1181 | Gene expression profiling to characterize anticancer drug sensitivity. **2005**, 111, 197-231 | |
| 1180 | Evaluation of experimental designs for two-color cDNA microarrays. **2005**, 12, 1202-20 | 5 |
| 1179 | Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response. **2005**, 5, 1069-83 | 44 |
| 1178 | Death-from-cancer signatures and stem cell contribution to metastatic cancer. **2005**, 4, 1171-5 | 98 |
| 1177 | Chemosensitivity: Volume II. **2005**, | 3 |
| 1176 | Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. **2005**, 65, 1909-17 | 147 |
| 1175 | Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. **2005**, 92, 147-55 | 126 |
| 1174 | Epidemiology informing clinical practice: from bills of mortality to population laboratories. **2005**, 2, 625-34 | 16 |
| 1173 | Individualised cancer therapeutics: dream or reality?. **2005**, 9, 1189-201 | 7 |
| 1172 | Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis. **2005**, 65, 6864-73 | 35 |

| | | |
|---|---|---|
| 1171 | Limits of predictive models using microarray data for breast cancer clinical treatment outcome. **2005**, 97, 927-30 | 104 |
| 1170 | Ovarian suppression for breast cancer: an effective treatment in search of a home. **2005**, 23, 5869-72 | 7 |
| 1169 | Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target. **2005**, 280, 12935-43 | 35 |
| 1168 | Identification of proteins released by pancreatic cancer cells by multidimensional protein identification technology: a strategy for identification of novel cancer markers. **2005**, 19, 1125-7 | 114 |
| 1167 | Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. **2005**, 11, 4003-11 | 143 |
| 1166 | Global gene expression profiling: a complement to conventional histopathologic analysis of neoplasia. **2005**, 42, 735-52 | 14 |
| 1165 | Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. **2005**, 65, 4530-43 | 49 |
| 1164 | Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. **2005**, 65, 2170-8 | 186 |
| 1163 | Prediction of radiation sensitivity using a gene expression classifier. **2005**, 65, 7169-76 | 155 |
| 1162 | Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. **2005**, 102, 3738-43 | 823 |
| 1161 | Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. **2005**, 102, 5814-9 | 389 |
| 1160 | Multiclass molecular cancer classification by kernel subspace methods with effective kernel parameter selection. **2005**, 3, 1071-88 | 3 |
| 1159 | The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation. **2005**, 1, 2005.0022 | 60 |
| 1158 | Genomic profiling of cancer: what next?. **2005**, 23, 7253-6 | 10 |
| 1157 | Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. **2005**, 23, 732-40 | 283 |
| 1156 | CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. **2005**, 11, 3309-14 | 72 |
| 1155 | Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. **2005**, 11, 3184-90 | 74 |
| 1154 | Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. **2005**, 3, 203-18 | 68 |

| | | |
|---|---|---|
| 1153 | Tissue inhibitor of metalloproteinases-1 in breast cancer. **2005**, 12, 215-27 | 95 |
| 1152 | Breast cancer molecular subtypes respond differently to preoperative chemotherapy. **2005**, 11, 5678-85 | 1415 |
| 1151 | Molecular basis of therapeutic strategies for breast cancer. **2005**, 5, 379-96 | 21 |
| 1150 | A unique gene expression signature discriminates familial Alzheimer's disease mutation carriers from their wild-type siblings. **2005**, 102, 14854-9 | 39 |
| 1149 | Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. **2005**, 65, 1376-83 | 58 |
| 1148 | In silico identification of breast cancer genes by combined multiple high throughput analyses. **2005**, 15, 205 | 0 |
| 1147 | Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. **2005**, 26, 329 | 4 |
| 1146 | How to best classify breast cancer: Conventional and novel classifications (Review). **2005**, 27, 1307 | 3 |
| 1145 | Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer. **2005**, 11, 6226-32 | 32 |
| 1144 | Targeted activation of beta-catenin signaling in basal mammary epithelial cells affects mammary development and leads to hyperplasia. **2005**, 132, 267-77 | 125 |
| 1143 | Targeted Therapy for BRCA2 Deficient Tumors. **2005**, 4, 707-8 | 1 |
| 1142 | Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. **2005**, 365, 671-9 | 2172 |
| 1141 | The 2000 EBCTCG overview: a widening gap. **2005**, 365, 1665-6 | 36 |
| 1140 | Laparoscopic-assisted resection of colorectal carcinoma. **2005**, 365, 1666-8 | 14 |
| 1139 | Breast cancer. **2005**, 365, 1727-41 | 346 |
| 1138 | Identification of transcriptional targets of HOXA5. **2005**, 280, 19373-80 | 39 |
| 1137 | In search of a stem cell hierarchy in the human breast and its relevance to breast cancer evolution. **2005**, 113, 903-21 | 37 |
| 1136 | Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. **2005**, 6, 107 | 99 |

| | | |
|---|---|---|
| 1135 | Adjuvant treatment of early breast cancer. **2005**, 3, 149-166 | 1 |
| 1134 | 2005 Highlights From: Controversies in Breast Cancer Adjuvant and Neoadjuvant Therapy; New York, NY September 2005. **2005**, 6, 288-291 | |
| 1133 | Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. **2005**, 23, 7350-60 | 696 |
| 1132 | Beyond lymph node staging: molecular predictors of outcome in breast cancer. **2005**, 14, 69-84, vi | 1 |
| 1131 | Nipple Aspirate Fluid Collection, Ductal Lavage, or Random Periareolar Fine-Needle Aspiration: Which Method is Best for Risk Stratification?. **2005**, 16, 220-222 | |
| 1130 | 1â89 Gene Expression Profiles Predict Complete Pathologic Response to Neoadjuvant Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy in Breast Cancer. **2005**, 16, 74-76 | |
| 1129 | A Multigene Assay for Predicting the Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer. **2005**, 16, 219-220 | 1 |
| 1128 | Medical Biomethods Handbook. **2005**, | 2 |
| 1127 | Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. **2005**, 65, 9155-8 | 264 |
| 1126 | Pathology of the Future: Molecular Profiling for Targeted Therapy. **2005**, 23, 36-46 | 58 |
| 1125 | Environmental health research in the post-genome era: new fields, new challenges, and new opportunities. **2005**, 8, 71-94 | 2 |
| 1124 | Mining the tumor phosphoproteome for cancer markers. **2005**, 11, 3163-9 | 74 |
| 1123 | . **2005**, | 13 |
| 1122 | Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer. **2005**, 2, 246-54 | 77 |
| 1121 | Cancer diagnostics: decision criteria for marker utilization in the clinic. **2005**, 5, 357-64 | 22 |
| 1120 | Missing value estimation for DNA microarray gene expression data: local least squares imputation. **2005**, 21, 187-98 | 314 |
| 1119 | P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. **2005**, 11, 5869-77 | 200 |
| 1118 | The distinctive nature of HER2-positive breast cancers. **2005**, 353, 1652-4 | 341 |

| | | |
|---|---|---|
| 1117 | A history of microarrays in biomedicine. **2005**, 5, 315-28 | 26 |
| 1116 | Molecular diagnostics in melanoma. **2005**, 52, 743-75; quiz 775-8 | 120 |
| 1115 | Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. **2005**, 95, 105-11 | 15 |
| 1114 | Discovery metabolite profiling--forging functional connections between the proteome and metabolome. **2005**, 77, 1759-66 | 43 |
| 1113 | The choice of systemic adjuvant therapy in receptor-positive early breast cancer. **2005**, 41, 357-64 | 10 |
| 1112 | Breast cancer metastasis to the central nervous system. **2005**, 167, 913-20 | 327 |
| 1111 | Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. **2005**, 166, 1205-16 | 41 |
| 1110 | New insights into the tumor metastatic process revealed by gene expression profiling. **2005**, 166, 1291-4 | 19 |
| 1109 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. **2005**, 86, 127-41 | 218 |
| 1108 | Molecular, Cellular, and Developmental Biology of Breast Cancer. **2005**, 27-41 | |
| 1107 | Molecular Pathology Assays for Breast Cancer. **2005**, 145-168 | |
| 1106 | Multimodality Treatment of Breast Cancer. **2005**, 355-382 | |
| 1105 | Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients. **2005**, 4, 26 | 22 |
| 1104 | Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures. **2005**, 3, 32 | 39 |
| 1103 | Comparison of normal and breast cancer cell lines using proteome, genome, and interactome data. **2005**, 4, 1952-60 | 29 |
| 1102 | cDNA Microarrays. **2005**, 255-271 | |
| 1101 | Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior. **2005**, 39, 39-51 | 31 |
| 1100 | Utility of microarrays in the management of breast cancer patients. **2005**, 2, 307-311 | |

| | | |
|---|---|---|
| 1099 | Molecular prediction of tamoxifen resistance in breast cancer. **2005**, 7, 1 | 78 |
| 1098 | Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. **2005**, 12, 903-16 | 65 |
| 1097 | The promise of gene signatures in cancer diagnosis and prognosis. **2005**, | |
| 1096 | Simple decision rules for classifying human cancers from gene expression profiles. **2005**, 21, 3896-904 | 287 |
| 1095 | Erythropoietin abuse and erythropoietin gene doping: detection strategies in the genomic era. **2005**, 35, 831-40 | 45 |
| 1094 | Genomics in breast cancer-therapeutic implications. **2005**, 2, 26-33 | 41 |
| 1093 | Mechanisms of Disease: prediction and prevention of breast cancer--cellular and molecular interactions. **2005**, 2, 635-46 | 24 |
| 1092 | Arylamine N-acetyltransferases: what we learn from genes and genomes. **2005**, 37, 511-64 | 117 |
| 1091 | Computational Life Sciences. **2005**, | 3 |
| 1090 | Molecular Biology of Human Cancers. **2005**, | 4 |
| 1089 | Molecular mechanisms in gliomagenesis. **2005**, 94, 1-27 | 55 |
| 1088 | Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions. **2005**, 7, 255-7 | 4 |
| 1087 | Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. **2005**, 7, R953-64 | 597 |
| 1086 | Myoepithelial cells: good fences make good neighbors. **2005**, 7, 190-7 | 161 |
| 1085 | Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. **2005**, 7, R634-44 | 93 |
| 1084 | Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. **2005**, 7, 143-8 | 191 |
| 1083 | The promise of microarrays in the management and treatment of breast cancer. **2005**, 7, 100-4 | 20 |
| 1082 | Genomic analysis of human breast cancer in families and populations. **2005**, 7, 1 | 78 |

| | | |
|---|---|---|
| 1081 | Dynamic imaging of plasticity and escape in tumor cell invasion. **2005**, 7, 1 | 78 |
| 1080 | Comparative genomic hybridization using oligonucleotide arrays and total genomic DNA. **2005**, 7, 1 | 78 |
| 1079 | Hypoxia promotes invasion and metastasis of breast cancer cells by increasing lysyl oxidase expression. **2005**, 7, 1 | 1 |
| 1078 | Brn-3b transcription factor in breast tumourigenesis: regulation of genes associated with growth and migration of cancer cells. **2005**, 7, 1 | 78 |
| 1077 | Mammary development fate and breast cancer risk. **2005**, 7, 1 | 78 |
| 1076 | Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome. **2005**, 7, 1 | 1 |
| 1075 | Real-time PCR-based expression profiling of BRCA1-induced genes in primary breast tumors. **2005**, 7, 1 | 78 |
| 1074 | Breast tumors induced by high-dose radiation display similar genetic profiles. **2005**, 7, 1 | 78 |
| 1073 | Stromal and epithelial TGF-β signaling in mammary tumorigenesis. **2005**, 7, 1 | 78 |
| 1072 | The extracellular matrix composition and responsiveness to breast carcinoma therapy. **2005**, 7, 1 | 78 |
| 1071 | Determining the factors affecting breast cancer infectivity by oncolytic adenovirus. **2005**, 7, 1 | 78 |
| 1070 | HER2 and ERβ2 downregulate estrogen-responsive element-mediated transcription activity of ERα-positive cells in response to estrogen stimulation. **2005**, 7, 1 | 1 |
| 1069 | Establishment and characterization of two breast cancer xenografts in immunodeficient mice for studies on hormone-dependent and hormone-independent tumor growth, progression and invasion. **2005**, 7, 1 | 2 |
| 1068 | Functional genomic approaches to breast cancer. **2005**, 7, 1 | 78 |
| 1067 | Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines. **2005**, 7, 1 | 3 |
| 1066 | Potential mechanisms whereby estrogens induce breast cancer in women. **2005**, 7, 1 | 1 |
| 1065 | Potentiated phospho-protein networks in cancer cells. **2005**, 7, 1 | 1 |
| 1064 | Identification of molecular apocrine breast tumours by microarray analysis. **2005**, 7, 1 | 8 |

| | | |
|---|---|---|
| 1063 | Identification of novel sequence alterations and the functional analysis of the BRCA1 promoter/5'-UTR in families from Upper Silesia, Poland. **2005**, 7, 1 | 78 |
| 1062 | Comparison of the expression profile in breast cancer and ovarian cancer. **2005**, 7, 1 | 1 |
| 1061 | Targeting estrogen to kill ER-positive and ER-negative breast cancer. **2005**, 7, 1 | 78 |
| 1060 | High-throughput experimental verification of predicted tissue-specific and tumor-specific splice isoforms. **2005**, 7, 1 | 78 |
| 1059 | The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. **2005**, 7, 1 | 0 |
| 1058 | Cigarette smoking and breast cancer risk among non-drinking women. **2005**, 7, 1 | 78 |
| 1057 | Screening for germline rearrangements in BRCA1 and BRCA2in Norwegian families with breast or breast/ovarian cancer. **2005**, 7, 1 | 78 |
| 1056 | Genome-wide expression profiling of microdissected human breast tumor cells: tumor classification predictive of metastases and clinical outcome. **2005**, 7, 1 | 78 |
| 1055 | Gene expression profiling in breast cancer challenges the existence of intermediate histological grade. **2005**, 7, 1 | 78 |
| 1054 | Molecular approaches to understanding pregnancy-induced protection against breast cancer. **2005**, 7, 1 | 78 |
| 1053 | Cooperation between extracellular signaling and intracellular Ras activation leads to immortalization and epithelial-to-mesenchymal transition of variant human mammary epithelial cells. **2005**, 7, 1 | 78 |
| 1052 | Immortalization-associated gene signature in breast cancer. **2005**, 7, 1 | 78 |
| 1051 | Genetic determinants of breast cancer characteristics and outcome in women under 50 years of age. **2005**, 7, 1 | 78 |
| 1050 | Identification of differentially expressed genes in canine mammary tumor cell lines using a newly developed canine-specific cDNA microarray. **2005**, 7, 1 | 78 |
| 1049 | Genetic and epigenetic changes in early carcinogenesis. **2005**, 7, 1 | 78 |
| 1048 | Biological features and xenograft models of a very early human premalignant breast lesion. **2005**, 7, 1 | 78 |
| 1047 | Myoepithelial cell layer disruption and human breast cancer invasion. **2005**, 7, 1 | 1 |
| 1046 | HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells. **2005**, 7, 1 | 78 |

| | | |
|---|---|---|
| 1045 | Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy. **2005**, 7, 1 | 78 |
| 1044 | Chromosomal imbalances mapped by array-based comparative genomic hybridization in an integrated approach to combat breast cancer in Denmark. **2005**, 7, 1 | 1 |
| 1043 | DNA copy number changes in breast cancer samples using array-CGH profiling. **2005**, 7, 1 | 78 |
| 1042 | Genomic and transcriptional events associated with poor clinical responses to conventional therapies. **2005**, 7, 1 | 78 |
| 1041 | Expression profiling of peripheral blood cells for early detection. **2005**, 7, 1 | 78 |
| 1040 | HIN-1, an inhibitor of cell growth, invasion, and AKT1 activation. **2005**, 7, 1 | 78 |
| 1039 | Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2. **2005**, 7, 1 | 78 |
| 1038 | Mapping the location of recurring amplicons in array-CGH data. **2005**, 7, 1 | 78 |
| 1037 | Predicting survival from gene expression data by generalized partial least squares regression. **2005**, 7, 1 | 2 |
| 1036 | Large-scale single nucleotide polymorphism analysis of candidates for low-penetrance breast cancer genes. **2005**, 7, 1 | 1 |
| 1035 | Molecular distinctions among ERBB2-overexpressing breast cancers. **2005**, 7, 1 | 78 |
| 1034 | In vitro models for tumor protein d52 function in cancer cells. **2005**, 7, 1 | 78 |
| 1033 | Protein expression and gene amplification of primary cyclins (A, B1, D1, D3and E) and secondary cyclins (C and H) in relation to prognosis in breast cancer patients. **2005**, 7, 1 | 0 |
| 1032 | TP53 mutations among molecular subtypes of HER2-positive tumors. **2005**, 7, 1 | 78 |
| 1031 | Comparison of methods for pharmacogenomics: SNaPshot, SNPstream UHT, Nanogen, and RFLP. **2005**, 7, 1 | 78 |
| 1030 | Targeting the cell cycle for prognosis and therapy of breast cancer. **2005**, 7, 1 | 78 |
| 1029 | Expression profiling as a prognostic and predictive factor in breast cancer. **2005**, 7, 1 | 78 |
| 1028 | Lack of evidence for nuclear IGFBP5 in mammary epithelial cells. **2005**, 7, 1 | 78 |

1027 Expression of wild-type and mutated TP53in breast carcinomas. **2005**, 7, 1 78

1026 Cancer gene mutation discovery and detection using array-based resequencing. **2005**, 7, 1 78

1025 The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. **2005**, 7, 1 78

1024 High-resolution representational oligonucleotide microarray analysis and fluorescence in situ hybridization analysis of aneuploid and diploid breast tumors. **2005**, 7, 1 78

1023 A single nucleotide polymorphism in the HDM-2 gene regulates the p53 apoptotic response and influences the age of onset of cancers in humans: the SNP 309 HDM-2 polymorphism. **2005**, 7, 1 78

1022 Microcell-mediated transfer of chromosome 6 into the breast cancer cell line MDA-MB-231: a specific set of genes is involved in the reversion of the tumorigenic phenotype. **2005**, 7, 1 78

1021 Prognostic value genotypes and LOH at TP53 codon 72 and TP53mutations in primary breast cancer. **2005**, 7, 1 78

1020 Detection of minimal disease in breast cancer. **2005**, 7, 1 78

1019 Association of NCOA3 (AIB1) polymorphisms with breast cancer risk. **2005**, 7, 1 1

1018 A critical need for molecular markers of breast cancer risk and risk reduction. **2005**, 7, 1 78

1017 TP53 and additional pathways in therapy resistance. **2005**, 7, 1 78

1016 Hypermethylation of cyclin D2 and DAP kinase is associated with the lobular subtype of breast cancer. **2005**, 7, 1 78

1015 Development of a rapid screening approach for candidate gene sets in cancer. **2005**, 7, 1 78

1014 Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. **2005**, 7, 1 78

1013 High-density screening of the Zbtb7gene in breast cancer patients. **2005**, 7, 1 1

1012 Effects of oestrogen on gene expression in the epithelium and stroma of the normal human breast. **2005**, 7, 1 78

1011 Role of HER2 in local relapse and metastasis. **2005**, 7, 1 78

1010 Development of CDK inhibitors as cancer therapeutics. **2005**, 7, 1 1

| | | |
|---|---|---|
| 1009 | Expression profiling of Wnt pathway genes in breast cancer. **2005**, 7, 1 | 78 |
| 1008 | Gene expression studies in radiation-sensitive cell lines. **2005**, 7, 1 | 78 |
| 1007 | Breast tumors induce the recruitment of AC133+KDR+ endothelial precursor cells mobilized by plasma vascular endothelial growth factor. **2005**, 7, 1 | 2 |
| 1006 | Identification of drug targets for the treatment of Basal-like tumors. **2005**, 7, 1 | 1 |
| 1005 | BRCA1 directly modulates gene expression required for estrogen biosynthesis: a possible mechanism of tissue-specific tumor suppression. **2005**, 7, 1 | 78 |
| 1004 | The search for low-penetrance breast cancer genes. **2005**, 7, 1 | 2 |
| 1003 | Molecular characterization of breast cell lines: a tool for breast cancer studies. **2005**, 7, 1 | 78 |
| 1002 | SNPS in putative regulatory loci controlling gene expression in cancer. **2005**, 7, 1 | 78 |
| 1001 | Characterization of extracellular matrix composition in breast carcinoma. **2005**, 7, 1 | 78 |
| 1000 | The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling. **2005**, 7, 1 | 78 |
| 999 | Proteomic approaches to early detection of breast cancer. **2005**, 7, 1 | 78 |
| 998 | Reproducibility of molecular portraits in early stage breast cancer. **2005**, 7, 1 | 78 |
| 997 | Gene expression signature of hereditary breast cancer. **2005**, 7, 1 | 78 |
| 996 | ATM mutations associated with breast cancer. **2005**, 7, 1 | 78 |
| 995 | The future of breast cancer prevention. **2005**, 7, 1 | 78 |
| 994 | A model of the BRCA1/BRCA2 network. **2005**, 7, 1 | 78 |
| 993 | The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90RSK in tamoxifen-resistant MCF-7 cells. **2005**, 7, 1 | 4 |
| 992 | Gene expression profiling to identify parity-induced changes in the human mammary gland. **2005**, 7, 1 | 1 |

| | | |
|---|---|---|
| 991 | Envisioning new targets and new approaches for molecular-based cancer therapeutics. **2005**, 7, 1 | 78 |
| 990 | High prevalence of a BRCA1 gene founder mutation, 5083del19, in unselected breastâ□ovarian cancer patients from Southern Italy: genotypeâ□phenotype correlations. **2005**, 7, 1 | 2 |
| 989 | Lymph node metastases display gene expression profiles of their primary breast carcinomas. **2005**, 7, 1 | 78 |
| 988 | Comparative expressed sequence hybridisation revealed distinct chromosomal regions of differential gene expression in breast cancer subtypes. **2005**, 7, 1 | 78 |
| 987 | ER□in normal and malignant breast. **2005**, 7, 1 | 78 |
| 986 | RNA integrity number: towards standardization of RNA quality assessment for better reproducibility and reliability of gene expression experiments. **2005**, 7, 1 | 1 |
| 985 | Essential functions of the Janus kinase 2 (Jak2) during mammary gland development and tumorigenesis. **2005**, 7, 1 | 78 |
| 984 | Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families. **2005**, 7, 1 | 78 |
| 983 | Promoter composition predicts gene classes in microarray expression analyses of breast cancer. **2005**, 7, 1 | 78 |
| 982 | Predicting response/resistance to endocrine therapy for breast cancer. **2005**, 7, 1 | 78 |
| 981 | The role of the tumor microenvironment in breast cancer progression. **2005**, 7, 1 | 78 |
| 980 | Ex vivo isolation of adult stem cells from normal and tumour mouse mammary parenchyma. **2005**, 7, 1 | 78 |
| 979 | 6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone exerts anti-angiogenic activity via inhibition of vascular endothelial cell growth factor and hypoxia-inducible factor 1 alpha in hypoxia-exposed MCF breast cancer cells. **2005**, 7, 1 | 78 |
| 978 | Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS). **2005**, 7, 1 | 78 |
| 977 | Discovering genetic profiles by array-CGH in familial breast tumors. **2005**, 7, 1 | 78 |
| 976 | A breast cancer progression model: the importance of three-dimensional tissue architecture and metalloproteinases. **2005**, 7, 1 | 1 |
| 975 | Regulation of epithelial cell polarity during carcinogenesis. **2005**, 7, 1 | 1 |
| 974 | Imprint as a reliable diagnostic tool in breast cancer and possible usefulness for research purposes. **2005**, 7, 1 | 78 |

| | | |
|---|---|---|
| 973 | Altered signaling in anti-estrogen-resistant human breast cancer cells. **2005**, 7, 1 | 78 |
| 972 | Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). **2005**, 7, 1 | 78 |
| 971 | Morphogenesis of the mammary gland and the role of keratin expression. **2005**, 7, 1 | 78 |
| 970 | Outcome signature genes in breast cancer: is there a unique set?. **2005**, 7, 1 | 5 |
| 969 | Quality control of DNA with on-chip electrophoresis for oligonucleotide-array comparative genomic hybridization. **2005**, 7, 1 | 78 |
| 968 | DNA polymorphisms of several genes and predisposition to breast cancer. **2005**, 7, 1 | 1 |
| 967 | Stem cells in human breast development and cancer. **2005**, 7, 1 | 78 |
| 966 | Expression of STAT1 target genes and interferon gamma in human mammary carcinoma tissue. **2005**, 7, 1 | 78 |
| 965 | Who gets cancer?. **2005**, 7, 1 | 78 |
| 964 | Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer. **2005**, 7, 1 | 1 |
| 963 | Chromosome-wide pharmacogenetics: localisation and linkage disequilibrium of genes coding for ROS metabolism and signalling. **2005**, 7, 1 | 78 |
| 962 | Insulin-like growth factor regulation of mammary gland development and tumorigenesis. **2005**, 7, 1 | 78 |
| 961 | Tailored therapies based upon tumor subtype biology. **2005**, 7, 1 | 78 |
| 960 | Functional characterization of genes involved in the development of breast cancer. **2005**, 7, 1 | 78 |
| 959 | IL-8 is a novel marker for breast cancer. **2005**, 7, 1 | 1 |
| 958 | Mutant p53 exerts its gain of function through activation of the NF-B pathway. **2005**, 7, 1 | 78 |
| 957 | Evaluation of the arrayed primer extension resequencing assay for TP53mutation detection. **2005**, 7, 1 | 78 |
| 956 | Genetic polymorphisms in the 5' flanking region of glutathione S-transferase P1 affect promoter methylation. **2005**, 7, 1 | 78 |

| | | |
|---|---|---|
| 955 | Apoptotic chemotherapies. **2005**, 7, 1 | 78 |
| 954 | Genomic profiling of breast cancer. **2005**, 7, 1 | 78 |
| 953 | Deletions at the chromosome 3 common eliminated region 1 on 3p21.3 in human breast tumors. **2005**, 7, 1 | 78 |
| 952 | Identification of clinically relevant gene sets and pathways using functional models of breast tumor suppression. **2005**, 7, 1 | 78 |
| 951 | Independent prognostic value of somatic TP53gene mutations in 1794 breast cancer patients. **2005** , 7, 1 | 78 |
| 950 | Detection of circulating cancer cells in peripheral blood as a prognostic factor in early breast cancer. **2005**, 7, 1 | 78 |
| 949 | Alpha-1 antitrypsin genotypes in breast cancer patients. **2005**, 7, 1 | 2 |
| 948 | ZBTB7 HapMap in a worldwide population study. **2005**, 7, 1 | 1 |
| 947 | Evading p53 action during tumor development and therapy. **2005**, 7, 1 | 78 |
| 946 | Epigenetic silencing of tropomyosin alters transforming growth factor beta control of cell invasion and metastasis. **2005**, 7, 1 | 78 |
| 945 | Postoperative serum proteomic profiles and identification of biomarkers with prognosis value in high-risk early breast cancer patients. **2005**, 7, 1 | 78 |
| 944 | Polymorphisms in the CRK gene and their association with breast cancer risk. **2005**, 7, 1 | 78 |
| 943 | Gene expression profiling in whole-blood samples from postmenopausal women exposed to hormone replacement therapy. **2005**, 7, 1 | 78 |
| 942 | Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer. **2005**, 7, 1 | 78 |
| 941 | Methylation profiling of carcinogenesis-associated genes in sporadic breast cancer. **2005**, 7, 1 | 78 |
| 940 | Application of microarray analyses to identify genes involved in radiation-induced fibrosis. **2005**, 7, 1 | 1 |
| 939 | Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. **2005**, 7, 1 | 1 |
| 938 | Subclassification and molecular characterization of early stage breast carcinomas using Applied Biosystems Human Genome Survey Microarrays. **2005**, 7, 1 | 1 |

| | | |
|---|---|---|
| 937 | DNA damage response pathways in cancer causation and treatment. **2005**, 7, 1 | 78 |
| 936 | Magnetic resonance spectroscopy of breast cancer tissue used for tumor classification and lymph node prediction. **2005**, 7, 1 | 1 |
| 935 | Sex-hormone binding globulin receptor-mediated growth inhibition in breast cancer cells: a proteomics approach. **2005**, 7, 1 | 78 |
| 934 | Hereditary breast cancer âa spectrum of pathogenic mutations and unknown variants of BRCA1 and BRCA2 genes in the Czech Republic: efficiency of testing and clinical follow-up. **2005**, 7, 1 | 78 |
| 933 | Genes, genomes, and cancer. **2005**, 7, 1 | 78 |
| 932 | Abstract withdrawn. **2005**, 7, 1 | 78 |
| 931 | Abstract withdrawn. **2005**, 7, 1 | 78 |
| 930 | The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use. **2005**, 7, 1 | 0 |
| 929 | Update on HER2-directed therapy. **2005**, 7, 1 | 1 |
| 928 | Present situation and future of genetic profiling for prognosis and treatment. **2005**, 7, 1 | 78 |
| 927 | Tumor microenvironments, the immune system and cancer survival. **2005**, 6, 211 | 20 |
| 926 | A DNA microarray survey of gene expression in normal human tissues. **2005**, 6, R22 | 172 |
| 925 | GATA3 protein as a MUC1 transcriptional regulator in breast cancer cells. **2006**, 8, R64 | 24 |
| 924 | Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. **2006**, 8, R66 | 108 |
| 923 | Establishment of the epithelial-specific transcriptome of normal and malignant human breast cells based on MPSS and array expression data. **2006**, 8, R56 | 103 |
| 922 | CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. **2006**, 8, R59 | 716 |
| 921 | Gene expression signatures of morphologically normal breast tissue identify basal-like tumors. **2006**, 8, R58 | 107 |
| 920 | Predicting a local recurrence after breast-conserving therapy by gene expression profiling. **2006**, 8, R62 | 163 |

| | | |
|---|---|---|
| 919 | Classification of ductal carcinoma in situ by gene expression profiling. **2006**, 8, R61 | 128 |
| 918 | Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patients. **2006**, 8, R34 | 188 |
| 917 | The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. **2006**, 8, R32 | 56 |
| 916 | A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. **2006**, 8, R25 | 387 |
| 915 | Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. **2006**, 8, R23 | 150 |
| 914 | Dissection of a metastatic gene expression signature into distinct components. **2006**, 7, R117 | 34 |
| 913 | Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. **2006**, 8, R47 | 39 |
| 912 | Genetics of soft tissue tumors. **2006**, 1, 435-66 | 28 |
| 911 | Microarray analysis of stem cells and differentiation. **2006**, 420, 225-54 | 10 |
| 910 | Cardiovascular Disease. **2006**, | |
| 909 | Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative. **2006**, 8, 31-9 | 93 |
| 908 | Cancer du sein. **2006**, | |
| 907 | Breast Cancer and Molecular Medicine. **2006**, | 2 |
| 906 | Breast Cancer Research Protocols. **2006**, | 2 |
| 905 | Biomarkers in Breast Cancer. **2006**, | 3 |
| 904 | A novel method for gene expression mapping of metastatic competence in human bladder cancer. **2006**, 8, 181-9 | 13 |
| 903 | Histopathologic and Metabolic Criteria for Assessment of Treatment Response in Breast Cancer. **2006**, 1, 83-94 | |
| 902 | Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. **2006**, 5, 2947-55 | 32 |

| | | |
|---|---|---|
| 901 | Cancer Drug Resistance. **2006**, | 17 |
| 900 | Cancer survivorship--genetic susceptibility and second primary cancers: research strategies and recommendations. **2006**, 98, 15-25 | 233 |
| 899 | Detection of circulating tumour cells in blood by quantitative real-time RT-PCR: effect of pre-analytical time. **2006**, 44, 1082-7 | 25 |
| 898 | Molecular biomarkers for cancer detection in blood and bodily fluids. **2006**, 43, 497-560 | 13 |
| 897 | Complex Systems Science in Biomedicine. **2006**, | 18 |
| 896 | Cancer Genome Anatomy Project. **2006**, | 3 |
| 895 | High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. **2006**, 8, 214 | 25 |
| 894 | Toxicogenomics and cross-species biomarker discovery: applications in drug discovery and safety assessment. **2006**, 16, 79-87 | 6 |
| 893 | Proteomics of breast cancer: principles and potential clinical applications. **2006**, 5, 1772-86 | 58 |
| 892 | Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. **2006**, 24, 3726-34 | 2031 |
| 891 | In Vitro Transformation Models: Modeling Human Cancer. **2006**, 5, 631-635 | 4 |
| 890 | 2005 Curt Stern Award address. Exploring along a crooked path. **2006**, 79, 429-33 | 1 |
| 889 | The role of nicotinamide adenine dinucleotide phosphate oxidase-derived reactive oxygen species in the acquisition of metastatic ability of tumor cells. **2006**, 169, 294-302 | 43 |
| 888 | Erbb2 regulates inflammation and proliferation in the skin after ultraviolet irradiation. **2006**, 169, 1402-14 | 31 |
| 887 | Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. **2006**, 12, 1533-9 | 282 |
| 886 | Molecular classification of breast tumors: toward improved diagnostics and treatments. **2007**, 360, 91-114 | 50 |
| 885 | The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. **2006**, 313, 1929-35 | 3392 |
| 884 | Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. **2006**, 24, 2137-50 | 2806 |

| | | |
|---|---|---|
| 883 | Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. **2006**, 98, 262-72 | 1485 |
| 882 | Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. **2006**, 24, 5652-7 | 824 |
| 881 | Jointly analyzing gene expression and copy number data in breast cancer using data reduction models. **2006**, 3, 2-16 | 35 |
| 880 | Breast cancer: not a single disease. **2006**, 4, 1-3 | 2 |
| 879 | Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes. **2006**, 6, 59 | 7 |
| 878 | Exploring the human genome in cancer with genomic approaches. **2006**, 17, 1225-33 | 6 |
| 877 | The Basal Phenotype of BRCA1-Related Breast Cancer. **2006**, 17, 22-25 | |
| 876 | A Molecular Profiling of Breast Cancer. **2006**, 9, 19-24 | 2 |
| 875 | Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. **2006**, 131, 925-33 | 124 |
| 874 | Heterogeneity of mammary lesions represent molecular differences. **2006**, 6, 275 | 29 |
| 873 | Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters. **2006**, 5, 47 | 19 |
| 872 | A systems approach to clinical oncology: focus on breast cancer. **2006**, 4, 5 | 37 |
| 871 | Identification of prognostic signatures in breast cancer microarray data using Bayesian techniques. **2006**, 3, 367-81 | 12 |
| 870 | Concordance among gene-expression-based predictors for breast cancer. **2006**, 355, 560-9 | 1071 |
| 869 | Multipotent, dedifferentiated cancer stem-like cells from brain gliomas. **2006**, 15, 423-35 | 45 |
| 868 | Multistability and Multicellularity: Cell Fates as High-Dimensional Attractors of Gene Regulatory Networks. **2006**, 293-326 | 3 |
| 867 | Gene expression profiling and clinical outcome in breast cancer. **2006**, 10, 429-43 | 47 |
| 866 | Tumor-protective and tumor-promoting actions of dietary whey proteins in an N-methyl-N-nitrosourea model of rat mammary carcinogenesis. **2006**, 55, 171-7 | 5 |

| | | |
|---|---|---|
| 865 | Technology Insight: tuning into the genetic orchestra using microarrays--limitations of DNA microarrays in clinical practice. **2006**, 3, 501-16 | 63 |
| 864 | Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. **2006**, 66, 4636-44 | 235 |
| 863 | Cancer biomarkers--an invitation to the table. **2006**, 312, 1165-8 | 171 |
| 862 | Gene selection using support vector machines with non-convex penalty. **2006**, 22, 88-95 | 188 |
| 861 | Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. **2006**, 580, 2935-44 | 41 |
| 860 | Gene expression analysis and clinical diagnosis. **2006**, 363, 157-64 | 26 |
| 859 | GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. **2006**, 127, 1041-55 | 479 |
| 858 | Cancer metastasis: building a framework. **2006**, 127, 679-95 | 3126 |
| 857 | Spotting and validation of a genome wide oligonucleotide chip with duplicate measurement of each gene. **2006**, 344, 1111-20 | 11 |
| 856 | Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. **2006**, 42, 1057-61 | 7 |
| 855 | Mammary stem and progenitor cells: tumour precursors?. **2006**, 42, 1225-36 | 16 |
| 854 | What clinicians need to know about antioestrogen resistance in breast cancer therapy. **2006**, 42, 2692-705 | 43 |
| 853 | Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. **2006**, 42, 3149-56 | 164 |
| 852 | Constructing gene expression-based diagnostic rules for understanding individualized etiology of heart failure. **2006**, 1, 33-40 | 1 |
| 851 | Deconstructing the molecular portrait of basal-like breast cancer. **2006**, 12, 537-44 | 119 |
| 850 | Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. **2006**, 37, 1217-26 | 259 |
| 849 | New approaches to identification of antigenic candidates for future prostate cancer immunotherapy. **2006**, 1, 273-284 | 4 |
| 848 | Data Perturbation Independent Diagnosis and Validation of Breast Cancer Subtypes Using Clustering and Patterns. **2006**, 2, 117693510600200 | 10 |

| | | |
|---|---|---|
| 847 | Identification of genes with altered expression in medullary breast cancer vs. ductal breast cancer and normal breast epithelia. **2006**, 28, 1327 | 2 |
| 846 | Gene array studies in renal neoplasia. **2006**, 6, 502-11 | 12 |
| 845 | Operational criteria for selecting a cDNA microarray data normalization algorithm. **2006**, 15, 983-996 | 7 |
| 844 | Characterization of microarray data using wavelet power spectrum. **2006**, 10, 493-501 | |
| 843 | Diffusion limitation: a possible source for the occurrence of doughnut patterns on DNA microarrays. **2006**, 41, 609-16 | 17 |
| 842 | Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. **2006**, 3, e47 | 476 |
| 841 | . **2006**, | 25 |
| 840 | Towards a Unified Approach to New Target Discovery in Breast Cancer: Combining the Power of Genomics, Proteomics and Immunology. **2006**, 167-207 | |
| 839 | References. **2006**, 401-449 | |
| 838 | Microarray-based Expression Profiling: From Technological Basics to Diagnostic Perspectives. 728-754 | |
| 837 | New Technologies/New Markers/New Challenges. **2006**, 325-331 | |
| 836 | Gene Expression Profiling with DNA Microarrays. **2006**, 47-61 | |
| 835 | Microarrays and Expression Profiling in Cancer. **2006**, | |
| 834 | Tumor biology of breast cancer in young women. **2005**, 23, 9-15 | 53 |
| 833 | INVASIVE MICROPAPILLARY CARCINOMA OF THE BREAST (IMPCa): GENE EXPRESSION PROFILE. **2006**, | |
| 832 | Fast-Lane Evolution in the Tumor Microenvironment. **2006**, 317-329 | 0 |
| 831 | Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report. **2006**, 4, 28-38 | 10 |
| 830 | Genomic approach to biomarker identification and its recent applications. **2006**, 2, 103-33 | 31 |

| | | |
|---|---|---|
| 829 | Personalized medicine for breast cancer: moving forward and going back. **2006**, 3, 363-370 | 1 |
| 828 | Apoptotic inducing ability of a novel photosensitizing agent, Ge sulfophthalocyanine, on oesophageal and breast cancer cell lines. **2006**, | 2 |
| 827 | Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. **2006**, 16, 147-55 | 11 |
| 826 | Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. **2006**, 9, 1-3 | |
| 825 | Herceptin (Trastuzumab) in the Adjuvant Setting: The Need for Accurate HER-2 Testing in Breast Cancer. **2006**, 13, 200-201 | |
| 824 | Microarray Approaches to Gene Expression Analysis. **2006**, 121-148 | 1 |
| 823 | Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast activation protein and endosialin. **2006**, 15, 35-42 | 29 |
| 822 | Subclasses of Breast Carcinoma and Their Clinical Significance. **2006**, 13, 200 | |
| 821 | Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. **2006**, 30, 1357-66 | 36 |
| 820 | Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance. **2006**, 29, 90-5 | 28 |
| 819 | Breast Carcinomas With Basal and Myoepithelial Differentiation. **2006**, 13, 333-334 | |
| 818 | Inflammatory breast cancer: current understanding. **2006**, 18, 563-71 | 31 |
| 817 | Molecular profiling of breast cancer. **2006**, 18, 59-63 | 23 |
| 816 | Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1. **2006**, 16, 515-25 | 43 |
| 815 | A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. **2006**, 17, 1201-9 | 11 |
| 814 | Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. **2006**, 30, 1097-104 | 206 |
| 813 | Molecular Pathogenesis of Human Cancer. **2006**, 349-374 | |
| 812 | Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. **2006**, 30, 300-9 | 176 |

| | | |
|---|---|---|
| 811 | Learning Kernels from Distance Constraints. **2006**, 2, 441-451 | |
| 810 | Comparative expressed sequence hybridization reveals differential gene expression in morphological breast cancer subtypes. **2006**, 208, 486-94 | 11 |
| 809 | Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. **2006**, 208, 495-506 | 248 |
| 808 | Recent Advances in Carbohydrate Microarrays. **2006**, 25, 1027-1032 | 57 |
| 807 | The challenging estrogen receptor-negative/ progesterone receptor-negative/HER-2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy?. **2006**, 12, 360-2 | 40 |
| 806 | Chipping into the human genome: novel insights for transplantation. **2006**, 210, 138-55 | 12 |
| 805 | Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. **2006**, 19, 146-57 | 7 |
| 804 | DNA microarray technology for target identification and validation. **2006**, 33, 496-503 | 49 |
| 803 | Comparative transcriptome maps: a new approach to the diagnosis of colorectal carcinoma patients using cDNA microarrays. **2006**, 69, 218-27 | 8 |
| 802 | Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. **2006**, 49, 22-34 | 257 |
| 801 | Metaplastic breast carcinomas are basal-like tumours. **2006**, 49, 10-21 | 244 |
| 800 | Clinical significance of CK5/6 and PTEN protein expression in patients with bilateral breast carcinoma. **2006**, 49, 248-55 | 15 |
| 799 | Cytokeratin profiles of male breast cancers. **2006**, 49, 365-70 | 20 |
| 798 | Genetic regulators of large-scale transcriptional signatures in cancer. **2006**, 38, 421-30 | 185 |
| 797 | Genome-wide analysis of estrogen receptor binding sites. **2006**, 38, 1289-97 | 1115 |
| 796 | Tumor metastasis: mechanistic insights and clinical challenges. **2006**, 12, 895-904 | 1588 |
| 795 | Common markers of proliferation. **2006**, 6, 99-106 | 402 |
| 794 | Linking oncogenic pathways with therapeutic opportunities. **2006**, 6, 735-41 | 139 |

| | | |
|---|---|---|
| 793 | Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. **2006**, 95, 1334-41 | 53 |
| 792 | Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. **2006**, 19, 264-71 | 806 |
| 791 | Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. **2006**, 19, 307-19 | 75 |
| 790 | Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. **2006**, 19, 617-21 | 175 |
| 789 | Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. **2006**, 19, 1506-11 | 103 |
| 788 | Molecular profiling reveals myeloid leukemia cell lines to be faithful model systems characterized by distinct genomic aberrations. **2006**, 20, 994-1001 | 36 |
| 787 | Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. **2006**, 25, 981-9 | 102 |
| 786 | Laser microdissection and microarray analysis of breast tumors reveal ER-alpha related genes and pathways. **2006**, 25, 1413-9 | 60 |
| 785 | Gene expression profiling of breast cell lines identifies potential new basal markers. **2006**, 25, 2273-84 | 425 |
| 784 | Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. **2006**, 25, 2328-38 | 156 |
| 783 | An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. **2006**, 25, 3994-4008 | 431 |
| 782 | Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. **2006**, 25, 5837-45 | 87 |
| 781 | Basal-like breast cancer and the BRCA1 phenotype. **2006**, 25, 5846-53 | 368 |
| 780 | Histopathology of BRCA1- and BRCA2-associated breast cancer. **2006**, 59, 27-39 | 73 |
| 779 | Machine learning in bioinformatics: a brief survey and recommendations for practitioners. **2006**, 36, 1104-25 | 64 |
| 778 | Transcriptional profiling of mammary gland side population cells. **2006**, 24, 1065-74 | 44 |
| 777 | Gene expression profiling of breast cancer. **2006**, 13, 2-7 | 17 |
| 776 | Embracing the complexity of genomic data for personalized medicine. **2006**, 16, 559-66 | 103 |

| | | |
|---|---|---|
| 775 | Timing of dietary estrogenic exposures and breast cancer risk. **2006**, 1089, 14-35 | 64 |
| 774 | Proteomic and genomic technologies for biomarker discovery. **2006**, 2, 5-11 | 2 |
| 773 | A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. **2006**, 6, 803-9 | 48 |
| 772 | Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. **2006**, 23, 1951-8 | 10 |
| 771 | The role of the epidermal growth factor receptor in breast cancer. **2006**, 11, 3-11 | 55 |
| 770 | The ErbB2 signaling network as a target for breast cancer therapy. **2006**, 11, 13-25 | 51 |
| 769 | Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. **2006**, 95, 219-28 | 77 |
| 768 | Elevated EDAR signalling promotes mammary gland tumourigenesis with squamous metaplasia.. **2021**, | 0 |
| 767 | Survival outcomes in elderly Taiwanese women according to breast cancer subtype and lymph node status: A single-center retrospective study.. **2021**, 16, e0261258 | |
| 766 | Can Systems Biology Advance Clinical Precision Oncology?. **2021**, 13, | 1 |
| 765 | EZH2 Protein Expression in Triple-negative Breast Cancer Treated With Neoadjuvant Chemotherapy: An Exploratory Study of Association With Tumor Response and Prognosis.. **2022**, 30, 157-164 | 0 |
| 764 | JOINT AND INDIVIDUAL ANALYSIS OF BREAST CANCER HISTOLOGIC IMAGES AND GENOMIC COVARIATES.. **2021**, 15, 1697-1722 | 2 |
| 763 | Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.. **2021**, 22, | 2 |
| 762 | Pathology of Neoadjuvant Systemic Therapy Response. **2022**, 269-290 | |
| 761 | The Role of Breast Cancer Stem Cells in Chemoresistance and Metastasis in Triple-Negative Breast Cancer.. **2021**, 13, | 3 |
| 760 | Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer. **2021**, 13, | 1 |
| 759 | Integration of DNA Microarray with Clinical and Genomic Data.. **2022**, 2401, 239-248 | |
| 758 | Design and synthesis of chromone-nitrogen mustard derivatives and evaluation of anti-breast cancer activity.. **2022**, 37, 431-444 | 1 |

| | | |
|---|---|---|
| 757 | Bayesian multistudy factor analysis for high-throughput biological data. **2021**, 15, | 3 |
| 756 | Molecular analysis of TCGA breast cancer histologic types.. **2021**, 1, | 2 |
| 755 | . **2021**, 108, 11S1-11S7 | 0 |
| 754 | DRAIC promotes growth of breast cancer by sponging miR-432-5p to upregulate SLBP. **2021**, | 1 |
| 753 | Stem cells and fundamental problems of classical histology. **2020**, 158, 139-150 | |
| 752 | CoMI: consensus mutual information for tissue-specific gene signatures.. **2022**, 22, 624 | |
| 751 | Research Progress of Long Noncoding RNA in Breast Cancer. **2022**, 12, 52-60 | |
| 750 | Challenges and Gaps in Clinical Trial Genomic Data Management.. **2022**, 6, e2100193 | |
| 749 | Immunotherapy in triple-negative breast cancer: A literature review and new advances.. **2022**, 13, 219-236 | 2 |
| 748 | Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.. **2022**, 47, | 1 |
| 747 | Breast cancer in the era of integrating "Omics" approaches.. **2022**, 11, 17 | 0 |
| 746 | Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review.. **2022**, 14, | 1 |
| 745 | Evolution of gene expression signature in mammary gland stem cells from neonatal to old mice.. **2022**, 13, 335 | 0 |
| 744 | [1. Seek for Complete Cure of Breast Cancer-Understanding Breast Image from Breast Pathology].. **2022**, 78, 413-420 | |
| 743 | Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.. **2022**, 1 | 1 |
| 742 | ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation.. **2022**, 13, 2011 | 0 |
| 741 | Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis.. **2022**, | 0 |
| 740 | Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.. **2022**, 9, 881551 | 2 |

| | | |
|---|---|---|
| 739 | Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers.. **2022**, 8, 51 | 0 |
| 738 | 'On the Spot' Digital Pathology of Breast Cancer Based on Single-Cell Mass Spectrometry Imaging.. **2022**, | 3 |
| 737 | A comprehensive study of mRNA and long noncoding RNAs in Indian Breast cancer patients using transcriptomics approach. | |
| 736 | Identifying a confused cell identity for esophageal squamous cell carcinoma.. **2022**, 7, 122 | 0 |
| 735 | Immunohistochemical Markers for Distinguishing Metastatic Breast Carcinoma from Other Common Malignancies: Update and Revisit.. **2022**, | 1 |
| 734 | Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients.. **2022**, 2022, 1525245 | 2 |
| 733 | Clinical Impact of 11q13.3 Amplification on Immune Cell Infiltration and Prognosis in Breast Cancer.. **2022**, 15, 4037-4052 | 0 |
| 732 | The ELEANOR non-coding RNA expression contributes to cancer dormancy and predicts late recurrence of ER-positive breast cancer.. **2022**, | 1 |
| 731 | Breast tumor microenvironment structures are associated with genomic features and clinical outcome.. **2022**, | 4 |
| 730 | MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Unique Proteomic Networks and Variable Clinical Significance. | 0 |
| 729 | Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions.. **2022**, 167, 92-102 | 0 |
| 728 | Stabilization of Notch1 and □catenin in response to ER- breast cancer-specific up-regulation of PSAT1 mediates distant metastasis.. **2022**, 20, 101399 | 0 |
| 727 | Systems biology of cancer progression. 1-6 | |
| 726 | Deregulated signaling networks in lung cancer. 421-442 | |
| 725 | Prognosis of cancer. 473-498 | |
| 724 | Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery. 499-517 | |
| 723 | Focusing Target Discovery and Validation Through Proteogenomics and Molecular Imaging. **2005**, 151-163 | |
| 722 | Image_1.pdf. **2020**, | |

721 Table_1.XLSX. **2020**,

720 Data_Sheet_1.XLSX. **2018**,

719 Data_Sheet_2.XLSX. **2018**,

718 Image_1.PDF. **2018**,

717 Image_2.PDF. **2018**,

716 Table_1.docx. **2018**,

715 Table_2.DOCX. **2018**,

714 Table_3.PDF. **2018**,

713 Data_Sheet_1.pdf. **2018**,

712 Table_1.xlsx. **2018**,

711 Table_2.xlsx. **2018**,

710 Image_1.JPEG. **2019**,

709 Image_2.JPEG. **2019**,

708 Table_1.XLSX. **2019**,

707 Image_1.TIF. **2018**,

706 Image_2.TIF. **2018**,

705 Image_3.TIF. **2018**,

704 Image_4.TIF. **2018**,

703 Image_5.TIF. **2018**,

702 Table_1.docx. **2018**,

701 DataSheet_1.zip. **2019**,

700 Image_1.tif. **2019**,

699 Image_10.png. **2019**,

698 Image_11.tif. **2019**,

697 Image_12.tif. **2019**,

696 Image_2.png. **2019**,

695 Image_3.tif. **2019**,

694 Image_4.tif. **2019**,

693 Image_5.tif. **2019**,

692 Image_6.tif. **2019**,

691 Image_7.tif. **2019**,

690 Image_8.tif. **2019**,

689 Image_9.tif. **2019**,

688 Table_1.xlsx. **2019**,

687 Data_Sheet_1.PDF. **2020**,

686 DataSheet_1.docx. **2019**,

685 Data_Sheet_1.PDF. **2020**,

684 DataSheet_1.docx. **2020**,

683 Image_1.TIF. **2020**,

682 Table_1.xlsx. **2020**,

681 Image_1.tif. **2020**,

680 Table_1.docx. **2020**,

679 Data_Sheet_1.pdf. **2018**,

678 Video_1.AVI. **2018**,

677 Data_Sheet_1.docx. **2020**,

676 Data_Sheet_1.PDF. **2020**,

675 Table_1.XLSX. **2019**,

674 Table_2.DOCX. **2019**,

673 Table_3.XLS. **2019**,

672 Table_1.docx. **2020**,

671 Table_2.docx. **2020**,

670 Table_3.docx. **2020**,

669 Table_1.DOCX. **2019**,

668 Data_Sheet_1.PDF. **2020**,

667 Table_1.XLSX. **2020**,

666 Data_Sheet_1.PDF. **2020**,

665 Table_1.XLSX. **2020**,

664 Table_2.XLSX. **2020**,

663 Table_3.XLSX. **2020**,

662 Table_4.XLSX. **2020**,

661 Data_Sheet_1.docx. **2020**,

660 Table_1.docx. **2020**,

659 Table_2.docx. **2020**,

658 Table_1.xlsx. **2020**,

657 Table_2.xlsx. **2020**,

656 Table_3.xlsx. **2020**,

655 Image_1.png. **2020**,

654 Table_1.docx. **2020**,

653 Table_2.docx. **2020**,

652 Data_Sheet_1.zip. **2018**,

651 DataSheet_1.zip. **2020**,

650 DataSheet_2.pdf. **2020**,

649 Presentation_1.pdf. **2019**,

648 Image_1.pdf. **2020**,

647 Image_2.pdf. **2020**,

646 Image_3.pdf. **2020**,

645 Image_4.pdf. **2020**,

644 Image_5.pdf. **2020**,

643 Image_6.pdf. **2020**,

642 Image_7.pdf. **2020**,

641 Table_1.pdf. **2020**,

640 Data_Sheet_1.ZIP. **2020**,

639 Data_Sheet_1.xlsx. **2020**,

638 Image_1.TIF. **2020**,

637 Image_2.TIF. **2020**,

636 Image_3.TIF. **2020**,

635 Image_4.TIF. **2020**,

634 Image_5.TIF. **2020**,

633 Subclassifying triple-negative breast cancers and its potential clinical utility.. **2022**, 1 0

632 Histological and Immunohistochemical Characteristics for Hereditary Breast Cancer Risk in a Cohort of Brazilian Women.. **2022**, 1

| | | |
|---|---|---|
| 631 | Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells.. **2022**, 16, 11782234221080553 | |
| 630 | Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy. **2020**, 35, 361-370 | 4 |
| 629 | Inverse correlation between Ki67 expression as a continuous variable and outcomes in luminal HER2-negative breast cancer.. **2019**, 5, 72-78 | 3 |
| 628 | Differences in clinicopathologic features and subtype distribution of invasive breast cancer between women older and younger than 40 years.. **2019**, 5, 92-97 | 2 |
| 627 | Differences in clinicopathologic features and subtype distribution of invasive breast cancer between elderly and non-elderly women.. **2021**, 7, 59-64 | |
| 626 | Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes.. **2021**, 7, 130-135 | |
| 625 | Nanomaterial Technology and Triple Negative Breast Cancer.. **2021**, 11, 828810 | 1 |
| 624 | Comprehensive comparison of theranostic nanoparticles in breast cancer.. **2022**, 11, 1-27 | |
| 623 | Triple-negative breast cancer - an aggressive subtype of breast cancer. **2022**, 1-28 | |
| 622 | Precision diagnostics in cancer: Predict, prevent, and personalize. **2022**, | |
| 621 | Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2022**, 1-27 | |
| 620 | Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.. **2022**, 6, e2100463 | 1 |
| 619 | CmP Signaling Network Leads to Identification of Prognostic Biomarkers for Triple-Negative Breast Cancer in Caucasian Women.. **2022**, 26, 198-219 | 3 |
| 618 | Density-Dependent Migration Characteristics of Cancer Cells Driven by Pseudopod Interaction.. **2022**, 10, 854721 | 0 |
| 617 | PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives.. **2022**, 14, | 1 |
| 616 | Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC). **2022**, 15, 542 | 0 |
| 615 | The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer.. **2022**, 3, 224-239 | |
| 614 | Leveraging Deep Learning Techniques and Integrated Omics Data for Tailored Treatment of Breast Cancer. **2022**, 12, 674 | 0 |

| | | |
|---|---|---|
| 613 | Personalisierte Medizin â Innovative Therapiemöglichkeiten für das metastasierte Mammakarzinom. **2022**, 55, 335-343 | |
| 612 | Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.. **2022**, 8, 56 | 1 |
| 611 | Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. **2022**, 14, 2404 | |
| 610 | Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1.. **2022**, 1 | 0 |
| 609 | Comprehensive Landscape of STEAP Family Members Expression in Human Cancers: Unraveling the Potential Usefulness in Clinical Practice Using Integrated Bioinformatics Analysis. **2022**, 7, 64 | 2 |
| 608 | Muscarinic Receptors Associated with Cancer.. **2022**, 14, | |
| 607 | Mouse Mammary Tumor Virus (MMTV) and MMTV-like Viruses: An In-depth Look at a Controversial Issue. **2022**, 14, 977 | 0 |
| 606 | CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.. **2022**, 13, 2642 | 0 |
| 605 | Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. **2022**, 14, 2405 | |
| 604 | Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration Resistant Prostate Cancer.. **2022**, | 1 |
| 603 | Subtype-Specific Tumour Immune Microenvironment in Risk of Recurrence of Ductal Carcinoma In Situ: Prognostic Value of HER2. **2022**, 10, 1061 | 0 |
| 602 | Association between tumor F-fluorodeoxyglucose metabolism and survival in women with estrogen receptor-positive, HER2-negative breast cancer.. **2022**, 12, 7858 | 0 |
| 601 | Early-Stage Progression of Breast Cancer. **2022**, 113-123 | |
| 600 | Implications of BRCA1, BRCA2 Gene in Overall Development and Prognosis of Breast Cancer. **2022**, 87-112 | |
| 599 | Utility of Personalized Medicine in the Treatment of Different Subtypes of Breast Cancer. **2022**, 337-366 | |
| 598 | Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials. **2022**, 367-401 | |
| 597 | Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer.. **2022**, 22, 548 | 0 |
| 596 | Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression.. **2022**, 102029 | 1 |

| | | |
|---|---|---|
| 595 | Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies. 1 | 0 |
| 594 | Molecular Characterization of the Transition to Malignancy in a Genetically Engineered Mouse-Based Model of Ductal Carcinoma In situ. **2004**, 2, 453-463 | 36 |
| 593 | The Current State of Precision Medicine and Targeted-Cancer Therapies: Where Are We?. **2022**, 119-200 | |
| 592 | Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer.. **2022**, 12, 8176 | 0 |
| 591 | Breast Cancer-Stromal Interactions: Adipose-derived stromal/stem cell Age and Cancer Subtype Mediated Remodeling.. **2022**, | 0 |
| 590 | Mir-4728 is a Valuable Biomarker for Diagnostic and Prognostic Assessment of HER2-Positive Breast Cancer. **2022**, 9, | 1 |
| 589 | Fractionated irradiation of MCF7 breast cancer cells rewires a gene regulatory circuit towards a treatment-resistant stemness phenotype.. **2022**, | |
| 588 | Transcriptional repression by FoxM1 suppresses tumor differentiation and promotes metastasis of breast cancer.. **2022**, | 1 |
| 587 | Socioeconomic, Clinical, and Molecular Features of Breast Cancer Influence Overall Survival of Latin American Women.. **2022**, 12, 845527 | 0 |
| 586 | Evaluation of Anti-Cancer and Anti-Metastatic Effects of Folate-PEGylated Niosome for Co-Delivery of Letrozole and Ascorbic Acid on Breast Cancer Cells. | 0 |
| 585 | Adenoid Cystic Carcinoma of the Breast: A Case Report. **2022**, | |
| 584 | Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer. **2022**, 14, 2509 | 1 |
| 583 | Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies. **2022**, 12, | 0 |
| 582 | Clinicopathological characteristics and prognosis of microinvasive breast cancer: A population-based analysis. | |
| 581 | The AKT1E17K Allele Promotes Breast Cancer in Mice. **2022**, 14, 2645 | |
| 580 | Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. **2022**, 14, 2615 | 2 |
| 579 | Molecular Diagnostic and Prognostication Assays for the Subtyping of Urinary Bladder Cancer Are on the Way to Illuminating Our Vision. **2022**, 23, 5620 | |
| 578 | Wnt Signaling in the Breast: From Development to Disease. **2022**, 10, | 1 |

| | | |
|---|---|---|
| 577 | Exploring BODIPY-Based Sensor for Imaging of Intracellular Microviscosity in Human Breast Cancer Cells. **2022**, 23, 5687 | |
| 576 | Learning from Small Medical Data - Robust Semi-Supervised Cancer Prognosis Classifier with Bayesian Variational Autoencoder. | |
| 575 | The prognostic significance of immunophenotypes in canine malignant mammary tumors. **2022**, 74, 299-309 | 0 |
| 574 | AZD4547 and calcitriol synergistically inhibited BT-474 cell proliferation while modified stemness and tumorsphere formation. **2022**, 106132 | |
| 573 | FOXF2 oppositely regulates stemness in luminal and basal-like breast cancer cells through the Wnt/beta-catenin pathway. **2022**, 102082 | 0 |
| 572 | Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping. **2022**, 14, 2571 | 0 |
| 571 | Molecular Subtypes As Emerging Predictors of Clinicopathological Response to Neoadjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC): A Single-Centre Experience in Western India. **2022**, | |
| 570 | Necroptosis-Related LncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer. 12, | 1 |
| 569 | Use of Radionuclide-Based Imaging Methods in Breast Cancer. **2022**, | 0 |
| 568 | High expression of SLC20A1 is less effective for endocrine therapy and predicts late recurrence in ER-positive breast cancer. **2022**, 17, e0268799 | |
| 567 | EpsteinâBarr Virus Association with Breast Cancer: Evidence and Perspectives. **2022**, 11, 799 | 0 |
| 566 | Breast Cancer Therapy: The Potential Role of Mesenchymal Stem Cells in Translational Biomedical Research. **2022**, 10, 1179 | |
| 565 | CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review. 12, | 2 |
| 564 | EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. **2022**, 23, 6122 | 0 |
| 563 | Metabolomics and EMT Markers of Breast Cancer: A Crosstalk and Future Perspective. **2022**, 29, 200-222 | 2 |
| 562 | Dihydropyrazole-Carbohydrazide Derivatives with Dual Activity as Antioxidant and Anti-Proliferative Drugs on Breast Cancer Targeting the HDAC6. **2022**, 15, 690 | 1 |
| 561 | Identification of Crucial lncRNAs for Luminal A Breast Cancer through RNA Sequencing. **2022**, 2022, 1-14 | 0 |
| 560 | Proteomic analysis reveals stage-specific reprogramed metabolism for the primary breast cancer cell lines MGSO-3 and MACL-1. 2200095 | 1 |

| | | |
|---|---|---|
| 559 | The role of radiogenomics in the diagnosis of breast cancer: a systematic review. **2022**, 23, | 2 |
| 558 | Fringe family genes and their modulation of Notch signaling in cancer. **2022**, 188746 | 0 |
| 557 | Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtype. | 0 |
| 556 | Cellular Senescence in Normal Mammary Gland and Breast Cancer. Implications for Cancer Therapy. **2022**, 13, 994 | 0 |
| 555 | Breast cancer recurrence and survival rates in patients who underwent breast-conserving surgery under non-mechanically ventilated anesthesia. | 0 |
| 554 | HOXA1, a breast cancer oncogene. **2022**, 188747 | 0 |
| 553 | Synthesis, anti-cancer activity, gene expression and docking stimulation of 2-thioxoimidazolidin-4-one derivatives. **2022**, 1265, 133401 | 2 |
| 552 | Polo-Like Kinase 1 Regulates Chromosomal Instability and Paclitaxel Resistance in Breast Cancer Cells. 25, | 0 |
| 551 | A review of bioinformatics tools and web servers in different microarray platforms used in cancer research. **2022**, | 0 |
| 550 | miR-638 Serves as a Biomarker of 5-Fluorouracil Sensitivity to Neoadjuvant Chemotherapy in Breast Cancer. 25, | 1 |
| 549 | COVID-19 and its impact on cancer, HIV, and mentally ill patients. **2022**, 95-137 | |
| 548 | Breast. **2022**, 253-292 | |
| 547 | Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors. **2022**, 18, e1010109 | |
| 546 | Evaluation of the Prognostic Value of CD56 (140 kDa Isoform) Expression in Breast Cancer Tissues: an Eight-Year Retrospective Study. **2022**, 26, 175-182 | |
| 545 | Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers. **2022**, 17, e0270139 | |
| 544 | The COVID-19 Pandemic Impact on Breast Cancer Diagnosis: A Retrospective Study. | 1 |
| 543 | Breast Cancer Genomics: Primary and Most Common Metastases. **2022**, 14, 3046 | |
| 542 | Differential Private Deep Learning Models for Analyzing Breast Cancer Omics Data. 12, | 0 |

| | | |
|---|---|---|
| 541 | Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment. **2022**, 12, | 0 |
| 540 | The importance of cardiovascular disease in breast cancer survivors. mini review. **2022**, 6, 106-108 | |
| 539 | Response-based molecular subtypingâ€emergence of the third generation of breast cancer subtypes. **2022**, 40, 592-594 | |
| 538 | Clinical relevance of receptor conversion in metastatic breast cancer. **2022**, 101, e29136 | 0 |
| 537 | Glioma Subtypes Based on the Activity Changes of Immunologic and Hallmark Gene Sets in Cancer. 13, | 1 |
| 536 | Upregulated GATA3/miR205-5p Axis Inhibits MFNG Transcription and Reduces the Malignancy of Triple-Negative Breast Cancer. **2022**, 14, 3057 | 0 |
| 535 | Evaluation of doxorubicin in three-dimensional culture of breast cancer cells and the response in PI3K/AKT/PTEN signaling pathways: a pilot study. 1-9 | |
| 534 | Construction of ceRNA Networks Associated With CD8 T Cells in Breast Cancer. 12, | 1 |
| 533 | The Breast Cancer Protooncogenes HER2, BRCA1 and BRCA2 and Their Regulation by the iNOS/NOS2 Axis. **2022**, 11, 1195 | 0 |
| 532 | Global Trends in Research of Androgen Receptor Associated With Breast Cancer From 2011 to 2020: A Scientometric Analysis. 13, | 0 |
| 531 | Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review. **2022**, 23, | 0 |
| 530 | Identifying the Best Ki-67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification. | |
| 529 | Advances in the Prevention and Treatment of Obesity-Driven Effects in Breast Cancers. 12, | 4 |
| 528 | Clinicopathological Characteristics and Prognosis of HER2-Low Early-Stage Breast Cancer: A Single-Institution Experience. 12, | 3 |
| 527 | Euclidean distance-optimized data transformation for cluster analysis in biomedical data (EDOtrans). **2022**, 23, | 0 |
| 526 | Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series. | |
| 525 | Breast cancer in the era of precision medicine. | 0 |
| 524 | Intra- and Peritumoral Radiomics Model Based on Early DCE-MRI for Preoperative Prediction of Molecular Subtypes in Invasive Ductal Breast Carcinoma: A Multitask Machine Learning Study. 12, | 1 |

| | | |
|---|---|---|
| 523 | Tailoring the Omission of Radiotherapy for Early-Stage Breast Cancer Based on Tumor Biology. **2022**, 32, 198-206 | 1 |
| 522 | Association of Obesity and Diabetes With the Incidence of Breast Cancer in Louisiana. **2022**, 63, S83-S92 | 0 |
| 521 | Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. **2005**, 4, 151-170 | 17 |
| 520 | Aspectos clînicos y terap˙ uticos del carcinoma de mama metastßico triple negativo. **2022**, 67, 119-130 | |
| 519 | Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data. 25, | 0 |
| 518 | The evolution of gene expression profiling in breast cancer âA narrative review. **2022**, | |
| 517 | Gene Expression Signatures of the Tumor Microenvironment: Relation to Tumor Phenotypes and Progress in Breast Cancer. **2022**, 401-424 | |
| 516 | A Novel YTHDF3-Based Model to Predict Prognosis and Therapeutic Response in Breast Cancer. 9, | 0 |
| 515 | Machine learning for multi-parametric breast MRI: radiomics-based approaches for lesion classification. | 1 |
| 514 | A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. | 0 |
| 513 | Relationship of micro-RNA, mRNA and eIF Expression in Tamoxifen-Adapted MCF-7 Breast Cancer Cells: Impact of miR-1972 on Gene Expression, Proliferation and Migration. **2022**, 12, 916 | |
| 512 | MicroRNAs miR-142-5p, miR-150-5p, miR-320a-3p, and miR-4433b-5p in Serum and Tissue: Potential Biomarkers in Sporadic Breast Cancer. 13, | 0 |
| 511 | Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance. 12, | 0 |
| 510 | Progesterone Receptor Expression as a Prognostic Factor in Luminal B Breast Cancer. **2022**, 10, 46-52 | |
| 509 | Association of Serum Levels of Plasticizers Compounds, Phthalates and Bisphenols, in Patients and Survivors of Breast Cancer: A Real Connection?. **2022**, 19, 8040 | |
| 508 | Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer. **2022**, 2022, 1-10 | 0 |
| 507 | Ductal keratin 15+ luminal progenitors in normal breast exhibit a basal-like breast cancer transcriptomic signature. **2022**, 8, | 0 |
| 506 | Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes. **2022**, 22, | 0 |

| | | |
|---|---|---|
| 505 | Diagnosing molecular subtypes of breast cancer by means of Raman spectroscopy. | |
| 504 | Update of the 100 Most Cited Articles on Breast Cancer: A Bibliometric Analysis. **2022**, 18, 258-270 | |
| 503 | A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score™. **2022**, 12, 1117 | |
| 502 | Machine learning techniques for identification of carcinogenic mutations, which cause breast adenocarcinoma. **2022**, 12, | 4 |
| 501 | Classification of intrinsic subtypes and histological grade for breast cancers by multimodality images. **2022**, | |
| 500 | Predictive biomarkers for personalized medicine in breast cancer. **2022**, 215828 | 0 |
| 499 | From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. **2022**, 14, 3469 | 1 |
| 498 | Integrative analysis of LncRNA-mRNA signature reveals a functional LincRNA in triple-negative breast cancer. **2022**, 1, | |
| 497 | Anti-breast cancer sinomenine derivatives via mechanisms of apoptosis induction and metastasis reduction. **2022**, 37, 1870-1883 | 0 |
| 496 | Loss of RPTP□primes breast tissue for acid extrusion, promotes malignant transformation and results in early tumour recurrence and shortened survival. | |
| 495 | ALYREF, a novel factor involved in breast carcinogenesis, acts through transcriptional and post-transcriptional mechanisms selectively regulating the short NEAT1 isoform. **2022**, 79, | 0 |
| 494 | EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1□pathway. **2022**, 119, | |
| 493 | The Clinicopathological Profile of Breast Cancer in Young Women from a Tertiary Care Center. | |
| 492 | Celastrol attenuates amphiregulin expression by inhibiting MAPK signaling pathway in triple-negative breast cancer cells. **2022**, 100319 | |
| 491 | Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer. **2022**, 194, 517-529 | |
| 490 | Melatonin has an inhibitory effect on MCF-7 and MDA-MB-231 human breast cancer cell lines by inducing autophagy and apoptosis. | 1 |
| 489 | CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. **2022**, 14, 3361 | 1 |
| 488 | The development of molecular typing in canine mammary carcinomas. | |

| | | |
|---|---|---|
| 487 | ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells. | |
| 486 | Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptorâ€Positive Breast Cancer. OF1-OF12 | 1 |
| 485 | Rethinking breast cancer follow-up based on individual risk and recurrence management. **2022**, 102434 | 1 |
| 484 | Triple-Negative Breast Cancer circRNAome Reveals Hsa_circ_0072309 as a Potential Risk Biomarker. **2022**, 14, 3280 | 0 |
| 483 | LncRNAs in breast cancer: a link to future approaches. | 0 |
| 482 | Comparative Efficacy of Tyrosine Kinase Inhibitors and Antibodyâ€Drug Conjugates in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A Systematic Review and Network Meta-Analysis. **2022**, 14, 3372 | 1 |
| 481 | Circulating proteins as predictive and prognostic biomarkers in breast cancer. **2022**, 19, | 6 |
| 480 | Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study. **2022**, 8, | 1 |
| 479 | Fucoxanthinol Promotes Apoptosis in MCF-7 and MDA-MB-231 Cells by Attenuating Laminin5â€Integrins Axis. **2022**, 2, 145-163 | |
| 478 | Metabolomics of Breast Cancer: A Review. **2022**, 12, 643 | 1 |
| 477 | Clinical trials of immunotherapy in triple-negative breast cancer. | 1 |
| 476 | Concordance between Ki-67 index in invasive breast cancer and molecular signatures: EndoPredict and MammaPrint. **2022**, 17, | 2 |
| 475 | Triple-Negative Breast Cancer: A Review of Current Curative Intent Therapies. **2022**, 29, 4768-4778 | 1 |
| 474 | The crosstalk of the human microbiome in breast and colon cancer: A metabolomics analysis. **2022**, 176, 103757 | 1 |
| 473 | Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts. **2004**, 3, 111-121 | 24 |
| 472 | Predicting continuous values of prognostic markers in breast cancer from microarray gene expression profiles. **2004**, 3, 161-168 | 6 |
| 471 | Comparative Genomic Hybridization Profiles in Human BRCA1 and BRCA2 Breast Tumors Highlight Differential Sets of Genomic Aberrations. **2005**, 65, 822-827 | 18 |
| 470 | Protein Expression Profiling Identifies Subclasses of Breast Cancer and Predicts Prognosis. **2005**, 65, 767-779 | 37 |

| | | |
|---|---|---|
| 469 | Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNF□Receptors in Human Triple-Negative Breast Cancer. **2022**, 14, 3513 | 0 |
| 468 | DNA Damage Response: A Therapeutic Landscape For Breast Cancer Treatment. **2022**, 62-85 | |
| 467 | Changes in kinetic heterogeneity of breast cancer via computer-aided diagnosis on MRI predict the pathological response to neoadjuvant systemic therapy. | |
| 466 | Emerging Trends in Bioinformatics for Breast Cancer Molecular Research. **2022**, 86-108 | |
| 465 | A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes. **2022**, 8, | 0 |
| 464 | Role of Nitric Oxide in Breast Cancer. **2022**, 109-128 | |
| 463 | Radiogenomics analysis reveals the associations of dynamic contrast-enhancedâ□MRI features with gene expression characteristics, PAM50 subtypes, and prognosis of breast cancer. 12, | 2 |
| 462 | Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer - A Prospective, Multicenter Clinical Trial. Publish Ahead of Print, | 2 |
| 461 | Contrast Subgraphs Allow Comparing Homogeneous and Heterogeneous Networks Derived from Omics Data. | |
| 460 | Clinical Efficacy of Trastuzumab, Pertuzumab and Docetaxel as First-Line Treatment for Metastatic Triple-Positive Breast Cancer. **2022**, 12, 7808-7814 | |
| 459 | Personalized Approaches for the Prevention and Treatment of Breast Cancer. **2022**, 12, 1201 | |
| 458 | Firmas g□nicas en el c□cer de mama. **2022**, 35, S67-S86 | |
| 457 | Dietary Polyphenols and its Molecular Mechanism in the Management of Breast Cancer. **2022**, 196-218 | |
| 456 | The regrouping of Luminal B ( HER2 negative), a better discriminator of outcome and recurrence score. | 1 |
| 455 | Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine. **2022**, 14, 3876 | 2 |
| 454 | Mapping the cancer cell states conserved across solid tumors. **2022**, 54, 1066-1067 | 0 |
| 453 | Dynamic changes in intrinsic subtype, immunity status, and risk score before and after neoadjuvant chemo- and HER2-targeted therapy without pCR in HER2-positive breast cancers: A cross-sectional analysis. **2022**, 101, e29877 | 0 |
| 452 | Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologistâ□ Decision on Systemic Therapy in a Real-World Setting. **2022**, 23, 8716 | 1 |

| | | |
|---|---|---|
| 451 | Dual Function of Secreted APE1/Ref-1 in TNBC Tumorigenesis: An Apoptotic Initiator and a Regulator of Chronic Inflammatory Signaling. **2022**, 23, 9021 | |
| 450 | Clinical applications of mass spectrometry-based proteomics in cancer: Where are we?. 2200238 | 2 |
| 449 | PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?. **2022**, 14, 4039 | 3 |
| 448 | A signature constructed with mitophagy-related genes to predict the prognosis and therapy response for breast cancer. **2022**, 14, 6169-6186 | 0 |
| 447 | HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. **2022**, 104205 | 0 |
| 446 | UMAP guided topological analysis of transcriptomic data for cancer subtyping. | 0 |
| 445 | Application of Fluorescence In Situ Hybridization Assisted by Fluorescence Microscope in Detection of Her2 Gene in Breast Cancer Patients. **2022**, 2022, 1-6 | |
| 444 | Triple negative breast cancer: approved treatment options and their mechanisms of action. | 1 |
| 443 | PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation. | 0 |
| 442 | STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges. **2022**, | 0 |
| 441 | Elevated insulin-like growth factor 2 mRNA binding protein 1 levels predict a poor prognosis in patients with breast carcinoma using an integrated multi-omics data analysis. 13, | |
| 440 | Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration. Volume 14, 211-227 | |
| 439 | Triple negative breast cancer: Pitfalls and progress. **2022**, 8, | 8 |
| 438 | Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin. **2022**, 14, | 1 |
| 437 | Accurate determination of CRISPR-mediated gene fitness in transplantable tumours. **2022**, 13, | |
| 436 | Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer. **2022**, 12, | 0 |
| 435 | A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer. | 0 |
| 434 | Breast cancer stage prediction: a computational approach guided by transcriptome analysis. | |

| | | |
|---|---|---|
| 433 | Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. 9, | 2 |
| 432 | Distinctive gene expression patterns in pregnancy-associated breast cancer. 13, | 1 |
| 431 | Connecting omics signatures and revealing biological mechanisms with iLINCS. **2022**, 13, | 1 |
| 430 | Impact on breast cancer susceptibility and clinicopathological traits of common genetic polymorphisms in TP53, MDM2 and ATM genes in Sardinian women. **2022**, 24, | 0 |
| 429 | Luminal androgen receptor (LAR) subtype of triple-negative breast cancer: molecular, morphological, and clinical features. **2022**, 23, 617-624 | 0 |
| 428 | BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance. | |
| 427 | Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. **2022**, 14, 4064 | 0 |
| 426 | Fate decisions of breast cancer stem cells in cancer progression. 12, | |
| 425 | Precision Breast Cancer Medicine: Early Stage Triple Negative Breast CancerâA Review of Molecular Characterisation, Therapeutic Targets and Future Trends. 12, | 3 |
| 424 | Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers. | 1 |
| 423 | CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. 12, | 0 |
| 422 | Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine. | |
| 421 | Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors. | 0 |
| 420 | Depletion of Mdig Changes Proteomic Profiling in Triple Negative Breast Cancer Cells. **2022**, 10, 2021 | |
| 419 | In Vitro and In Silico Study to Assess Toxic Mechanisms of Hybrid Molecules of Quinone-Benzocaine as Plastoquinone Analogues in Breast Cancer Cells. | 1 |
| 418 | Loss of genes in chromosome arms 5q and 16q in breast cancer. **2022**, 41, 331-341 | |
| 417 | Dysregulated FOXM1 signaling in the regulation of cancer stem cells. **2022**, | 3 |
| 416 | Noncanonical Wnt/Ror2 signaling regulates cell-matrix adhesion to prompt directional tumor cell invasion in breast cancer. | |

| | | |
|---|---|---|
| 415 | S-phase fraction, lymph node status and disease staging as the main prognostic factors to differentiate between young and older patients with invasive breast carcinoma. **2022**, 24, | |
| 414 | Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. **2022**, 349, 844-875 | 2 |
| 413 | The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?. **2022**, 178, 103781 | 1 |
| 412 | Dual function miR-205 is positively associated with ER and negatively with five-year survival in breast cancer patients. **2022**, 238, 154080 | 0 |
| 411 | Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers. **2022**, 25, 101511 | |
| 410 | Improved Detection of Viral RNA Isolated From Liquid-based Cytology Samples. **2001**, 6, 125-130 | 0 |
| 409 | Gene Expression Profiling of Breast Cancer in Relation to Estrogen Receptor Status and Estrogen-Metabolizing Enzymes: Clinical Implications. **2005**, 11, 878s-883s | 4 |
| 408 | Wavelet Transformations of Tumor Expression Profiles Reveals a Pervasive Genome-Wide Imprinting of Aneuploidy on the Cancer Transcriptome. **2005**, 65, 186-194 | 4 |
| 407 | Racial Disparity in Quadruple Negative Breast Cancer: Aggressive Biology and Potential Therapeutic Targeting and Prevention. **2022**, 14, 4484 | 0 |
| 406 | Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. Volume 14, 259-280 | 0 |
| 405 | Analysis of RANK-c interaction partners identifies TRAF3 as a critical regulator of breast cancer aggressiveness. **2022**, 33, 100836 | 0 |
| 404 | Cellular reprogramming, chemoresistance, and dietary interventions in breast cancer. **2022**, 179, 103796 | 0 |
| 403 | Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer. **2022**, 6, 100065 | 0 |
| 402 | Disease and Treatment Monitoring. **2023**, 71-85 | 0 |
| 401 | Biomarkers, Prognosis, and Prediction Factors. **2023**, 49-70 | 0 |
| 400 | DNA mikromatriser â□□smâ□□brikker med store konsekvenser. **2002**, 112, | 0 |
| 399 | Pilot Study of Combination Gemogenovatucel-T (Vigil) and Durvalumab in Women With Relapsed BRCA-wt Triple-Negative Breast or Ovarian Cancer. **2022**, 16, 117955492211105 | 0 |
| 398 | Pattern of local recurrence and metastasis in carcinoma breast according to molecular subtype in patients treated with definitive intent. **2022**, 0 | 0 |

| | | |
|---|---|---|
| 397 | Breast cancer stem cells and their role in tumor microenvironment. **2022**, 221-248 | 0 |
| 396 | Role of Tumor-associated neutrophils in the breast tumor microenvironment. **2022**, 171-194 | 0 |
| 395 | Real-world data on metastatic breast cancer in Goiñia, Brazil: a 17-year analysis (1995â2011). 32, | 0 |
| 394 | Breast cancer: introduction. **2022**, 3-26 | 0 |
| 393 | Complexity and Integration. **2022**, 65-88 | 0 |
| 392 | Using classification and K-means methods to predict breast cancer recurrence in gene expression data. **2022**, 12, 122 | 0 |
| 391 | Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. **2022**, 171-194 | 0 |
| 390 | Diagnostic Applications of Nuclear Medicine: Breast Cancer. **2022**, 715-741 | 0 |
| 389 | Breast Carcinoma Receptor Expression in a Caribbean Population. **2022**, 08, e262-e265 | 0 |
| 388 | Prognostic value of neutrophil-to-lymphocyte ratio for patients with triple-negative breast cancer: A meta-analysis. **2022**, 101, e29887 | 0 |
| 387 | Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement. **2022**, 12, 1404 | 1 |
| 386 | The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. **2022**, 13, 1555 | 1 |
| 385 | Stabilization of c-Myc by the atypical cell cycle regulator, Spy1, decreases efficacy of breast cancer treatments. | 0 |
| 384 | DESMOND 2.0: Identification of differentially expressed biclusters for unsupervised patient stratification. | 0 |
| 383 | Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer. **2022**, 13, 1538 | 0 |
| 382 | LncRNA SEMA3B-AS1 inhibits breast cancer progression by targeting miR-3940/KLLN axis. **2022**, 13, | 1 |
| 381 | Time tracking and multidimensional influencing factors analysis on female breast cancer mortality: Evidence from urban and rural China between 1994 to 2019. 10, | 0 |
| 380 | Can EGFR be a therapeutic target in breast cancer?. **2022**, 1877, 188789 | 1 |

| | | |
|---|---|---|
| 379 | Invasive ductal breast cancer molecular subtype prediction by MRI radiomic and clinical features based on machine learning. 12, | 1 |
| 378 | Role of Syndecan-4 in breast cancer pathophysiology. | 1 |
| 377 | Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study. | 0 |
| 376 | Divergence of mutational signatures in association with breast cancer subtype. | 1 |
| 375 | Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. **2022**, 41, | 4 |
| 374 | Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes â an observational cohort study in Sweden. **2022**, 22, | 1 |
| 373 | Presence of peritumoral edema on T2w MRI: a poor non-invasive prognostic marker in breast cancer patients. **2022**, 53, | 0 |
| 372 | Development and validation of nomograms for predicting overall survival and cancer specific survival in locally advanced breast cancer patients: A SEER population-based study. 10, | 0 |
| 371 | Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics. | 0 |
| 370 | Bench to bedside: research influencing clinical practice in breast cancer. **2022**, | 1 |
| 369 | Attention-based GCN Integrates Multi-omics Data for Breast Cancer Subtype Classification and Patient-specific Gene Marker Identification. | 0 |
| 368 | Overexpression of PBK/TOPK relates to poor prognosis of patients with breast cancer: a retrospective analysis. **2022**, 20, | 0 |
| 367 | Relative quantification of proteins in formalin-fixed paraffin-embedded breast cancer tissue using multiplexed mass spectrometry assays. **2022**, 100416 | 0 |
| 366 | Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF- receptors. **2022**, 13, | 0 |
| 365 | Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness. **2022**, 14, 4280 | 4 |
| 364 | Regulatory mechanisms and function of hypoxia-induced long noncoding RNA NDRG1-OT1 in breast cancer cells. **2022**, 13, | 0 |
| 363 | Five decades of progress in surgical oncology: Breast. **2022**, 126, 852-859 | 0 |
| 362 | Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. 13, | 2 |

| | | |
|---|---|---|
| 361 | Claudins: The Newly Emerging Targets in Breast Cancer. **2022**, | 0 |
| 360 | Loss of SNAI1 induces cellular plasticity in invasive triple-negative breast cancer cells. **2022**, 13, | 0 |
| 359 | A vicious circle in breast cancer: The interplay between inflammation, reactive oxygen species, and microRNAs. 12, | 0 |
| 358 | Molecular Classification of Breast Cancer. **2022**, | 0 |
| 357 | Molecular Classification of Breast Carcinoma in a Tertiary Hospital of India: the Recent Trends. | 0 |
| 356 | Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCFâ7/SC Breast Cancer Cells. **2022**, 23, 11340 | 0 |
| 355 | CmPn signaling networks in the tumorigenesis of breast cancer. 13, | 3 |
| 354 | Reproductive history differs by molecular subtypes of breast cancer among women aged â50´years in Scotland diagnosed 2009â2016: a cross-sectional study. | 0 |
| 353 | Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors. 13, | 0 |
| 352 | Terminal differentiation and anti-tumorigenic effects of prolactin in breast cancer. 13, | 0 |
| 351 | Robust analysis of cancer heterogeneity for high-dimensional data. | 0 |
| 350 | Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer. **2022**, 23, 10539 | 0 |
| 349 | Delving into the Heterogeneity of Different Breast Cancer Subtypes and the Prognostic Models Utilizing scRNA-Seq and Bulk RNA-Seq. **2022**, 23, 9936 | 1 |
| 348 | The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry. Publish Ahead of Print, | 1 |
| 347 | Removing unwanted variation from large-scale RNA sequencing data with PRPS. | 1 |
| 346 | Paired evaluation defines performance landscapes for machine learning models. | 0 |
| 345 | Current landscape of personalized clinical treatments for triple-negative breast cancer. 13, | 1 |
| 344 | Investigation of the Role of PUFA Metabolism in Breast Cancer Using a Rank-Based Random Forest Algorithm. **2022**, 14, 4663 | 0 |

[-]

| | | |
|---|---|---|
| 343 | The roles of small extracellular vesicles as prognostic biomarkers and treatment approaches in triple-negative breast cancer. 12, | 0 |
| 342 | In situ single-cell analysis of canonical breast cancer biomarkers: phenotypic heterogeneity and implications on response to HER2 targeting agents. | 0 |
| 341 | Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. **2022**, 23, 10119 | 0 |
| 340 | Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. **2022**, 23, 11046 | 1 |
| 339 | Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study. **2022**, 18, 315-322 | 0 |
| 338 | Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity. 11, | 1 |
| 337 | Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation. **2022**, 100131 | 2 |
| 336 | Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy. **2022**, 54, 2581-2597 | 2 |
| 335 | Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents. 12, | 0 |
| 334 | Predicting hormone receptors and PAM50 subtypes of breast cancer from multi-scale lesion images of DCE-MRI with transfer learning technique. **2022**, 150, 106147 | 1 |
| 333 | Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients. **2022**, 155, 113787 | 0 |
| 332 | Expression of MiRNA-29b and MiRNA-31 and their diagnostic and prognostic values in Egyptian females with breast cancer. **2022**, 7, 248-257 | 0 |
| 331 | Predictive factors of recurrence free survival of patients with luminal breast cancer in southern Sri Lanka. **2021**, 1, 78 | 0 |
| 330 | Recent Progress in Detection of Breast Cancer Biomarkers by Clinical and Imprinting Polymer-Based Sensors. **2022**, 303-330 | 0 |
| 329 | Caveolin-1-deficient fibroblasts promote migration, invasion, and stemness via activating the TGF-β/Smad signaling pathway in breast cancer cells. **2022**, | 0 |
| 328 | A panel of four miRNAs (miR-190b, miR-584-5p, miR-452-5p, and miR-1306-5p) is capable of classifying luminal and non-luminal breast cancers. | 0 |
| 327 | Transcriptomic profiling of Indian breast cancer patients revealed subtype-specific mRNA and lncRNA signatures. 13, | 0 |
| 326 | A genome-wide cell-free DNA methylation analysis identifies an episignature associated with metastatic luminal B breast cancer. 10, | 0 |

| | | |
|---|---|---|
| 325 | Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer. | 0 |
| 324 | Identification of prognostic genes for early basal-like breast cancer with weighted gene co-expression network analysis. **2022**, 101, e30581 | 2 |
| 323 | NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. **2022**, 22, | 1 |
| 322 | Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis. **2022**, 14, 5336 | 0 |
| 321 | A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer. **2022**, 12, | 1 |
| 320 | Molecular phenotyping of malignant canine mammary tumours: Detection of high-risk group and its relationship with clinicomolecular characteristics. | 0 |
| 319 | Optimizing pathological assessment of breast cancer in Brazil: recommendations from a multidisciplinary working group on the tumor-tissue journey. **2022**, 5, | 0 |
| 318 | The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. 12, | 0 |
| 317 | Progreso y utilidad actual de la radiómica dentro del estudio PET/TC en cáncer de mama no metastásico: una revisión sistemática. **2022**, | 0 |
| 316 | Differential Cytotoxicity of Curcumin-Loaded Micelles on Human Tumor and Stromal Cells. **2022**, 23, 12362 | 0 |
| 315 | A gene expression signature in HER2+ breast cancer patients related to neoadjuvant chemotherapy resistance, overall survival, and disease-free survival. 13, | 0 |
| 314 | Molecular Biology, Genetics, and Translational Models of Human Cancer. 1-34 | 0 |
| 313 | Cancer Genomics and Evolution. 1-30 | 0 |
| 312 | Cellular Plasticity and Heterotypic Interactions during Breast Morphogenesis and Cancer Initiation. **2022**, 14, 5209 | 1 |
| 311 | The Transcriptomic Landscape of Pediatric Astrocytoma. **2022**, 23, 12696 | 0 |
| 310 | ICSDA: a multi-modal deep learning model to predict breast cancer recurrence and metastasis risk by integrating pathological, clinical and gene expression data. | 1 |
| 309 | Development of a High-Affinity Antibody against the Tumor-Specific and Hyperactive 611-p95HER2 Isoform. **2022**, 14, 4859 | 0 |
| 308 | Hypoxia and ERα Transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer. **2022**, 14, 4934 | 0 |

| | | |
|---|---|---|
| 307 | Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. **2022**, 24, | 0 |
| 306 | Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway. **2022**, 39, | 1 |
| 305 | A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming. | 0 |
| 304 | 6. Relationships between Histomorphology, Imaging Findings and Subtypes in Breast Cancer. **2022**, 78, 1224-1229 | 0 |
| 303 | Recurrence Score Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Settingâ Results of the IRMA Trial. **2022**, 14, 5365 | 1 |
| 302 | Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification. | 0 |
| 301 | Intrinsic subtypes in Ethiopian breast cancer patient. **2022**, 196, 495-504 | 0 |
| 300 | Genomic Profiling and Liquid Biopsies for Breast Cancer. **2022**, | 0 |
| 299 | Association of CD206 Protein Expression with Immune Infiltration and Prognosis in Patients with Triple-Negative Breast Cancer. **2022**, 14, 4829 | 2 |
| 298 | Tinengotinib (TT-00420), a Novel Spectrum-Selective Small Molecule Kinase Inhibitor, Is Highly Active Against Triple Negative Breast Cancer. | 1 |
| 297 | A genomic and transcriptomic study toward breast cancer. 13, | 0 |
| 296 | The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective. **2022**, 14, 5326 | 0 |
| 295 | Identification of miRNA biomarkers for breast cancer by combining ensemble regularized multinomial logistic regression and Cox regression. **2022**, 23, | 0 |
| 294 | A cellular and transcriptomic dissection of the human breast for studying mechanisms of cell and tissue function. | 0 |
| 293 | Identifying enhancer-driven subtype-specific prognostic markers in breast cancer based on multi-omics data. 13, | 0 |
| 292 | Mass spectroscopy-based proteomics and metabolomics analysis of triple-positive breast cancer cells treated with tamoxifen and/or trastuzumab. | 0 |
| 291 | A Novel Mouse Model that Recapitulates the Heterogeneity of Human Triple Negative Breast Cancer. | 0 |
| 290 | USP7 Induces Chemoresistance in Triple-Negative Breast Cancer via Deubiquitination and Stabilization of ABCB1. **2022**, 11, 3294 | 0 |

| | | |
|---|---|---|
| 289 | Classification of Subgroups with Immune Characteristics Based on DNA Methylation in Luminal Breast Cancer. **2022**, 23, 12747 | 0 |
| 288 | K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. **2022**, 14, 5322 | 0 |
| 287 | Strong prognostic value of SLAMF7 protein expression in patients with lymph node-positive breast cancer. **2022**, 24, | 0 |
| 286 | Neoplasms of the Breast. 1-62 | 0 |
| 285 | Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer. 13, | 0 |
| 284 | Breast Cancer Metastatic Dormancy and Relapse: An enigma of microenvironment(s). | 2 |
| 283 | Crosstalk between CXCR4/ACKR3 and EGFR Signaling in Breast Cancer Cells. **2022**, 23, 11887 | 0 |
| 282 | Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: a systematic review. **2022**, | 2 |
| 281 | Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review. **2022**, | 0 |
| 280 | Breast Cancer Cells Reprogram the Oncogenic lncRNAs/mRNAs Coexpression Networks in Three-Dimensional Microenvironment. **2022**, 11, 3458 | 0 |
| 279 | Circular RNAs: New layer of complexity evading breast cancer heterogeneity. **2023**, 8, 60-74 | 0 |
| 278 | A trans-Pt(ii) hedgehog pathway inhibitor complex with cytotoxicity towards breast cancer stem cells and triple negative breast cancer cells. | 1 |
| 277 | Identification of prognostic biomarkers among ICAMs in the breast cancer microenvironment. **2022**, 1-15 | 0 |
| 276 | La proteña 7 unida al receptor del factor de crecimiento (GRB7) en cï¿½cer de mama. **2022**, 31, 223-229 | 0 |
| 275 | The Monocyte, a Maestro in the Tumor Microenvironment (TME) of Breast Cancer. **2022**, 14, 5460 | 1 |
| 274 | Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers. | 0 |
| 273 | Unsupervised Analysis Based on DCE-MRI Radiomics Features Revealed Three Novel Breast Cancer Subtypes with Distinct Clinical Outcomes and Biological Characteristics. **2022**, 14, 5507 | 2 |
| 272 | The clinical significance of HER2 expression in DCIS. **2023**, 40, | 0 |

| | | |
|---|---|---|
| 271 | Effects of hirsuteine on MDA-MB-453 breast cancer cell proliferation. **2022**, 25, | 0 |
| 270 | Genetic Ancestry and Breast Cancer Subtypes in Hispanic/Latina Women. **2023**, 79-88 | 0 |
| 269 | Zincâ Association with the CmPn/CmP Signaling Network in Breast Cancer Tumorigenesis. **2022**, 12, 1672 | 2 |
| 268 | Progress and current utility of radiomics in PET/CT studies of non-metastatic breast cancer: a systematic review. **2022**, | 0 |
| 267 | Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. 12, | 0 |
| 266 | SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRFOXM1 pathway independently of REV-ERBs. **2022**, 13, | 0 |
| 265 | Jackstraw inference for AJIVE data integration. **2022**, 107649 | 0 |
| 264 | MLSP: A Bioinformatics Tool for Predicting Molecular Subtypes and Prognosis in Patients with Breast Cancer. **2022**, | 0 |
| 263 | PDIA3 Activity Promotes Extracellular Accumulation of Proteins Relevant to Basal Breast Cancer Outcomes in Human MDA-MB-A231 Breast Cancer Cells. | 0 |
| 262 | Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer. **2022**, 13, 2065 | 1 |
| 261 | Identification of a Risk Predictive Signature Based on Genes Associated with Tumor Size and Lymph Node Involvement in Breast Cancer. | 0 |
| 260 | Classic and New Markers in Diagnostics and Classification of Breast Cancer. **2022**, 14, 5444 | 3 |
| 259 | Association between Obesity, Race or Ethnicity, and Luminal Subtypes of Breast Cancer. **2022**, 10, 2931 | 0 |
| 258 | The application of exosomes in the treatment of triple-negative breast cancer. 9, | 0 |
| 257 | Investigation of mRNA Expression Levels of Tip60 and Related DNA Repair Genes in Molecular Subtypes of Breast Cancer. **2022**, | 0 |
| 256 | Single-cell imaging based prognosis prediction identifies new breast cancer survival subtypes. | 0 |
| 255 | Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins. **2022**, 24, | 0 |
| 254 | Identification of a minority population of LMO2 + breast cancer cells that integrate into the vasculature and initiate metastasis. **2022**, 8, | 0 |

| | | |
|---|---|---|
| 253 | Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts. **2022**, | 0 |
| 252 | Immunohistochemical Staining Characteristics of Well Differentiated Invasive Ductal Carcinoma Using the ADH5 Cocktail (CK5/14, P63, and CK7/18): a Potential Interpretative Pitfall. | 0 |
| 251 | Signatures of Breast Cancer Progression in the Blood: What Could Be Learned from Circulating Tumor Cell Transcriptomes. **2022**, 14, 5668 | 1 |
| 250 | De novo design of dual-target JAK2, SMO inhibitors based on deep reinforcement learning, molecular docking and molecular dynamics simulations. **2022**, | 0 |
| 249 | The Future of Clinical Cancer Management: One Tumor, One Chip. **2003**, 69, 41-44 | 4 |
| 248 | Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. **2022**, 895-915 | 0 |
| 247 | Optimizing pathological assessment of breast cancer in Brazil: recommendations from a multidisciplinary working group on the tumor-tissue journey. 32, | 0 |
| 246 | Breast carcinogenesis induced by organophosphorous pesticides. **2022**, | 0 |
| 245 | Current Standard Clinical Predictive Markers. **2022**, 873-894 | 0 |
| 244 | Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. **2023**, 112, 102496 | 0 |
| 243 | HER2-low breast cancer: Novel detections and treatment advances. **2023**, 181, 103883 | 0 |
| 242 | Status of breast cancer in Latin American: Results of the breast cancer revealed initiative. **2023**, 181, 103890 | 0 |
| 241 | Omission of chemotherapy for hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer: patterns of treatment and outcomes from the Korean Breast Cancer Society Registry. **2022**, 103, 313 | 0 |
| 240 | Clinical Features and Prognosis Analysis of Hormone Receptor-Positive, HER2-Negative Breast Cancer with Differential Expression Levels of Estrogen and Progesterone Receptors: A 10-Year Retrospective Study. **2022**, 2022, 1-11 | 1 |
| 239 | Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits. | 0 |
| 238 | Multiparametric MR Imaging Radiomics Signatures for Assessing the Recurrence Risk of ER +/ HER2 âBreast Cancer Quantified With 21-Gene Recurrence Score. | 0 |
| 237 | Exploring the Role of the Inhibitor of Apoptosis BIRC6 in Breast Cancer: A Database Analysis. **2022**, | 0 |
| 236 | High SURF4 expression is associated with poor prognosis of breast cancer. **2022**, 14, 9317-9337 | 0 |

| | | |
|---|---|---|
| 235 | Identification of prognostically significant DNA methylation signatures in patients with various breast cancer types. **2022**, | 0 |
| 234 | Establishment and Validation of a Model for Disease-Free Survival Rate Prediction Using the Combination of microRNA-381 and Clinical Indicators in Patients with Breast Cancer. Volume 14, 375-389 | 0 |
| 233 | The deubiquitinating enzyme STAMBP is a newly discovered driver of triple-negative breast cancer progression that maintains RAI14 protein stability. **2022**, 54, 2047-2059 | 0 |
| 232 | ERK MAP Kinase Signaling Regulates RAR Signaling to Confer Retinoid Resistance on Breast Cancer Cells. **2022**, 14, 5890 | 0 |
| 231 | The POLR3G Subunit of Human RNA Polymerase III Regulates Tumorigenesis and Metastasis in Triple-Negative Breast Cancer. **2022**, 14, 5732 | 0 |
| 230 | Subclassification of Breast Cancer through Comprehensive Multi-omics Data to Benefit Distinct Survival Outcomes. | 0 |
| 229 | Clinical implications and immunological features of iron metabolism-related gene prognostic signature in breast cancer. | 0 |
| 228 | Choice of High-Throughput Proteomics Method Affects Data Integration with Transcriptomics and the Potential Use in Biomarker Discovery. **2022**, 14, 5761 | 0 |
| 227 | Is it possible to identify subpopulations of triple negative breast cancer?. **2022**, 13, 352-360 | 0 |
| 226 | The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target. **2022**, 12, 1992 | 1 |
| 225 | Multiparametric MRI Features of Breast Cancer Molecular Subtypes. **2022**, 58, 1716 | 1 |
| 224 | Suicide risk among female breast cancer survivors: A populationâBased study. 12, | 0 |
| 223 | Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer. Publish Ahead of Print, | 0 |
| 222 | Classification of breast cancer subtypes based on RNA profiling and immunohistochemical methods: clinical and biological aspects: A review. **2022**, 24, 351-354 | 0 |
| 221 | Correlations between serum lipid and Ki-67 levels in different breast cancer molecular subcategories. **2022**, 25, | 1 |
| 220 | Using ensemble learning and genetic algorithm on magnetic resonance imaging radiomics to classify molecular subtypes of breast cancer. | 0 |
| 219 | Impact of age on indication for chemotherapy in early breast cancer patients in Germany. | 0 |
| 218 | A 5-Pathway Signature Predicts Prognosis Based on Immune-Derived lncRNAs in Patients with Breast Cancer. **2022**, 2022, 1-17 | 0 |

| | | |
|---|---|---|
| 217 | Transcriptomic pan-cancer analysis using rank-based Bayesian inference. | 0 |
| 216 | Identifying Associations between DCE-MRI Radiomic Features and Expression Heterogeneity of Hallmark Pathways in Breast Cancer: A Multi-Center Radiogenomic Study. **2023**, 14, 28 | 0 |
| 215 | Optoacoustic Imaging With Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study. | 1 |
| 214 | Long term trends of breast cancer incidence according to proliferation status. **2022**, 22, | 0 |
| 213 | Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. **2022**, 16, | 1 |
| 212 | MicroRNAs: A Link between Mammary Gland Development and Breast Cancer. **2022**, 23, 15978 | 0 |
| 211 | Update on triple-negative breast cancers â highlighting subtyping update and treatment implication. **2023**, 82, 17-35 | 2 |
| 210 | Immune subtype identification and multi-layer perceptron classifier construction for breast cancer. 12, | 0 |
| 209 | Characterisation of the immune microenvironment of primary breast cancer and brain metastasis reveals depleted T-cell response associated to ARG2 expression. **2022**, 7, 100636 | 0 |
| 208 | Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance. **2022**, 14, 6267 | 0 |
| 207 | Obesity and breast cancer. **2022**, 18, 40-51 | 0 |
| 206 | Novel markers in breast pathology. **2023**, 82, 119-139 | 1 |
| 205 | Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. **2022**, 14, 6034 | 1 |
| 204 | Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy. Volume 14, 475-487 | 0 |
| 203 | Dalpiciclib Partially Abrogates ER Signaling Activation Induced by Pyrotinib In HER2+HR+Breast Cancer. | 0 |
| 202 | Discovery and Chemical Development of Amcenestrant: An Oral Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. 275-300 | 0 |
| 201 | Long-term oncological outcomes of organ-sparing treatment of patients with early breast cancer aged 65 years and older who had no postoperative radiation therapy. **2022**, 18, 24-28 | 0 |
| 200 | Overrepresentation of human epidermal growth factor receptor 2 positive- and Luminal B breast cancer metastases in the eyes and orbit. | 0 |

| | | |
|---|---|---|
| 199 | Hydroxychavicol as a potential anticancer agent (Review). **2022**, 25, | 0 |
| 198 | An update on the pathological classification of breast cancer. **2023**, 82, 5-16 | 1 |
| 197 | Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases. | 0 |
| 196 | The molecular portrait of triple-negative breast cancer: the LAG3 gene single nucleotide polymorphism rs2365094 has no impact on the clinical picture. | 0 |
| 195 | Blockade of Store-operated Calcium Entry Sensitizes Breast Cancer Cells to Cisplatin Therapy via Modulating Inflammatory Response. **2022**, | 0 |
| 194 | Adipocytes secretome from normal and tumor breast favor breast cancer invasion by metabolic reprogramming. | 0 |
| 193 | Predicting transcription factor activity using prior biological information. | 0 |
| 192 | Evaluating Fate of Emerging Resistance Hitting the Brakes on Conventional Treatment Approach. **2023**, 99-122 | 0 |
| 191 | A Clinical Cognizance of Molecular and Pathological Diagnostic Approach of TNBC. **2023**, 26-46 | 0 |
| 190 | Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases. **2023**, 28, | 1 |
| 189 | Hormone Receptors and HER-2 Status as Surrogates for Breast Cancer Molecular Subtypes Prognosticate for Disease Control in Node Negative Asian Patients Treated with Breast Conservation Therapy. **2011**, 40, 90-96 | 0 |
| 188 | Unique Sphingolipid Signature Identifies Luminal and Triple-Negative Breast Cancer Subtypes. | 0 |
| 187 | Impact of age on indication for chemotherapy in early breast cancer patients: results from 104 German institutions from 2008 to 2017. | 0 |
| 186 | Phenotypic subtyping via contrastive learning. | 0 |
| 185 | Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy. | 0 |
| 184 | Etiological Insights into TNBC and their Related Catastrophic Risks. **2023**, 1-25 | 0 |
| 183 | PRMT3 regulates the progression of invasive micropapillary carcinoma of the breast. | 0 |
| 182 | Clinicopathological characteristics and features of molecular subtypes of breast cancer at high altitudes. 12, | 0 |

| | | |
|---|---|---|
| 181 | Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2+HR+ breast cancer. 12, | 0 |
| 180 | Learning from small medical dataâ€obust semi-supervised cancer prognosis classifier with Bayesian variational autoencoder. **2023**, 3, | 0 |
| 179 | Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. 12, | 0 |
| 178 | Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts. | 0 |
| 177 | Molecular Sub-Typing and Exploration of Key Signalling Pathways Involved in Complicating the Disease. **2023**, 47-72 | 0 |
| 176 | Analysis of Changes in the Expression of Selected Genes from the ABC Family in Patients with Triple-Negative Breast Cancer. **2023**, 24, 1257 | 0 |
| 175 | Effect of Ruai-Sanyin formula maintenance therapy after completion of standard adjuvant treatment on survival in women with early-stage triple negative breast cancer: A multicenter prospective cohort study. | 0 |
| 174 | Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?. **2023**, 30, 1220-1231 | 0 |
| 173 | On data normalization and batch-effect correction for tumor subtyping with microRNA data. **2023**, 5, | 0 |
| 172 | Breast cancer cells interact with tumor-derived extracellular matrix in a molecular subtype-specific manner. **2023**, 213301 | 0 |
| 171 | Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future. **2023**, 73-98 | 0 |
| 170 | Triple-negatives Mammakarzinom. | 0 |
| 169 | Correlation between late gadolinium enhancement sequences in MRI and pathologic response after neoadjuvant chemotherapy in breast cancer. **2023**, 36, 100438 | 0 |
| 168 | Evaluating the Role of Circulating MicroRNAs in Predicting Long-Term Survival Outcomes in Breast Cancer: A Prospective, Multicenter Clinical Trial. **2023**, 236, 317-327 | 1 |
| 167 | Expression and prognosis analyses of the fibronectin type-III domain-containing (FNDC) protein family in human cancers: A Review. **2022**, 101, e31854 | 0 |
| 166 | Analysis of Tumor Microenvironment Heterogeneity among Breast Cancer Subtypes to Identify Subtype-Specific Signatures. **2023**, 14, 44 | 0 |
| 165 | The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy. **2023**, 11, 98 | 0 |
| 164 | Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. **2023**, 15, 211 | 0 |

| | | |
|---|---|---|
| 163 | Special Techniques of Adjuvant Breast Carcinoma Radiotherapy. **2023**, 15, 298 | 0 |
| 162 | Ezrin accelerates breast cancer liver metastasis through promoting furin-like convertase-mediated cleavage of Notch1. | 0 |
| 161 | The Role of PPARs in Breast Cancer. **2023**, 12, 130 | 1 |
| 160 | Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial. **2022**, 22, | 0 |
| 159 | Proliferative epithelial changes in tumour adjacent tissue in Sri Lankan women with breast carcinoma: do morphological changes support molecular models of breast carcinogenesis?. **2022**, 17, | 0 |
| 158 | Mebendazole prevents distant organ metastases in part by decreasing ITG4 expression and cancer stemness. **2022**, 24, | 1 |
| 157 | Inferring sparse genetic regulatory networks based on maximum-entropy probability model and multi-objective memetic algorithm. | 0 |
| 156 | Combination of Conventional Drugs with Biocompounds Derived from Cinnamic Acid: A Promising Option for Breast Cancer Therapy. **2023**, 11, 275 | 0 |
| 155 | Expression of the Immunohistochemical Markers CK5, CD117, and EGFR in Molecular Subtypes of Breast Cancer Correlated with Prognosis. **2023**, 13, 372 | 0 |
| 154 | Triple-negative breast cancer and its correlation with viral agents. **2023**, 229-248 | 0 |
| 153 | Zebrafish Cancer Avatars: A Translational Platform for Analyzing Tumor Heterogeneity and Predicting Patient Outcomes. **2023**, 24, 2288 | 0 |
| 152 | Molekularpathologie in der Gynäkoonkologie—Beschreibung einer Revolution. | 0 |
| 151 | Gene Expression Profiles in Cancers and Their Therapeutic Implications. **2023**, 29, 9-14 | 0 |
| 150 | Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages. **2023**, 24, 1443 | 0 |
| 149 | Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data. **2023**, 12, 367 | 0 |
| 148 | Establishment and characterization of a HER2-enriched canine mammary cancerous myoepithelial cell line. **2023**, 19, | 0 |
| 147 | Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes. **2023**, 11, 10912-10924 | 0 |
| 146 | GRHL2-controlled gene expression networks in luminal breast cancer. **2023**, 21, | 0 |

| | | |
|---|---|---|
| 145 | The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis. **2023**, 13, | 0 |
| 144 | HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons. Publish Ahead of Print, | 0 |
| 143 | GLIS Family Zinc Finger 3 Promotes Triple-Negative Breast Cancer Progression by Inducing Cell Proliferation, Migration and Invasion, and Activating the NF-B Signaling Pathway. **2023**, 46, 209-218 | 0 |
| 142 | Utility of proteomics and phosphoproteomics in the tailored medication of cancer. **2023**, 319-332 | 0 |
| 141 | Introduction to Breast Cancer. **2023**, 1-22 | 0 |
| 140 | Molecular Subtypes of Breast Cancer and CDk Dysregulation. **2023**, 133-148 | 0 |
| 139 | <i>Dictyostelium</i> Differentiation-inducing Factor Derivatives Reduce the Glycosylation of PD-L1 in MDA-MB-231 Human Breast Cancer Cells. **2023**, | 0 |
| 138 | The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies. 14, | 0 |
| 137 | Robust biomarker discovery through multiplatform multiplex image analysis of breast cancer clinical cohorts. | 0 |
| 136 | Identification and characterization of a proliferative cell population in estrogen receptor-positive metastatic breast cancer through spatial and single-cell transcriptomics. | 0 |
| 135 | Summary: Appropriate Use Criteria for Estrogen Receptorâ□Targeted PET Imaging with 16□18F-Fluoro-17□Fluoroestradiol. **2023**, 64, 351-354 | 1 |
| 134 | Single cell lineage tracing reveals subclonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer. | 0 |
| 133 | Genetic ancestry of 1.127 Brazilian breast cancer patients and its correlation with molecular subtype and geographic region. **2023**, | 0 |
| 132 | Deciphering breast cancer: from biology to the clinic. **2023**, 186, 1708-1728 | 0 |
| 131 | Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study. Volume 15, 251-261 | 0 |
| 130 | Poor-prognosis molecular subtypes in adenocarcinomas of pancreato-biliary and gynecological origin: A systematic review. **2023**, 185, 103982 | 0 |
| 129 | Glycosylated proteins with abnormal glycosylation changes are potential biomarkers for early diagnosis of breast cancer. **2023**, 236, 123855 | 0 |
| 128 | A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. **2023**, 24, 6834 | 0 |

| | | |
|---|---|---|
| 127 | Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. **2023**, 8, 101214 | 0 |
| 126 | Fluorogenic bisazide cyanine probe as a highly efficient acrolein detection tool for diagnosing triple negative breast cancer. **2023**, 380, 133404 | 0 |
| 125 | Estrogen receptor targeting with genistein radiolabeled Technetium-99m as radiotracer of breast cancer: Its optimization, characterization, and predicting stability constants by DFT calculation. **2023**, 9, e13169 | 0 |
| 124 | MiR-6165 Dysregulation in Breast Cancer and Its Effect on Cell Proliferation and Migration. **2021**, 24, 439-453 | 0 |
| 123 | Precision medicine in early breast cancerâ€beginning of a successful story?. **2023**, 8, 100780 | 0 |
| 122 | IMMUNOLOGICAL FEATURES OF BREAST CANCER. **2022**, 27-36 | 0 |
| 121 | Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. **2023**, 23, 41-51 | 0 |
| 120 | Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer RevealsTP53Aneuploidyâ€driven Metabolic Reprogramming. **2023**, 3, 281-296 | 0 |
| 119 | Her2low breast cancer. New opportunities and challenges. **2022**, 30, 62-74 | 0 |
| 118 | Robust correlation estimation and UMAP assisted topological analysis of omics data for disease subtyping. **2023**, 155, 106640 | 0 |
| 117 | Survival Disparities in US Black Compared to White Women with Hormone Receptor Positive-HER2 Negative Breast Cancer. **2023**, 20, 2903 | 1 |
| 116 | Molecular profiling in contemporary breast cancer management. | 0 |
| 115 | A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: Progress in the past 17 years. 10, | 0 |
| 114 | Rise of Deep Learning Clinical Applications and Challenges in Omics Data: A Systematic Review. **2023**, 13, 664 | 0 |
| 113 | PCDHA1 High Expression is Associated With Poor Prognosis and Correlated With Immune Cell Infiltration in Breast Cancer. **2023**, | 0 |
| 112 | Diffsig: Associating Risk Factors With Mutational Signatures. | 0 |
| 111 | Early Assessment of Neoadjuvant Chemotherapy Response Using Multiparametric Magnetic Resonance Imaging in Luminal B-like Subtype of Breast Cancer Patients: A Single-Center Prospective Study. **2023**, 13, 694 | 0 |
| 110 | Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival. | 0 |

| | | |
|---|---|---|
| 109 | The activation of EP300 by F11R leads to EMT and acts as a prognostic factor in triple-negative breast cancers. **2023**, 9, 165-181 | 0 |
| 108 | Lessons from other fields of medicine, Part 1: Breast cancer. **2023**, 101-118 | 0 |
| 107 | Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis. **2023**, 22, | 0 |
| 106 | Breast cancer subtype and clinical characteristics in women from Peru. 13, | 0 |
| 105 | Characteristics of recurrence, predictors for relapse and prognosis of rapid relapse triple-negative breast cancer. 13, | 0 |
| 104 | Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. **2023**, 133, | 0 |
| 103 | The RUNX/CBF□Complex in Breast Cancer: A Conundrum of Context. **2023**, 12, 641 | 0 |
| 102 | Galectin functions in cancer-associated inflammation and thrombosis. 10, | 0 |
| 101 | Discovery of multi-state gene cluster switches determining the adaptive mitochondrial and metabolic landscape of breast cancer. | 0 |
| 100 | The role of LncRNAs in tumor immunotherapy. **2023**, 23, | 0 |
| 99 | Establishment of breast carcinoma cell lines. **2021**, 16, 15-23 | 0 |
| 98 | TRIM21 mediates the synergistic effect of Olaparib and Sorafenib by degrading BRCA1 through ubiquitination in TNBC. | 0 |
| 97 | Machine-learning and mechanistic modeling of primary and metastatic breast cancer growth after neoadjuvant targeted therapy. | 0 |
| 96 | Shaping of the Clinical Landscape of Immunotherapy by PD-L1 Expression in Breast Cancer. **2023**, 1-20 | 0 |
| 95 | Glutamine metabolism in breast cancer and possible therapeutic targets. **2023**, 210, 115464 | 0 |
| 94 | Variable Intrinsic Expression of Immunoregulatory Biomarkers in Breast Cancer Cell Lines, Mammospheres, and Co-Cultures. **2023**, 24, 4478 | 0 |
| 93 | Role of transcriptional and posttranscriptional regulation of sphingolipid genes in molecular heterogeneity of breast cancer. **2023**, 37-47 | 0 |
| 92 | CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer. **2023**, 133, | 1 |

| | | |
|---|---|---|
| 91 | Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy. **2023**, 49-73 | 0 |
| 90 | Contrast subgraphs allow comparing homogeneous and heterogeneous networks derived from omics data. **2022**, 12, | 0 |
| 89 | Breast Cancer. **2023**, 387-413 | 0 |
| 88 | Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes. OF1-OF10 | 0 |
| 87 | A Review of Endocrine Therapy in Early-stage Breast Cancer. Publish Ahead of Print, | 0 |
| 86 | Lineage plasticity enables low-ER luminal tumors to evolve and gain basal-like traits. **2023**, 25, | 0 |
| 85 | Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions. **2023**, 25, 491-500 | 0 |
| 84 | Genetic Considerations in the Locoregional Management of Breast Cancer: a Review of Current Evidence. **2023**, 15, 48-57 | 0 |
| 83 | Evaluation of the relationships between ER, PR, c-erbB2, Ki67, E-Cadherin expressions, Nottingham histological grade and some clinical parameters in breast carcinomas. | 0 |
| 82 | Tumor senescence leads to poor survival and therapeutic resistance in human breast cancer. 13, | 0 |
| 81 | Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer. | 0 |
| 80 | Editorial: Cancer stem cells as attractive targets for breast cancer therapy. 13, | 0 |
| 79 | CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. **2023**, 291-311 | 0 |
| 78 | Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs. | 0 |
| 77 | Psychotic disorders as a framework for precision psychiatry. | 0 |
| 76 | Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. **2023**, 15, 1582 | 0 |
| 75 | RANK is a poor prognosis marker and a therapeutic target in ER -negative postmenopausal breast cancer. **2023**, 15, | 0 |
| 74 | Evaluation of the efficacy of chemotherapy for tubular carcinoma of the breast: A Surveillance, Epidemiology, and End Results cohort study. | 0 |

| | | |
|---|---|---|
| 73 | Molecular subtypes of breast cancer: secular improvement in prognosis. | 0 |
| 72 | Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis. 14, | 0 |
| 71 | A Clinicopathological Analysis of Molecular Subtypes of Breast Cancer using Immunohistochemical Surrogates: A 6-Year Institutional Experience from a Tertiary Cancer Center in North India. | 0 |
| 70 | A Correlative Approach to Breast Imaging. **2023**, 351-382 | 0 |
| 69 | MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks. **2023**, 24, 5327 | 0 |
| 68 | The Chorioallantoic Membrane Xenograft Assay as a Reliable Model for Investigating the Biology of Breast Cancer. **2023**, 15, 1704 | 0 |
| 67 | Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers. **2023**, 24, 5474 | 0 |
| 66 | Position paper on CDK4/6 inhibitors in early breast cancer. | 0 |
| 65 | Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers. **2023**, 4, 100977 | 0 |
| 64 | Noninferiority of Artificial Intelligenceâ€Assisted Analysis of Ki-67 and Estrogen/Progesterone Receptor in Breast Cancer Routine Diagnostics. **2023**, 36, 100033 | 0 |
| 63 | Comparative assessment of projection and clustering method combinations in the analysis of biomedical data. | 0 |
| 62 | Female breast cancer subtypes in the Romagna Unit of the Emilia-Romagna cancer registry, and estimated incident cases by subtypes and age in Italy in 2020. | 0 |
| 61 | Revisiting the Syndecans: Master Signaling Regulators with Prognostic and Targetable Therapeutic Values in Breast Carcinoma. **2023**, 15, 1794 | 0 |
| 60 | High prevalance of triple negative markers in breast cancer patients in North Maharashtra. **2023**, 10, 29-33 | 0 |
| 59 | SERD-NHC-Au(I) complexes for dual targeting ER and TrxR to induce ICD in breast cancer. **2023**, 190, 106731 | 0 |
| 58 | Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer. **2023**, 80, | 0 |
| 57 | Intratumoral heterogeneity, treatment response, and survival outcome of ER -positive HER2 -positive breast cancer. | 0 |
| 56 | GE11-antigen-loaded hepatitis B virus core antigen virus-like particles efficiently bind to TNBC tumor. 13, | 0 |

| | | |
|---|---|---|
| 55 | Estrogen Receptor 4 Regulates Chemotherapy Resistance and Induces Cancer Stem Cells in Triple Negative Breast Cancer. **2023**, 24, 5867 | 0 |
| 54 | Identification of Breast Cancer Subtypes by Integrating Genomic Analysis with the Immune Microenvironment. **2023**, 8, 12217-12231 | 0 |
| 53 | The WAVE3/Catenin oncogenic signaling regulates chemoresistance in triple negative breast cancer. **2023**, 25, | 0 |
| 52 | Involvement of APOBEC3A/B Deletion in Mouse Mammary Tumor Virus (MMTV)-like Positive Human Breast Cancer. **2023**, 13, 1196 | 0 |
| 51 | Special Studies. **2013**, 279-304 | 0 |
| 50 | The Association between Early-Onset Diagnosis and Clinical Outcomes in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. **2023**, 15, 1923 | 0 |
| 49 | S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720. **2023**, 12, 980 | 0 |
| 48 | The usefulness of nuclear area in the diagnosis of high-grade urothelial carcinoma cells in voided urine cytology. | 0 |
| 47 | Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay. | 0 |
| 46 | Recent advances in lab-on-a-chip systems for breast cancer metastasis research. | 0 |
| 45 | Triphenyltin(IV) Carboxylates with Exceptionally High Cytotoxicity against Different Breast Cancer Cell Lines. **2023**, 13, 595 | 0 |
| 44 | Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy. Volume 19, 301-312 | 0 |
| 43 | One-Way High-Dimensional ANOVA. **2023**, 2023, 1-11 | 0 |
| 42 | Metadynamics simulations for the investigation of drug loading on functionalized inorganic nanoparticles. | 0 |
| 41 | TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin. | 0 |
| 40 | Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer. | 0 |
| 39 | Altered Expression of CYSLTR1 is Associated With Adverse Clinical Outcome in Triple Negative Breast Tumors: An <i>In Silico</i> Approach. **2023**, 19, 148-158 | 0 |
| 38 | Clinical Phenotype Prediction From Single-cell RNA-seq Data using Attention-Based Neural Networks. | 0 |

| | | |
|---|---|---|
| 37 | Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis. **2023**, 15, 175883592311659 | 0 |
| 36 | Integrated pancancer analysis reveals the oncogene characteristics and prognostic value of DIP2B in breast cancer. **2023**, 23, | 0 |
| 35 | Compliance to adjuvant endocrine therapy and survival in breast cancer patients.. **2023**, 35, 100704 | 0 |
| 34 | Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors. | 0 |
| 33 | Cytokeratin 6 identifies basal-like subtypes of pancreatic ductal adenocarcinoma with decreased survival. | 0 |
| 32 | Homotypic Entosis as a Potential Novel Diagnostic Marker in Breast Cancer. **2023**, 24, 6819 | 0 |
| 31 | SRPKs: a promising therapeutic target in cancer. | 0 |
| 30 | Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far. Volume 16, 235-247 | 0 |
| 29 | Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. **2023**, 15, 2204 | 0 |
| 28 | SLC39A4 induces EMT and promotes triple-negative breast cancer cell proliferation and migration by activating ERK signaling. | 0 |
| 27 | Bioengineering and Bioinformatic Approaches to Study Extracellular Matrix Remodeling and Cancerâ Macrophage Crosstalk in the Breast Tumor Microenvironment. **2023**, 201-229 | 0 |
| 26 | Role of Secreted Frizzled-Related Protein 1 in Early Breast Carcinogenesis and Breast Cancer Aggressiveness. **2023**, 15, 2251 | 0 |
| 25 | Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment. | 0 |
| 24 | Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor **2023**, 25, | 0 |
| 23 | Expression pattern and prognostic implication of zinc homeostasis-related genes in AML. | 0 |
| 22 | How valuable can proteogenomics be in clinical breast cancer research?. 1-4 | 0 |
| 21 | Multimodal ultrasound features of breast cancers: correlation with molecular subtypes. **2023**, 23, | 0 |
| 20 | Assessing Breast Cancer Molecular Subtypes Using Extracellular Vesiclesâ mRNA. | 0 |

| | | |
|---|---|---|
| 19 | Diffusion-time dependent diffusion MRI: effect of diffusion-time on microstructural mapping and prediction of prognostic features in breast cancer. | 0 |
| 18 | COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. **2023**, 42, | 0 |
| 17 | Expression of type VI collagen Β chain in canine mammary carcinomas. **2023**, | 0 |
| 16 | The Role of transcription factor FOXA1/C2/M1/O3/P1/Q1 in breast cancer. | 0 |
| 15 | Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: a systematic review and network meta-analysis. **2023**, 8, 101216 | 0 |
| 14 | Deep learning approaches for high dimension cancer microarray data feature prediction: A review. **2023**, 13-41 | 0 |
| 13 | The regulation of the programmed death ligand 1 (PD-L1) by nitric oxide in breast cancer: Immunotherapeutic implication. **2023**, 173-192 | 0 |
| 12 | Neoadjuvant chemotherapy in non-metastatic breast cancer: The surgeon's perspective. **2023**, | 0 |
| 11 | XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes. **2023**, 84, 104979 | 0 |
| 10 | Spatial Technologies: A Game Changer for Studying the Tumor Microenvironment. **2023**, 1-34 | 0 |
| 9 | Basal epithelial cells in prostate development, tumorigenesis, and cancer progression. 1-16 | 0 |
| 8 | Sustained Shugoshin 1 downregulation reduces tumor growth and metastasis in a mouse xenograft tumor model of triple-negative breast cancer. **2023**, 18, | 0 |
| 7 | Multimodal analysis of genome-wide methylation, copy number aberrations, and end motif signatures enhances detection of early-stage breast cancer. 13, | 0 |
| 6 | A Novel Exosome-derived Prognostic Signature and Risk Stratification for Breast Cancer Based on Multi-omics and Systematic Biological Heterogeneity. **2023**, | 0 |
| 5 | DNA aneuploidy identifies a subset of Luminal subtype breast carcinoma patients with worse clinical outcome. **2023**, 246, 154513 | 0 |
| 4 | Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from EpithelialâMesenchymal Transition. | 0 |
| 3 | LINC00426 is a potential immune phenotype-related biomarker and an overall survival predictor in PAM50 luminal B breast cancer. 14, | 0 |
| 2 | Oncogenic role of an uncharacterized cold-induced zinc finger protein 726 in breast cancer. | 0 |

| | | |
|---|---|---|
| 1 | PrenatalBRCA1epimutations contribute significantly to triple-negative breast cancer development. | 0 |